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“Estudar os fenômenos da doença sem livros  
é como navegar em mares desconhecidos;  
mas estudar livros sem doentes  
é como não ir sequer para o mar”. 
William Osler 
RESUMO 
 A neuronopatia sensitiva (NS) representa a doença caracterizada pelo dano 
ao gânglio sensitivo da raíz dorsal. Sua expressão é de ataxia sensitiva e déficits 
exclusivamente sensitivos, multifocais que não comprimento-dependentes. O 
reconhecimento desse padrão é fundamental para a identificação de doenças 
associadas à NS. Todavia, sintomas como dor e a disautonomia ainda foram pouco 
explorados. A raridade da NS associada a sinais e sintomas como a pseudoparesia 
e a pseudoatetose tornam o cenário favorável ao erro e atraso diagnóstico. Além 
disso, a falta de instrumentos capazes de mensurar a evolução da doença torna 
impossível a avaliação da historia natural da doença bem como o delineamento de 
estudos de tratamento. Portanto, os objetivos desse trabalho são: 1.investigar novas 
etiologias de NS utilizando ferramentas de imunologia clínica e genética molecular; 
2.descrever aspectos clínicos, topográficos e a resposta terapêutica da dor nas NS; 
3.avaliar o comprometimento autonômico por meio de escala clínica e de exames 
neurofisiológicos nos pacientes com NS; 4.avaliar o atraso e o erro diagnóstico aos 
quais estão submetidos os pacientes com NS e, 5.propor e validar um instrumento 
capaz de quantificar as alterações clínicas dos pacientes com NS. 
 Um total de 61 pacientes foram avaliados e frações deste número foram 
incluídas em cada um dos estudos. Foram descritos dois pacientes com NS 
associada a causas infecciosas: a primeira descrição clínica da associação entre NS 
e a infecção pelo vírus da Zika e a descrição da associação da infecção pelo HTLV-1 
e o fenótipo combinado de NS e paraparesia espástica. A avaliação dos anticorpos 
anti-FGFR3 demonstrou positividade em 38% (16/42) explicando 37,5% (9/24) dos 
pacientes com etiologia até então, idiopática. Cinco pacientes com a associação NS-
hepatite autoimune foram identificados, representando 7% do total de pacientes 
avaliados (5/70). Esses pacientes destacam-se pela positividade do anti-FGFR3 (3/5 
– 60%) e pela não-responsividade do quadro neurológico contraposta à remissão do 
quadro hepático instituída a imunossupressão. Dando prosseguimento à 
investigação etiológica, 22 pacietes com NS idiopática foram submetidos ao 
sequenciamento completo do exoma por tecnologia de nova geração. Nenhum 
paciente teve seu diagnóstico realizado. Todavia, variantes relacionada a genes que 
podem levar à ataxia sensitiva, foram encontradas em quatro pacientes (CUBN, 
POLG, FXN e FLVCR1). 
 Queixas álgicas estavam presentes em 76%, com assimetria e características 
neuropáticas em mais da metade dos pacientes cuja terapia medicamentosa 
promoveu remissão satisfatória em 19%(7/36). Uma prevalência ainda maior foi 
observada na investigação autonômica. Alteracões do volume de sudorese pelo 
reflexo axonal sudomotor estavam presentes em 91% indicando disfunção simpática 
pós-ganglionar a qual estava associada à disfunção parassimpática descrita por 
alterações nas provas cardiovagais dos testes de variabilidade cardíaca.  
 Os pacientes com NS em média levam 5,4±5,4 anos entre o início de 
sintomas e a conclusão diagnóstica, passando por 4,3 ± 2,4 especialistas com 
3,08±1,4 diagnósticos incorretos. Por fim, propusemos um instrumento com 10 itens 
capazes de avaliar os pacientes com NS. Essa escala apresentou consistência 
interna com alfa de Cronbach padronizado de 0,83 com coeficientes de correlação 
interclasse para concordância inter/intraobservador de 0,96 e 0,98 respectivamente. 
   
Palavras-chave: Doenças do Sistema Nervoso Periférico; Gânglios Sensitivos; 
Ataxia; Sistema Nervoso Autônomo; Sequenciamento Completo do Exoma; 
Receptores de Fatores de Crescimento de Fibroblastos; Escala de avaliação de 
ataxia sensitiva. 
  
	ABSTRACT 
	 Sensory neuronopathies (SN) represent a disorder characterized by dorsal 
root ganglia damage. The emerging clinical picture is composed by sensory ataxia 
and multifocal non-length dependent sensory deficits. The identification of this 
pattern opens a window of opportunity for the recognition of possible underlying 
diseases. Moreover, frequent symptoms such as pain and those related to autonomic 
dysfunction have not been clinically nor neurophysiologically evaluated. Another 
milestone to be mentioned is the rarity of SN added to unusual signs such as 
pseudoathetosis and pseudoparesis that turn usual the diagnostic delay. Additionally, 
the lack of reliable instruments capable of measuring the disease progression makes 
impossible natural history studies and the design of clinical trials.  Hence, our 
objectives were: 1.to investigate novel etiologies for SN using clinical immunology 
and molecular biology techniques; 2.to describe clinical, topographic and treatment 
response characteristics of SN-related pain; 3.to evaluate clinical and 
neurophysiological functioning of the autonomic nervous system in SN patients; 4.to 
assess diagnostic delay and misdiagnoses of SN and 5.design and validate a clinical 
instrument capable to measure sensory ataxia. 
    A total of 61 SN patients were enrolled, and different proportions of this group 
were included in each study. Two patients with infectious diseases-related SN were 
described: the first one was the first description of Zika virus-related SN and the 
second one was also the first description of a patient with SN and spastic 
paraparesis related to the HTLV1 infection. Anti-FGFR3 antibodies tested positive in 
38% (16/42) of the patients and likely explained the disease cause in a significant 
proportion of the “idiopathic cases” 37.5% (9/24).  Five patients (7% - 5/70) were 
diagnosed with the SN-autoimmune hepatitis association. These patients had 
positive screening for anti-FGFR3 antibodies (3/5 - 60%) and had, characteristically, 
unresponsiveness to the immunosuppressive treatment regarding the neurological 
clinical picture, whereas the hepatic disease underwent remission. Exome 
sequencing through new generation technology was another effort towards the 
etiologic approach of NS. Twenty-two idiopathic SN patients were enrolled but none 
of them had a definite diagnosis. Four patients had heterozygote variants in genes 
related to sensory ataxias (CUBN, POLG, FXN e FLVCR1) what raises the 
hypothesis that these are predisposing genes for SN. 
	    Pain complaints were present in 75% of the SN patients in this cohort, and more 
than half of them had asymmetric and neuropathic characteristics. Only 19% of the 
treated patients reached satisfactory pain remission. Autonomic manifestations were 
even more prevalent. Indeed, axonal sudomotor reflex evaluation disclosed abnormal 
sweat volumes in 91% of the patients what represents a post-ganglionic sympathetic 
dysfunction. Parasympathetic dysfunction was also revealed by the abnormal 
cardiovagal tests observed during heart rate variability tests. 
    Considering the diagnostic delay, the mean interval from disease onset to the 
correct diagnosis was 5.4±5.4 years. On average, each patient had 3.08±1.4 
misdiagnoses after consulting 4,3 ± 2,4 specialists. At last, we have proposed a 
clinical instrument to evaluate SN patients. This 10-item scale had a standardized 
Cronbach`s alpha of 0.83 and intraclass correlation coefficient for interrater and 
intrarater evaluations of 0.96 and 0.98 respectively. 
 
Key Words: Peripheral Nervous System Diseases; Ganglia, Sensory; Ataxia; 
Autonomic Nervous System; Whole Exome Sequencing; Receptors, Fibroblast 
Growth Factor; SEARS, Sensory Ataxia Rating Scale. 
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LANSS: do inglês, Leeds assessment of neuropathic symptoms and signs  
LCA: do inglês, lateral cricoarytenoid muscle 
LEMG: do inglês, laryngeal electromyography 
	LES: do inglês, systemic eritematous lupus  
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LMI: do inglês, lateral medullary infarction  
MFS: do inglês, Miller-Fisher syndrome 
MM: do inglês, multiple mononeuropathy 
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MRI: do inglês, magnetic resonance imaging 
MUP: do inglês, motor unit potentials 
NAC: neuropatia autonômica cardíaca 
NCS:do inglês, nerve conduction study 
npSN: do inglês, non-paraneoplastic sensory neuronopathy 
NS: neuronopatia sensitiva 
NST: do inglês, nucleus of the solitary tract 
OH: Orthostatic hypotension 
ORI:do inglês, orbicularis oris muscle 
p-ANCA: do inglês, perinuclear antineutrophil-cytoplasm antibody 
PAN: do inglês, polyarteritis nodosa 
PCA: do inglês, posterior cricoarytenoid muscle 
PCR: do inglês, polimerase chain reaction 
PD: do inglês, piecemeal deglution 
PE: do inglês, plasma exchange 
PICA: do inglês, posterior inferior cerebellar artery 
PN: do inglês, peripheral neuropathy 
	pNN50: do inglês, percentage of successive RR intervals that differ by more than 
50ms  
PNS: do inglês, peripheral nervous system  
PSA: do inglês, power spectral analysis 
QSART: do inglês, quantitative sudomotor axon reflex test 
RA: do inglês, rheumatoid arthrits 
RRNN: do inglês, mean RR normal-to-normal intervals 
RSA: do inglês, respiratory sinus arrhythmia  
SARA: do inglês, scale for the assessment and rating ataxia 
SBA: do inglês, single bolus analysis 
SEARS: do inglês, sensory ataxia rating scale 
SCOPA-Aut: do inglês, Scale for Outcomes in Parkinson’s disease for Autonomic 
Symptoms 
SDNN: do inglês, mean of the standard deviations of all the intervals without artifacts 
SM: do inglês, suprahyoid/submental muscles 
SMF: sindrome de Miller-Fisher  
SN: sensory neuronopathy 
SNAP: do inglês, sensory nerve amplitude potential 
SS: do inglês, Sjogren Syndrome 
SSI: do inglês, systemic sclerosis 
SSR: do inglês, sympathetic skin response 
SVE: do inglês, special visceral efferent fibers 
SVA: do inglês, special visceral afferent fibers 
SW: do inglês, swallowing  
SWS: do inglês, sequential water swallowing 
	TA:do inglês, thyreoarytenoideus muscle 
TNF: do inglês, tumor necrosis factor 
UNICAMP: Universidade Estadual de Campinas 
VAS: do inglês, visual analog scale 
Vca: variabilidade cardíaca 
VHS: velocidade de hemossedimentação 
VLF: do inglês, very low frequency 
VM: do inglês, Valsalva maneuver 
VR: do inglês, Valsalva ratio 
ZIKV: do inglês, Zika virus
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INTRODUÇÃO 
 
 As ganglionopatias ou neuronopatias sensitivas (NS) constituem um 
grupo de doenças do sistema nervoso periférico cujo denominador comum é o dano 
ao gânglio sensitivo da raiz dorsal (GRD) (1,2). A estrutura histológica do GRD é 
composta por capilares fenestrados e corpos celulares neuronais com 
prolongamentos axonais extensos (3). Essas características trazem como 
consequência o aumento da permeabilidade da barreira hemato-neural e alta 
demanda metabólica. Dessa maneira, a exposição de sua microestrutura à ação 
lesiva de anticorpos e agentes agressores sistêmicos torna-se facilitada (4).  
Outra peculiaridade dos neurônios abrigados no interior dos GRD e que 
possui íntima ligação com o quadro clínico que emerge de sua lesão é sua 
morfologia pseudo-unipolar. A partir da lesão no corpo celular, há a degeneração 
tanto dos prolongamentos direcionados ao sistema nervoso central que constituem 
cordão medular posterior (Figura 1), como de sua porção periférica a qual é 
responsável pela aferência sensitiva (4).  
 
 
Figura 1: Imagem de ressonância nuclear magnética de coluna cervical ponderada 
em T2 de uma paciente com neuronopatia sensitiva demostrando hipersinal 
localizado no cordão medular posterior (seta).  
 
É justamente o acometimento das modalidades integradas pelo cordão 
posterior da medula que leva à ataxia sensitiva, manifestação mais característica 
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das NS (2,4). O refinamento da história e do exame clínico desses pacientes torna 
evidente um padrão de sinais e sintomas relacionado ao dano randômico aos GRDs: 
as queixas e os déficits sensoriais resultantes são caracteristicamente assimétricos 
e multifocais (2-5). Portanto, não obedecem a um padrão de comprimento-
dependência, estando, muitas vezes, ausente o gradiente distal. Outras 
manifestações estão ligadas à diminuição da propriocepção. Por exemplo, alguns 
pacientes com NS queixam-se de paresia a despeito de uma função motora normal. 
Na maioria das vezes, essa queixa está relacionada à chamada pseudoparesia a 
qual pode ser distinguida da paresia verdadeira quando a aparente fraqueza de um 
determinado grupo muscular é suplantada com o auxílio da visão direta do ato 
motor.  
Muito embora os fenômenos descritos sejam considerados clássicos no 
contexto das NS, outros sinais e sintomas persistem pouco explorados. Nesse 
grupo, podem ser encontradas a dor e as alterações autonômicas. A presença de 
queixas relativas à dor, as quais inclusive lembravam características neuropáticas, 
remonta às descrições originais de SN feitas em 1948 por Derek Denny-Brown (6). 
Todavia, uma abordagem sistematizada por meio de escalas clínicas, descrição da 
sua frequência,  características fundamentais, distribuição topográfica em termos de 
frequência de acometimento não estão disponíveis na literatura médica. De maneira 
paralela, as alterações relativas ao sistema nervoso autonômico nas NS, apesar de 
abordadas previamente em coortes menores ou casos anedóticos (7-9), não 
possuem metodologia capaz de fornecer de maneira objetiva dados sobre topografia 
lesional ou ainda sobre a real extensão do seu impacto clínico. Além do acima 
exposto, é conveniente lembrar que a relevância do melhor entendimento e 
reconhecimento desses dois aspectos das NS (dor e disautonomia) é fundamental já 
que também impõem aos pacientes redução da sua qualidade de vida e o mais 
importante, possuem opções para o seu controle sintomático. 
No campo da avaliação armada, as características clínicas ditas clássicas das 
NS podem ser referendadas pela eletroneuromiografia a qual demonstra os 
predicados supracitados de envolvimento multifocal não-comprimento dependente. 
Tais características colocam as NS em contraposição às polineuropatias, nas quais 
as alterações são nitidamente simétricas e distais (10,11). Na tentativa de tornar 
mais objetiva a abordagem aos pacientes com NS, Camdessanché e colaboradores 
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propuseram em 2009 um conjunto de critérios diagnósticos para as NS os quais 
podem ser encontrados na Tabela1. 
 
Tabela 1: Critérios diagnósticos para as neuronopatias sensitivas propostos por 
Camdessanché e colaboradores (10). 
A: Nos pacientes com neuropatia sensitiva pura o diagnóstico de neuronopatia 
sensitiva é considerado possível caso alcance escores >6,5 
a – Ataxia nos MMII ou MMSS no 
início ou no decorrer do quadro clínico 
+ 3,1 pontos 
b – Distribuição assimétrica dos 
déficits sensitivos no início ou no 
decorrer do quadro clínico 
+ 1,7 pontos 
c – Déficits sensitivos não restritos aos 
MMII no auge dos sintomas 
+ 2,0 pontos 
d – No mínimo um PAS ausente ou 3 
PAS <30% do LIN nos MMSS, não 
explicados por neuropatia 
compressiva 
+ 2,8 pontos 
e – Menos de dois nervos motores 
com condução alterada nos MMII 
+ 3,1 pontos 
B: O diagnóstico de neuronopatia sensitiva é considerado provável caso o 
paciente alcance escores >6,5 e: 
1: A investigação complementar não demonstre alterações ou achados de 
eletroneuromiografia que excluam a  neuronopatia sensitiva e 
2:  O paciente possua uma das seguintes condições: anticorpos onconeurais 
ou câncer dentro de cinco anos; história de uso de cisplatina ou SS 
3: Ou a ressonância nuclear magnética demonstre hipersinal no cordão 
medular posterior 
C: O diagnóstico de neuronopatia sensitiva é definitivo se a degeneração do 
gânglio da raiz dorsal é demonstrada por histopatologia muito embora, a 
biópsia do gânglio da raiz dorsal não seja recomendada. 
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MMII: membros inferiores; PAS: potencial de ação sensitivo; LIN: limite inferior da 
normalidade; MMSS: membros superiores; SS: síndrome de Sjögren. 
Embora o padrão clínico/neurofisiológico seja considerado clássico e existam 
critérios diagnósticos bem definidos,  a NS ainda persiste no subgrupo das doenças 
consideradas raras. Provavelmente não somente por sua baixa prevalência, mas 
graças também ao subdiagnóstico. A abordagem da questão do subdiagnóstico 
chega em um denominador comum de maior conscientização dos profissionais 
envolvidos no cuidado inicial desses pacientes no sistema de saúde. Todavia, para 
que medidas eficazes sejam propostas e executadas faz-se necessário um 
delineamento do problema. Para tal, é fundamental o conhecimento não somente do 
período que separa os pacientes desde o início dos seus sintomas até o diagnóstico 
final de NS, mas também de quais os profissionais realizam esses primeiros 
atendimentos e quais as condições mais frequentemente imputadas como 
responsáveis pelos sintomas que, em realidade, são causados pela NS. 
Existem numerosas etiologias implicadas na origem das NS como condições 
imunomediadas, tóxicas, carenciais, paraneoplásicas, infecciosas e hereditárias. No 
entanto, a despeito de uma extensa investigação com exames complementares, em 
cerca de metade dos casos uma etiologia específica não pode ser identificada, 
persistindo a nomenclatura de forma idiopática (5). Sendo assim, faz-se imperativa a 
descrição pormenorizada de possíveis novas etiologias ou mesmo o refinamento de 
algumas causas já conhecidas porém de menor frequência, como é o caso da 
hepatite autoimune e da infecção pelo HTLV. Ainda na tentativa de progredir no 
entendimento desses pacientes ditos idiopáticos e da própria fisiopatologia da NS, 
esforços têm sido empregados na descrição de novos biomarcadores.  
O contexto de disfunção imune no qual encontram-se vários pacientes com 
NS resultou na descrição dos anticorpos anti-receptor 3 do fator de crescimento de 
fibroblastos (anti-FGFR3) em uma parcela de pacientes com NS, inclusive em uma 
parte dos descritos como idiopáticos (12). Os fatores de crescimento de fibroblastos 
representam uma família de 23 membros com quatro receptores distintos 
fundamentais no processo de sinalização celular (13). O FGFR3 representa funções 
no sistema nervoso central relativas à renovação e à migração neuronal; já no 
sistema nervoso periférico, modelos animais apontam para sua expressão nos GRD 
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e neurônios sensitivos, expressão essa, aumentada no contexto de lesões a nervos 
periféricos (14,15). Além disso, outras evidências apontam para o fato de que 
aqueles animais knockout para o FGFR3 apresentam resistência à morte neuronal 
no GRD após lesão neural (16), dando possíveis contornos terapêuticos ao 
horizonte dos pacientes com SN anti-FGFR3. A despeito disso, até o momento 
temos uma única série descrita de pacientes soropositivos (n=9) (12). Dessa forma, 
ainda não se tem conhecimento nem do real valor diagnóstico desse biomarcador e 
nem do espectro fenotípico associado a ele.  
Considerando o corpo de evidências existentes que focam no tratamento das 
NS, não existem estudos metodologicamente robustos a ponto de nortear a conduta 
terapêutica nos pacientes com NS. Uma das possíveis razões para esse cenário 
povoado por  séries de casos e relatos anedóticos (17-19) é a inexistência de 
instrumentos capazes de fornecer medidas clínicas confiáveis e relacionadas ao 
estado clínico atual dos pacientes com NS. Considerando as escalas cínicas 
existentes, fica claro que nenhuma delas avalia adequadamente os pacientes com 
NS: de um lado estão os instrumentos de medida da função cerebelar (cuja ataxia é 
marcante,  mas acompanhada de outras alterações “exclusivamente” cerebelares 
como disartria, disdiadocinesia e alterações de motilidade ocular) e no outro, estão 
as escalas dedicadas à avaliação das neuropatias, que em sua maioria, conferem 
grande peso à força muscular. Além disso, as escalas voltadas para avaliação das 
neuropatias, via de regra, privilegiam os déficits sensitivos distais e também não 
levam em conta a sua possível assimetria. 
Dessa maneira, a despeito da caracterização fenomenológica envolvendo a 
doença também abranger os casos atípicos, algumas manifestações apresentadas 
pelos pacientes com NS ainda carecem de investigação mais aprofundada. Nesse 
ponto, faz-se relevante a descrição de novas etiologias bem como a exploração de 
aspectos clínicos, imunológicos e neurofisiológicos com enfoque especial nas 
manifestações envolvendo o sistema nervoso autonômico e as queixas de dor. Uma 
outra lacuna apontada a partir do estudo das NS é o envolvimento imunológico nos 
quadros ditos idiopáticos que, por possuírem a expressão laboratorial de alteração 
imune marcada pela presença de autoanticorpos (como o anti-FGFR3) podem 
ganhar inclusive, propostas terapêuticas individualizadas em um futuro breve. Para 
tal, conforme o que já foi apontado, escalas capazes de quantificar a evolução ou 
	 	 30	
	
mesmo estadiar a doença não existem e são fundamentais no desenvolvimento e 
planejamento de estudos que envolvam o tratamento das NS. Isso posto, esse 
trabalho visa descrever novas causas de NS, ampliar o entendimento desse grupo 
de doenças, especialmente no que tange à avaliação imunológica e autonômica, 
bem como facilitar a avaliação clínica desses pacientes pela confecção de 
instrumento de avaliação, na forma de escala clínica, que seja capaz de avaliar de 
maneira mais fidedigna os pacientes com NS. Outrossim, a descrição do tempo 
gasto desde o inicio dos sintomas relativos à NS e o seu efetivo diagnóstico, 
passando pelo cortejo dos pacientes dentro do sistema de saúde, explicitando não 
somente as especialidades envolvidas nesse processo, como também as doenças 
com as quais as NS podem ser confundidas.  
A forma com a qual esse trabalho será exposto seguirá a seguinte ordem: 1) 
revisão da literatura envolvendo aspectos históricos/gerais e as NS imunomediadas; 
2) descrição da metodologia empregada nas diferentes etapas; 3) resultados 
apresentados na forma de artigos científicos; 4) discussão geral dos resultados; 5) 
conclusões e por fim 6) referências bibliográficas. 
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ABSTRACT  
The authors present a historical review about the main contributions of Professor 
Derek Denny-Brown to Neurology. Some of his achievements include the first 
description of sensory neuronopathies and some of the essential textbooks of 
function and anatomy of the basal ganglia. In 2016, the year of his 35th death 
anniversary, the modern neurologists are still strongly influenced by his legacy.  
Key-words: Denny-Brown, neurology, dorsal root ganglia, basal ganglia, movement 
disorders. 
 
 
 
DEREK DENNY-BROWN: O HOMEM POR DETRÁS DOS GÂNGLIOS DAS RAIZES 
DORSAIS E DOS NÚCLEOS DA BASE. 
RESUMO  
Os autores apresentam uma revisão histórica sobre as principais contribuições do 
Professor Derek Denny-Brown à neurologia. Suas realizações incluem a primeira 
descrição da neuronopatia sensitiva e alguns dos livros fundamentais acerca da 
função e anatomia dos núcleos da base. Em 2016, ano do seu 35o aniversário de 
falecimento, os neurologistas atuais ainda são fortemente influenciados pelo seu 
legado.   
Palavras chave: Denny-Brown, neurologia, gânglios da raiz dorsal, núcleos da base, 
distúrbios do movimento 
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One hundred and fifteen years after his birth in New Zealand (June 1st 1901) 
and 35 years after his death anniversary (April 20th 1981), the accomplishments and 
scientific work of Derek Ernest Denny-Brown (DDB) are a strong foundation for 
several neurological advances even in present day1,2.(Figure 1) Considering his 
legacy of dozens of published papers and books, he has made substantial 
contributions for better understanding the basal ganglia’s functions and structure1,3,4. 
He also made the first description of sensory neuronopathy 5. In fact, he contributed 
in so many fields in Neurology that it would be unfair and impossible to point out only 
a few. 
 
Short Biography 
After earning his medical degree in New Zealand and initially seeking for a 
better comprehension of postural control, DDB moved to Oxford where he engaged 
deeper in neurophysiology research carried under the mentorship of Sir Charles 
Sherrington. Later in 1928, after achieving his PhD, he decided to return to clinical 
practice applying for house physician. In December of the same year he begins his 
works as a Resident Medical Officer at the National Hospital, Queen Square1. During 
the following years, he had as teachers, supervisors and colleagues some great 
medical bulwarks including Drs. William Adie, MacDonald Critchley, Charles 
Symonds, Gordon Holmes, Kinnier Wilson, Francis Walshe and James Collier1. For 
the next 11 years he continued at London where he introduced electromyography 
and muscular biopsy at Queen Square, as tools in neuromuscular investigation1. 
During the World War II he served as a physician in the Royal Army Medical Corps 
from 1939 to 1941, until James Conant, the President of Harvard University at that 
time, requested DDB’s duty releasing to Sir Winston Churchill. This allowed his 
transferal to Boston. 
In 1946 DDB assumed the position of Professor of Neurology at Harvard 
Medical School and Director of Harvard's Neurological Unit at the Boston City 
Hospital, chairs he held until his retirement in 1967. 1,4 
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Denny-Brown “self-experimentation”  
His commitment and eagerness for science and research may encounter solid 
examples in two peculiar and almost mythical stories. First, in order to evaluate and 
describe the phenomena of micturion reflexes, he and Graeme Robertson used 
themselves as subjects in what Robertson described years later as an “intimate 
scientific association” 6. Second and no less impressive is that, in the imminence of 
an amputation of his third finger due to a severe Dupuytren contracture, DDB 
induced a digital nerve injury to experience the symptoms of post-traumatic 
neuralgia. He later described his findings in a paper published in Brain 7. 
 
Denny-Brown and the Dorsal Root Ganglia 
 It was in 1939 that two patients crossed DDB’s path favoring one of his most 
remarkable accomplishments: the first description of Sensory Neuronopathies. Both 
patients presented with sensory ataxia, with a sensory loss following a non-length-
dependent and assymetric pattern. Through his analytical mindset, DDB identified 
the commonalities between the two cases: a massive destruction of the DRG, 
polymyositis and bronchial carcinoma. At that time, he attributed the disease to 
metabolic consequences of the neoplasm. Even though nowadays it is Known that 
the etiology of the DRG damage is not attributable simply to metabolic issues, the 
DDB’s work stands as the first description of sensory ataxia due to DRG injury, what 
is also known as Denny-Brown’s syndrome5. It is important not to mistake this entity 
with the Denny-Brown and Foley’s syndrome, which is related to benign 
fasciculations8.  
 
Denny-Brown and the Basal Ganglia 
Some other remarkable achievements were made by DDB towards the better 
understanding of the basal ganglia and their influence in movement disorders. In fact, 
between the 1940’s and 1960’s he published the three classical books regarding this 
topic: “Diseases of the Basal Ganglia and Subthalamic Nuclei”(1946),  “The Basal 
Ganglia” (1962) and “The cerebral control of movement” (1966) 1,2,4. In these books 
DDB made, for the first time, a deeply discussion of the anatomy and physiology of 
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the basal ganglia, and several types of movement disorders, such as, tremor chorea, 
athetosis, dystonia, and parkinsonism.1, 4 In his most famous book “The basal ganglia 
and their relation to disorders of movement” he also described his evaluation of 
classical diseases, including hepatolenticular degeneration (Wilson´s disease), 
Huntington´s chorea, dystonia musculorum deformans, Hallerworden-Spatz 
syndrome, among others.4 Finally, he presented the experimental lesions of the basal 
ganglia in monkeys, particularly in the caudate nucleus, putamen, and globus 
pallidus.4 The impressive amount of experimental data involving about 450 monkeys, 
acquired during his lifetime and specially during the period after his “retirement” from 
clinical practice (1967), when he worked in the New England Regional Primate 
Research Center, were published until very close to his death in 19812. 
It is well-known that Denny-Brown used for the first time in the world the 
expression “disorders of movement” (nowadays movement disorders), instead 
extrapyramidal syndromes.3,4,9 
 
Conclusion 
Even after DDB’s death, in consequence of a multiple myeloma, his legacy 
continued, in the memory of his wife Sylvia Summerhayes and their four siblings, and 
also in the annals of modern neurology1. He was known as one of the most 
embattled defenders of Neurology as a distinct specialty as he stated in his famous 
paper “The changing pattern of neurologic medicine” : “…equipped with a special 
knowledge of the vagaries of neurological disorders and their underlying pathology 
and with a flexibility of investigative technique, the neurologist has no difficulty in 
holding his own in a changing world…” 10.  
Notwithstanding, DDB impressed not only his trainees, which later became 
Neurology exponents, but also names like Gordon Holmes who wrote to DDB a letter 
in the 1950’s that read: “I have had many letters of congratulations on my 80th 
birthday, but not one pleased me more than that from you. Rosalie truthfully said that 
I became quite emotional in reading it. It at least has made me feel that my work at 
Queen Square has not been wasted . . .” 1. 
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Figura 2: Figure 1: Derek Denny-Brown (1901-1981). 
(Image in the public domain. Reproduced from The National Library of Medicine 
http://collections.nlm.nih.gov). 
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We read the review article entitled Sensory neuronopathies in the January 
2016 issue with great interest 1. However, we would like to point out a particular 
pitfall in terminology. There are a wide variety of terms used to refer to this condition, 
which is marked by primary degeneration of the dorsal root ganglia (DRG)2.  
 Denny-Brown, who first described the condition in 1948 in 2 patients with 
bronchial carcinoma and massive DRG destruction, chose a comprehensive and 
generic term to describe the clinical picture of sensory ataxia in those patients: 
“primary sensory neuropathy”3. 
 Since then, several terms have been used to describe a disorder 
characterized by a primary DRG lesion. The list is long and in addition to sensory 
neuronopathy includes: ganglionopathy, polyganglionopathy, sensory neuron 
disease, sensory neuropathies, sensory ataxic ganglionopathy, ataxic neuropathy, 
and non-length-dependent sensory neuropathy. Some of these terms should be 
abandoned for not only anatomical but also clinical reasons. First of all, DRG 
impairment leads to a peculiar clinical picture of sensory ataxia, multifocal and 
asymmetrical sensory deficits, and normal strength4,5. In addition, the prefix “poly” in 
nervous system diseases should be used to refer to symmetric deficits and usually 
refers in the peripheral nervous system to the length-dependent and symmetrical 
symptoms characteristic of the polyneuropathies. This is in striking contrast with the 
typical pattern seen in DRG-related disorders. Another term that leads to 
misunderstanding is ganglionopathy, which may not be strictly wrong, as it makes a 
direct reference to the anatomic structure involved. However, it can lead to being 
grouped with other unrelated diseases such as autonomic ganglia disorders, 
ganglion cysts, or even hematological conditions. 
Another important issue refers to the research involving this disease. A 
literature search for the terms “sensory neuronopathies”, “ganglionopathy,” or 
“sensory neuron disease” returned 50, 135, and 4 hits, respectively (MEDLINE 
database). In addition, there is considerable mismatch in the retrieved results. This 
makes not only the work of researchers more difficult but also complicates the task of 
physicians who seek straightforward information for patient care. In the end, this 
contributes to diagnostic delay, which is ominous in this particular situation, because 
DRG lesions may herald concurrent conditions amenable to treatment if detected 
early (e.g. paraneoplastic disease). 
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 That said, we make a call for those who do basic and clinical research in DRG 
disorders to adopt sensory neuronopathy as a uniform term, which is both 
anatomically and semiologically correct, just as Dr Gwathmey did.  
 
Editor’s note: Dr Gwathmey has reviewed this letter and has indicated that no further 
comment is needed. 
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Neuropatias Imunomediadas  
 
	
	
Autoimmune Neuropathies associated to Rheumatic Diseases  
Alberto R. M. Martinez, Ingrid Faber, Anamarli Nucci, Simone Appenzeller, 
Marcondes C. França Jr. 
Abstract 
Systemic manifestations are frequent in autoimmune rheumatic diseases and include 
peripheral nervous system damage. Neuron cell body, axons and myelin sheath may 
all affected in this context. This involvement results in severe and sometimes 
disabling symptoms. Sensory, motor and autonomic features may be present in 
different patterns that emerge as peculiar clinical pictures. Prompt recognition of 
these neuropathies is pivotal to guide treatment and reduce the risks of long term 
disability. In this review, we aim to describe the main immune-mediated neuropathies 
associated to rheumatic diseases: sensory neuronopathies, multiple 
mononeuropathies and chronic inflammatory demyelinating polyradiculoneuropathy, 
with an emphasis on clinical features and therapeutic options. 
Background 
The generic definition of peripheral neuropathy (PN) encompasses the 
involvement on any structure (neuron cell body, myelin, axon and even the glia cells) 
of the peripheral nervous system (PNS). Prevalence of PN ranges between 2.4-8% in 
	 	 42	
	
the general population and there are a myriad of causes, including autoimmune and 
rheumatological diseases.  On clinical grounds PN are characterized by 
heterogeneous manifestations and etiologies what leads to a challenging 
investigation workflow. A “shotgun” approach in which every cause of PN is ruled out 
at the same time, often fails to identify the correct etiology [2]. The patient history and 
a detailed physical examination play an important role since the recognition of one of 
the several PN patterns is critical for a rational etiological investigation. In this 
scenario, there are 3 major immune-mediated PN subtypes associated with 
autoimmune rheumatologic diseases: ganglionopathy or sensory neuronopathy (SN), 
multiple mononeuropathy (MM) and chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP) – Table 1. In the present review, we will focus in 
these PN and explore the association with different rheumatic illnesses.   
Sensory Neuronopathies 
 First described by Denny-Brown in 1948 in two patients with bronchial  
carcinoma that developed sensory ataxia, the ganglionopathies or sensory 
neuropathies (SN) represent clinically the expression of injury to the dorsal root 
ganglia (DRG) [3]. In the next few years after Denny-Brown’s report, several 
additional mechanisms underlying SN were described such as: toxic, genetic, 
infectious and immune-mediated [4]. 
 Some specific characteristics placed together help to explain the particular 
vulnerability of the DRG. First of all, the nerve-blood barrier in the DRG is not as tight 
as in other structures within the nervous system [5]. This is due to the fenestrated 
capillaries that supply the DRG and enable anti-bodies and toxic elements to easily 
reach the neuron cell bodies. Another important factor are the long projections of 
DRG neurons that place them under high metabolic demands, increasing the 
vulnerability of those structures to several hazards.  
  In terms of the clinical picture, DRG dysfunction results in a non-length 
dependent sensory impairment opposed to the classical length-dependent pattern of 
the polyneuropathies [6]. Consequently, the neurologic examination may reveal 
sensory impairment and deficits that are often worse in proximal limbs or face than in 
the extremities, for example. This distinct profile is derived from the multifocal 
involvement of long and short length projections [7].  
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The observed symptoms have a close relation to the type of neurons affected: 
if in one side the involvement of the large neurons lead to gait ataxia, loss of balance, 
arreflexia, loss of vibratory sensation and sense position, the “positive” sensory 
symptoms, such as burning, pain, hyperaesthesia and allodynia may arise from the 
medium/small neurons damage [5,7]. Autonomic and mild motor symptoms are often 
found, especially in paraneoplastic and immune-mediated etiologies [5].  
SN prevalence may reach around 20% of all paraneoplastic syndromes [8] 
and 10% of all Sjögren Syndrome (SS) patients [4,7], but underdiagnosis is certainly 
an issue and contributes to its apparent rarity. In order to solve this issue, several 
diagnostic criteria have been created. Asbury`s criteria were the first published and 
relied upon some aspects of SN such as its multifocal sensory impairment with an 
almost exclusive neurophysiological sensory abnormality [9,10]. Although those 
criteria were almost universally accepted, some queries regarding its validation, 
sensitivity and specificity remained. Thereafter, to address those points 
Camdessanché and cols. designed a score-based criteria encompassing clinical, 
neurophysiological, laboratorial and neuroimaging aspects of SN [11]. Recently, 
Antoine and cols have identified the fibroblast growth factor receptor 3 (FGFR3) as a 
target for IgG antibodies in SN patients, that proved to be highly specific (99.6%) but 
not very sensitive (19%) for SN diagnosis [12]. Those diagnostic strategies were all 
proposed because the actual gold standard test to diagnose SN is invasive, risky and 
available in few centers  ( excisional biopsy and histopathological analysis of DRG) 
[13].  
Once the diagnosis of SN is made, the efforts should be driven towards the 
identification of a possible underlying condition. Nevertheless, even with an extensive 
workup, nearly half of SN cases remain labeled as idiopathic [6]. The most frequent 
identifiable causes for SN are autoimmune diseases, including autoimmune hepatitis, 
Celiac disease and particularly Sjögren syndrome.  
 Since Mikulicz’s ancient descriptions of parotid and lacrimal glands 
involvement in the context of an inflammatory infiltrate in the late 19th century, 
passing through the systematic descriptions made by Sjögren in 1930’s, a lot of 
knowledge about SS accumulated [14]. Considered one of the most common 
autoimmune disorders with a prevalence of 0.5-3% in the general population [14-17], 
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SS is a systemic disorder that can be classified as primary or secondary (when 
associated to a established connective-tissue disease as rheumatoid arthritis, for 
example). 
 Almost 65% of the patients with SS exhibit extraglandular manifestations [16]; 
both central and peripheral nervous system (PNS) are potential targets.  The exact 
prevalence of PNS involvement is controversial and may change according to the 
diagnostic criteria adopted, the cohort being studied and the method of detection of 
PNS involvement. It varies  from as low as 1.8% to 66% [15,18-24]. Mori and cols 
retrospectively evaluated 92 patients with SS-associated neuropathy and divided the 
PNS involvement into seven different phenotypes: sensory ataxia, sensory 
neuropathy (without ataxia), trigeminal neuropathy, multiple cranial nerve 
involvement, autonomic neuropathy, multiple mononeuropathy and 
radiculoneuropathy [18]. SS-related neuropathies may begin before, after or 
concomitantly to sicca symptoms. Some reports found PN complaints to be the initial 
manifestation of the disease in at least 25% of the patients. In this subgroup, SS 
diagnosis may be delayed from 3 to 5 years [27]. Therefore, an interesting approach 
to the patients labeled with “neuropathy secondary to an indeterminate cause” may 
include SS testing.  
That pointed, it is important to recognize SN since the presence of a sensory 
ataxia phenotype, with or without “sicca” symptoms, significantly narrows the 
possibilities of an underling “rheumatologic” diagnose almost exclusively to SS. 
Some series of selected patients with SS and PNS involvement established SN as 
the most common neuropathy reaching rates as high as 33% of all PNS 
manifestations [18,25,28]. As previously described, the SN symptoms usually take 
months to years to be entirely settled and are mainly asymmetrical and multi-focally 
distributed as the result of a DRG impairment [16,24]. 
Delalande and cols demonstrated that only 21% of patients with SS-related 
neurological manifestations have positive anti-Ro/SS-A and/or anti–La/SS-B 
antibodies in the onset of the neurological deficit, and this number reaches only 43% 
after 7 years of disease [29]. Neuroimaging modalities showing abnormalities of the 
DRG itself and dorsal columns of the spine have been described as relevant tools for 
SN diagnosis [33]. In fact, histological DRG involvement with inflammation and 
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mononuclear cell infiltration was already present in the first SS reports [18].  
Pathogenesis of SS-related SN involves mostly cellular abnormal responses directed 
against DRG, but microvasculitis may also take place.   
Considering those pathophysiological insights, the treatment response is 
directly related to the described mechanisms. Several treatment options have been 
evaluated with controversial responses and with study designs almost restricted to 
case series and single case reports. Mori and cols reported 18% and 23% of 
favorable response to treatment with corticosteroids and intravenous 
immunoglobulin(IVIG) [18]. Other reports also found improved outcomes with IVIG 
[36,37], but this trend is not unanimous. Indeed, Rist and cols treated 9 patients with 
SS-related SN with IVIG, 2 improved and 4 actually worsened [38]. Other treatment 
alternatives have variable outcomes and include plasma exchange [39], azathioprine 
[27], cyclophosphamide [40], cyclosporine [39], D-penicillamine[22, 41], rituximab 
[42] and infliximab[27,43]. Considering all these options, in a recent study Pereira 
and cols. made a retrospective study including 13 patients with SS and SN and their 
response to several drug regimens. Seven patients were treated with corticosteroids, 
7 with mycophenolate mofetil, 6 with hydroxychloroquine, 5 with intravenous 
immunoglobulins, 4 with cyclophosphamide, and 2 patients received other 
immunosuppressive drugs. The strategy involving corticosteroids specially in 
association with mycophenolate mofetil, has a better trend toward positive results 
[44]. These findings go in accordance to our own experience; we were able to see 
some patients with SN secondary to SS that failed to sustain clinical responses after 
IVIG, but presented clear improvement with corticosteroids. 
The association between SN and rheumatologic diseases is almost restricted 
to SS, the exact relation to other rheumatologic diseases remains elusive and 
anecdotal [45]. Neither the mechanism of DRG involvement nor the best treatment 
options are known, despite some reports of satisfactory improvement on IVIG [45]. 
Multiple Mononeuropathy  
 Multiple Mononeuropathy or Mononeuritis Multiplex (MM) is a unusual subtype 
of PN. Since it may represent a final path of several conditions through different 
mechanisms, its exact prevalence is hard to establish [46]. A gross definition of MM 
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includes the impairment of two or more peripheral nerve trunks [47,48,49]. The 
clinical picture encompasses a distinctive triad of pain, asymmetry and multifocal 
deficits related to large-fiber motor/sensory neuron axonal damage. These deficits 
may comprehend both motor and sensory impairment and a peculiar characteristic 
may arise: in an affected nerve, a single modality, generally sensation, could be 
compromised in an asynchronous fashion to motor impairment. Generally, severe 
motor deficits indicate a worse prognosis [46] maybe due to the fact that sensory 
nerves are less resistant than motor ones to ischemic injuries [49].  
 An acute or even subacute course with relapsing or progressive deficits 
represents the classical pattern, however a chronic progression is not rare. 
Statistically, longer nerves of the lower limbs are more prone to be damaged, but still 
keeping the multifocality manner [50]. As the underlying disease progresses, some 
patients may exhibit atypical phenotypes, which resemble a length-dependent 
polyneuropathy, therefore in those cases, a careful history reassessment is 
necessary to identify early asymmetric features [49].   
Considering the scope of rheumatologic diseases, MM is tightly associated to 
primary vasculitides. It may occasionally take place in patients with inflammatory 
disorders of the connective tissue. The pathological findings demonstrated on nerve 
biopsy reveals damage to vasa nervorum (Figure 1) (often associated to granuloma 
formation) and a final common feature of axonal loss [47,48,51,52]. In inflammatory 
connective tissue disorders, there is also a direct immune cell infiltration and 
inflammation within nerve fascicles [18,53,54]. This axonal loss leads clinically to 
sensory-motor deficits with localized muscle atrophy (Figure 2). On nerve conduction 
studies and EMG, there is asymmetric reduction of motor and sensory potential 
amplitudes [55-57]. Nerve conduction velocities may also be compromised, but to a 
lesser extent. One may see partial motor conduction blocks in the infarcted nerve 
segments in the acute phase of infarction [58]. Another useful purpose of 
electrodiagnostic studies is to guide the nerve selection for biopsy avoiding those 
without signs of involvement. 
 Considering the high risk of permanent disability and even death, the early 
recognition of an underlying disease is critical to improve prognosis of MM [59]. The 
French Vasculitis Study Group [59] evaluated 108 patients with small-vessel 
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vasculitis without poor prognostic factors defined by the Five Factor Score [60]. After 
a mean follow-up of 98.2±41.9 months, the mean vasculitis damage index score was 
1.9±1.9, with PNS as the major site of sequelae and an overall mortality rate of 7 and 
14% after 5 and 8 years respectively. It is worth remembering that those rates only 
apply to milder cases.  
Although peripheral nervous system involvement is not an ominous prognostic sign in 
vasculitides, it may follow a relentless progressive course and lead to severe 
disability [60]. Proper treatment is essential to minimize these deficits, and the 
adequate drug regimen should be decided in conjunction by rheumatologists and 
neurologists. 
Primary Vasculitidis 
 Vasculitides are classified according to the size of the predominantly affected 
vessels (small, medium and large). Despite that, all blood vessels may virtually be 
affected no matter which specific vasculitic process is taking place [49,61]. Wolf and 
cols evaluated 89 consecutive patients with newly diagnosis of primary systemic 
vasculitis and 25% had peripheral neuropathy at initial presentation, 59% of cases 
consistent with MM [62]. Classically, MM is secondary to small vessel vasculitides 
such as microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis 
(EGPA or Churg-Strauss syndrome) and granulomatosis with polyangiitis (GPA or 
Wegener granulomatosis)[63]. Polyarteritis nodosa (PAN) is a small and medium-
size vessel vasculitis also associated with MM. Systemic symptoms such as fever, 
weight loss, arthralgia, myalgia and fatigue may be a clue that MM is related to a 
vasculitic neuropathy and not an isolated syndrome [49]. Treatment options follow an 
intensity-based drug selection: corticosteroids for mild cases and corticosteroids and 
cyclophosphamide (pulses or daily oral) for those cases with a diffuse organ damage 
or life-threatening conditions [64 ,65].  After remission, maintenance therapies 
include methotrexate, azathioprine, ciclosporin, mycophenolate mofetil or 
leflunomide, generally for 3-6 months [66]. For refractory cases, rituximab, 
intravenous immunoglobulin or even plasma exchange may be useful [67-70]. All 
patients should be continuously evaluated with functional disability scores, 
laboratorial exams and also nerve conduction studies for prompt relapse recognition 
since functional improvement may take 6-24 months after treatment start [61,71].  
	 	 48	
	
 Microscopic polyangiitis is a small-vessel vasculitis with prominent systemic 
features. PNS involvement is not a major feature in MPA patients with a variable 
prevalence (14-60%) of peripheral neuropathy [54,72]. Systemic features are by far 
more common with a typical pulmonary (40%) and renal (80%) involvement including 
pulmonary hemorrhage and progressive glomerulonephritis contributing to 
increments in morbi-mortality rates [61,73,74]. In fact, in a case series with 89 
consecutive patients with newly diagnosed primary systemic vasculitis, only 6% 
(1/16) of MPA patients had PNS as an associated condition [62]. However, as the 
disease progresses, PNS involvement becomes more obvious as demonstrated by 
Guillevin and cols in a retrospective series with MPA patients that reveled MM as the 
fifth most common symptom, present in 57.6% of the patients [75]. Considered a 
perinuclear antineutrophil-cytoplasm antibody-associated vasculitis (p-ANCA) with 
the presence of this antibody reaching up 80% [76], MPA also presents other 
laboratory features such as high erythrocyte sedimentation rate (ESR) and increased 
C-protein reactive levels (cPR) [49]. In the context of MM, the most affected nerves 
are deep and superficial peroneal, median and ulnar nerves [61,62], with cranial 
nerves rarely affected [75].  
 Following the p-ANCA-related vasculitides, eosinophilic granulomatous with 
polyangiitis, formerly Known as Churg-Strauss syndrome, is the primary vasculitis 
more frequently associated to peripheral neuropathy with near 70% of prevalence, 
most of them exhibiting MM [77,78]. This involvement is so relevant that the 
American College of Rheumatology diagnostic criteria includes monoreuropathy or 
polyneuropathy as one of the 6 diagnostic parameters [79]. Accordingly, the herein 
mentioned series of Wolf and cols, points to EGPA as the most common primary 
vasculitis in which peripheral neuropathy, especially MM, is present at the vasculitis 
onset [62]. Besides the p-ANCA, reaching 40% of positivity, and inflammatory 
markers such as cPR and ESR, EGPA is characteristically associated with blood 
eosinophilia and high IgE titers [77]. In addition to the general vasculitis-related MM 
treatment, the anti-CD20 quimeric antibody rituximab reduced for some patients not 
only eosinophilia but also IL-5 levels just as mepolizumab, an anti-IL5 antibody 
[80,81]. Considering specifically EGPA-related neuropathy, several treatment 
regimens, including for example cyclophosphamide with corticosteroid [82,83], have 
been evaluated with different outcomes. IVIG has proven to be useful in refractory 
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cases [80] and for patients with residual neuropathy even when EGPA is in remission 
as demonstrated by Koike and cols [84]. 
 Wegener’s granulomatosis or GPA is essentially a pulmonary vasculitis, but 
with the particular combination of  upper airways and kidneys involvement. PNS 
involvement is present at disease onset in 13% of the patients [62], but increases up 
to 43% with disease progression mostly within the first two years. This is  especially 
true for patients with male gender, older age at disease onset and high titers of 
cANCA [61,85,86]. MM accounts for most of cases of PNS involvement (80%) [49] 
and is related to higher functional disability with pain reported by 66% of all cases 
[85]. Immunosuppressive treatment of GPA leads to a moderate response regarding 
PNS manifestations [85]. When PNS manifestations are found, they may require 
early recognition and highly potent drugs such as infliximab or rituximab, to prevent 
lifelong deficits [87]. 
 Polyarteritis nodosa is slightly different from the previously described 
vasculitides, because it affects not only small but also medium caliber blood vessels.  
Neurologic manifestations are present in almost 80% of the patients with peripheral 
nerves as a major site of lesion [88]. Just as in EGPA, PNS impairment represents a 
diagnostic criteria [89]. Once again, MM is the most frequent PNS phenotype 
accounting for more than half of all PNS symptoms [50,89]. Disease onset is around 
50 years and 50% manifesting PNS symptoms by the time of diagnosis [62]. The 
French Vasculitis Study Group Database retrospectively evaluated 358 patients with 
PAN and described the frequency of peripheral nerve involvement as follows: 
common peroneal (82%), tibial (51%), ulnar (29%) and radial (14%) [88]. Clinical 
clues help to raise suspicion on PN diagnosis; systemic symptoms such as fever 
and/or weight loss are commonly present [88]. One must bear in mind that hepatitis B 
infection leads to PN in 32% of patients during the disease course [90]. In this 
particular scenario, treatment should follow the general immunosupressive 
management, but in association with antiviral agents. 
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Connective Tissue Disorders 
  A small proportion of patients with connective tissue disorders (CTD ) exhibit 
the features of MM. Two main mechanisms may lead to MM phenotype in subjects 
with CTD. The most straightforward would be due to vasculitis that occasionally takes 
place in CTD (secondary systemic vasculitidis). This has been reported for 
rheumatoid arthritis (RA), systemic eritematous lupus (LES), Systemic Sclerosis (SSl) 
and SS that in 10% of the patients exhibit vasculitis during their clinical courses 
[46,91,92]. Just like primary systemic vasculitides, blood vessels of all calibers can 
be affected but with a predominance of the small ones. The second mechanism is 
not fully understood, but involves direct damage to neurons and/or their supporting 
cells by inappropriate immune response and cell infiltration leading to inflammatory 
tissue destruction. Evidence of this mechanism derives from nerve biopsies 
demonstrating immune cell infiltrates [18,47,49]. There are not controlled studies to 
guide the treatment for CTD-related MM; in general, treatment options are those of 
the underlying  conditions, what is beyond the scope of this review. 
 
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) 
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an 
acquired immune-mediated neuropathy. It is characterized by a grossly symmetric 
pattern of weakness that involves distal as well as proximal limb segments with no or 
mild atrophy, accompanied by sensory disturbances, typically loss of vibration and 
joint position sense. Deficits in CIDP progress longer than 8 weeks, which is the main 
but not the only feature that distinguishes it from Guillain-Barré syndrome (GBS), an 
acute polyrradiculoneuropathy [93]. The disease prevalence ranges from 1 to 9 per 
100,000 across studies [94,95].  
Due to its relapsing course and responsiveness to steroids, CIDP is thought to 
have an immune basis [96]. Dyck and collegues first used the term chronic 
inflammatory demyelinating polyradiculoneuropathy, which summarizes the disease’s 
main features [97]. CIDP results from an autoimmune process involving both humoral 
and cellular immunity. Its triggers are unknown in most cases, but recently some 
proteins of the nodes of Ranvier, such as neurofascin, have been identified as the 
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possible immune targets in the disease [98].  The disease can be preceded by 
infectious and inflammatory disorders.  CIDP has been reported to occur in 
association with most rheumatologic disorders. The neuropathy may occur before, 
after or concomitantly to the initial symptoms of a connective tissue disorder.  
CIDP classic presentation is that of a subacute and progressive course of 
sensory and motor symptoms involving distal and proximal segments associated with 
arreflexia [99]. Electrophysiological studies demonstrate heterogeneous slowing of 
nerve conduction velocity with temporal dispersion and conduction block (Figure 3). 
These findings are indicative of acquired demyelination. Raised Cerebrospinal Fluid 
(CSF) protein content with normal leukocyte count (albuminocytologic dissociation) 
strongly supports the diagnosis but is not fully sensitive, nor specific for this 
condition. Hereditary neuropathies should always be included among the differential 
diagnoses, along with carcinomatous and infective polyradiculopathies. Atypical 
presentations of CIDP are frequently under diagnosed, including pure motor or 
sensory variants, focal, monomelic or asymmetrical variants. Also, in the cases were 
CIDP is associated with comorbidities such as diabetes or rheumatological disorders, 
a more extensive diagnostic work up is warranted, and nerve biopsy may be required 
[100].  
Steroids, IVIg [101] and plasma exchange (PE) are considered first line and 
equally effective therapies [102]. Steroids can be taken either orally, on a daily basis, 
or as intravenous pulses. Over 70 to 90% of patients respond satisfactorily to one of 
these three therapies [103,104]. A recent randomized controlled trial found that 
patients treated with IVIG were less likely to stop treatment because of inefficacy, 
intolerance or adverse effects compared to treatment with intravenous 
methylprednisolone. On the other hand, intravenous methylprednisolone produced 
more sustained remission after the treatment was resumed [105]. Two randomized 
trials have shown that most patients can improve in the short term with PE. However, 
relapses are frequent 1-2 weeks after discontinuation.  Adverse effects and venous 
access problems also hamper the long-term use of PE, which is therefore regarded 
as a second-line and short-term option. In refractory cases immunosuppressant 
drugs are usually introduced, although evidence for this approach is limited to small 
retrospective studies [102,106].  
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Systemic Lupus Erythematosus 
CIDP is an uncommon but important manifestation of Systemic Lupus 
Erythematosus (SLE) [107]. Less than 30 cases have been reported in the literature 
so far. The optimal treatment for the neuropathy in this scenario is not known. A 
reasonable approach is to start with first-line agents recommended for CIDP alone. 
Vina et all reported 6 cases, 3 of which failed to improve with steroids and 
subsequent IVIG therapy, 2 of those showed improvement after PE [108]. It is likely 
that the concomitance of the two inflammatory disorders reflects a more severe 
immune dysfunction. Some specialists suggest that resistant cases should be treated 
with high dose intravenous corticosteroids and immunosuppressant agents, 
especially cyclophosphamide, as it is the standard of care for SLE affecting the 
central nervous system, a manifestation that affects up to 40% of SLE patients 
[109,110]. One case report demonstrated marked improvement with anti-CD20 
chimeric monoclonal antibody Rituximab, in a patient with SLE and CIDP than had 
been resistant to multiple immunotheraphies (steroids, IVIG, PE, ciclosporin and 
ciclophosphamide) [111].  
 
Tumor necrosis factor antagonists  
Tumor necrosis factor antagonists (anti-TNF) are immunobiological drugs 
effective in the treatment of autoimmune disorders such as Ankylosing Spondylitis, 
Rheumatoid Arthritis, Inflammatory Bowel Disease and Psoriasis. Three drugs in this 
class are currently available: Infliximab, Etanercept and  Adalimumab. Although 
generally well tolerated, these drugs are implicated in induction of autoantibodies as 
well as autoimmune disease such as Systemic Lupus Erythematosus, Intersticial 
Lung disease, Multiple Sclerosis and a variety of inflammatory neuropathies [112]. 
CIDP is the most frequently reported neuropathy associated with anti-TNF drugs. Its 
occurrence has been documented as early as the first weak and as late as several 
years after the therapy initiation, especially during dosage increases [113]. Early and 
late occurrences of CIDP emphasize the importance of vigilance during the course of 
treatment with anti-TNF agents. Risks and potential benefits have to be weighted 
when initiating anti-TNF treatment in patients with a previously known neuropathy. 
	 	 53	
	
 Moderate to severely affected patients are usually treated with anti-TNF 
suspension and administration of steroids, IVIG or plasma exchange [114]. Favorable 
outcome solely with drug suspension or even dosage reduction has been reported, 
especially in mild cases [115]. However, dependence on long-term immunotherapy 
has occurred in most cases reported up to now, including patients followed for up to 
5 years [116]. Overall, the prognosis is good, with up to 2/3 of patients having near 
complete recovery. The decision to stop anti-TNF therapy depends on the severity of 
the rheumatological versus the neuropathic involvement, and should be discussed 
with the patient, rheumatologist and neurologist. It is unclear if the drug suspension 
influences positively the course of all cases once the demyelinating process has 
been triggered.   
 Guillain-Barré, acquired multifocal motor neuropathy and Lewis-Sumner 
syndrome are other examples of demyelinating neuropathies temporarily associated 
with anti-TNF agents [117]. The last one resembles clinically mononeuritis multiplex, 
but instead of axonal compromise there are multifocal areas of acquired 
demyelination. Currently, most authors consider Lewis-Sumner to be an 
asymmetrical and upper-limb predominant subtype of CIDP [115].  
Sjogren Syndrome  
Sjögren syndrome (SS) is associated with peripheral nerve disease in 1.8% to 
66% of the cases [15, 18-24]. The most prevalent forms are axonal polyneuropathy 
and sensory neuronopathy [118]. In contrast, polyradiculoneuropathy has been rarely 
reported. In a large clinical study, 4 out of 92 patients with SS and associated 
neuropathy presented with polyradiculopathy [18]. However, these patients did not 
fulfill electrodiagnostic criteria for CIDP, due to nearly normal conduction study, with 
the exception of prolonged F-waves. These findings combined with lumbar spine MRI 
scans showing abnormal gadolinium enhancement, led the author to classify these 
cases as polyradiculopathy. Rigamonti described a case of subacute inflammatory 
polyradiculopathy with full recovery with IVIG therapy [119]. There have been rare 
case reports of patient with SS fulfilling criteria for CIDP. Sanvito reported a patient 
with autoimmune alopecia and CIDP that developed SS a year after the onset of 
weakness and responded to IVIG [120]. Mochizuki reported a case of SS followed 
after two years by tetraparesis due to CIDP (confirmed by nerve biopsy). Clinical 
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symptoms were refractory to corticosteroids and showed consistent improvement 
with IVIG [121].  
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Figures and Figure Legends: 
 
Figura 3: Figure 1: Sural nerve biopsy of a 40 year-old man with polyarteritis nodosa 
demonstrating a small artery with a recent thrombosis and a chronic inflammatory 
infiltrate in the medial layer.  A: HE x100; B: HE x300. 
 
 
Figura 4: Figure 2. Clinical features in a patient with mononeuritis multiplex caused 
by systemic vasculitis: A – Dorsal interossei atrophy due to Ulnar nerve lesion. B: 
Dropped hand due to Radial nerve injury. C: purpuric rash in the dorsum of the left 
foot. D: Hypothenar atrophy and livedoid rash.   
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Figura 5: Figure 3. Typical neurophysiology findings in CIDP: A – Partial motor 
conduction block in the ulnar nerve along the forearm segment. B – Temporal 
dispersion of the compound muscle action potentials of the peroneal nerve below the 
fibular head. Note that these abnormalities were found outside entrapment sites.  
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Tabela 2: Table 1: Immune-mediated peripheral neuropathies associated with 
rheumatological Diseases: key clinical and paraclinical features 
Characteristics SN MM CIDP 
Sensory Deficits multifocal, asymmetric multifocal, asymmetric symetric 
Motor Deficits absent multifocal, asymmetric symetric 
DTR 
Hypo/arreflexia 
(global) 
Hypo/arreflexia  
(focal) 
Hypo/arreflexia 
(global) 
CSF Proteins   ↑ or normal  normal   ↑ ↑ 
Neuropathology 
Cell body damage/ 
Inflammatory 
infiltrates (CD8 
lymphocytes)  
Nerve trunks/ nerve 
infarction and axonal 
loss 
Nerves and roots/ 
Demyelination and 
inflammatory 
infiltrates 
Neurophysiology 
Purely sensory, 
multifocal  
Sensory and motor, 
multifocal, axonal 
Sensory and motor, 
diffuse, demyelinating 
Main Associated R 
diseases Sjögren Syndrome Vasculitides  SLE 
 
Abbreviations: DTR, eep tendom reflexes; CSF, cerebrospinal fluid; R, 
rheumatologic; SN, sensory neuronopathies; MM, mononeuritis Multiplex; CIDP, 
chronic inflammatory demyelinating neuropathy; SLE, systemic lupus erithematosus 
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OBJETIVOS 
 
Objetivo Geral 
 
Caracterizar clínica, eletrofisiologica, imunológica e geneticamente os 
pacientes com neuronopatia sensitiva. 
 
Objetivos específicos 
 
1. Investigar e caracterizar novas etiologias infecciosas, imunes e genéticas de 
NS; 
2. Descrever a frequência e o padrão da dor nos pacientes com NS; 
3. Caracterizar o comprometimento da função autonômica nas NS por meio de 
técnicas de neurofisiologia clínica; 
4. Avaliar a odisseia até o diagnóstico dos pacientes com NS; 
5. Propor e validar uma escala clínica de avaliação dos pacientes com NS.  
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MATERIAL E MÉTODOS 
 
Seleção dos Pacientes/Voluntários 
Foram incluídos os pacientes com diagnóstico de NS conforme os critérios 
propostos por Camdessanché e colaboradores (10) que eram  acompanhados no 
ambulatório de Neuromuscular do Hospital de Clínicas (HC) da Universidade 
Estadual de Campinas (UNICAMP), maiores de 18 anos e que concordassem em 
serem submetidos ao protocolo de estudo proposto. 
O protocolo do estudo em suas diferentes frentes de avaliação incluía a 
anamnese e exame físico neurológico com a aplicação de escalas clínicas conforme 
o objetivo de cada estudo, exames laboratoriais/imagem visando identificar possíveis 
doenças primárias associadas e investigação neurofisiológica para avaliação 
autonômica. A investigação de causas associadas incluiu:  
• Hemograma, transaminases, gama-GT, fosfatase alcalina; 
• FAN, anticorpos anti-DNA, anti-SSa (Ro), anti-SSb (La), anti-
endomísio, anti-músculo liso; 
• VHS, Eletroforese de proteínas séricas (imunofixação), pesquisa de 
crioglobulinas; 
• Sorologia para HIV, HTLV, VDRL e FTA-ABs, Hepatites B e C; 
• Dosagem sérica de vitaminas do complexo B, E, ácido fólico, cobre e 
ceruloplasmina; 
• Avaliação imaginológica para pesquisa de neoplasia com PET-CT e ou 
imagem por tomografia computadorizada/ultrassonografia. 
 
Aqueles pacientes cuja investigação de causas associadas acima descrita era 
normal, foram então considerados como portadores de NS idiopática. 
Foram excluídos os pacientes que porventura não concordassem com os 
procedimentos propostos ou ainda que possuíssem alguma contraindicação a 
alguma etapa específica do estudo. Dessa maneira o número final de pacientes para 
cada frente de avaliação foi o descrito na Figura 6: 
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Figura 6: Fluxograma descritivo do número de pacientes com neuronopatia sensitiva 
incluídos em cada frente de avaliação. 
 
A seleção de controles saudáveis obedeceu a critérios semelhantes aos da 
seleção de pacientes no sentido de que deveriam ser maiores de 18 anos, aderir de 
maneira voluntária ao procedimento proposto e assinar o termo de consentimento 
livre e esclarecido antes da sua inclusão. Como pré-requisito fundamental não 
poderiam ter nenhum diagnóstico de doença neurológica ou de condições que 
sabidamente levem ao dano do sistema nervoso periférico. 
Esse projeto foi aprovado pelo Comitê de Ética em Pesquisa da Faculdade de 
Ciências Médicas da Universidade Estadual de Campinas sob o certificado de 
apresentação para apreciação ética número 25789013.5.0000.5404 (nº parecer 
730.124). Antes da inclusão nos estudos, todos os pacientes e controles assinaram 
o Termo de Consentimento Livre e Esclarecido. 
Total	de	pacientes		
n=	61	
Avaliação	de	Dor	
n=	56	
Avaliação	
Autonômica	
n=	50		
Erro/Atraso	
Diagnóstico	
n=	48	
Valiadação	da	escala	
clínica	(SEARS)	
n=	48	
Avaliação	anti-FGFR3	
n=	42	
Sequenciamento	
completo	do	exoma		
n=	22	
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A metodologia envolvida em cada uma das frentes de trabalho será descrita 
de forma mais detalhada em cada um dos referidos artigos científicos, no entanto, 
uma descrição sumária pode ser encontrada abaixo e na Figura 7. 
	  
Figura 7: Fluxograma gerencial das frentes de trabalho exploradas. NS: 
neuronopatias sensitivas; HTLV: vírus T-linfotrópico humano; FGFR3: receptor 3 do 
fator de crescimento de fibroblasto; HAI: hepatite autoimune; SEARS: escala de 
pontuação para ataxia sensitiva. 
 
Avaliação da Dor 
Os pacientes incluídos nessa etapa foram entrevistados e encorajados a 
avaliar os tratamentos já propostos na tentativa de controle álgico. Paralelamente, foi 
feita a revisão de prontuário médico em busca de tais informações. Além do 
protocolo padrão de avaliação, foram submetidos também a avaliação por escalas 
clínicas (Inventário Breve de Dor (IBD) (20); grau de interferência nas atividades de 
vida diária conforme o IBD (21) e Leeds Assessment of neuropathic Symptoms and 
Signs (LANSS) (22)). A partir da descrição dos segmentos corporais mais 
acometidos foi construída um homúnculo de frequência com o auxilio do software 
Matlab (v. R2014b). Os tratamentos previamente utilizados também foram 
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acessados e o resultado subjetivo dos mesmos mensurado por uma escala visual 
analógica em que era marcado o percentual de alívio obtido. 
 
Avaliação Autonômica 
A avaliação do sistema nervoso autonômico dos pacientes com NS foi  
realizada incluindo os seguintes passos: avaliação clínica em busca de sinais 
clínicos de disautonomia como a hipotensão ortostática e pupila tônica de Adie, 
preenchimento da escala SCOPA-Aut (23,24), avaliação da variabilidade cardíaca 
(VCa) nos domínios de frequência e tempo, avaliação do reflexo simpático cutâneo 
nos quatro membros e avaliação quantitativa do reflexo axonal sudomotor por meio 
do QSWEAT® (WR Medical Electronic). As orientações ao paciente e o preparo do 
ambiente para a execução dos testes seguiram padronização do laboratório de 
estudo da função autonômica do Hospital de Clínicas da UNICAMP.  
Em linhas gerais, os exames foram realizados no período da manhã sendo os 
pacientes orientados a verstir-se com roupas confortáveis e evitar exercícios físicos, 
refeições copiosas, cafeína e tabaco no dia da avaliação. O ambiente onde eram 
realizados os exames eram silenciosos e tinham temperatura controlada mantendo-
se em 23o Celsius. Ao chegarem, os pacientes eram encaminhados ao local de 
exame onde permaneciam em decúbito dorsal por 15-20 minutos antes que os 
exames tivessem início. Outro ponto levado em consideração foi a suspenção de 
medicamentos que pudessem interferir com a avaliação autonômica por um período 
de duas meias-vidas nos casos em que tal suspenção não colocasse em risco a 
integridade física dos pacientes.  
 
Avaliação da Variabilidade Cardíaca 
 O protocolo completo utilizado para a avaliação da VCa encontra-se descrito 
no trabalho presente na seção de Apêndice (25). De maneira resumida, os pacientes 
eram colocados em decúbito dorsal e os eletrodos de captação posicionados nos 
quatro membros. O aparelho Poly-Spectrum-8/E digital system® (Neurosoft Ltd., 
Ivanovo, Russia) realizava a captação dos batimentos cardíacos na derivação 
periférica D2 que posteriormente seriam utilizados para a avaliação dos padrões 
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espectrais e temporais. Os batimentos cardíacos nos cinco minutos iniciais de 
exame eram utilizados para a determinação do padrão espectral (Figura 8). Sua 
decomposição em diferentes bandas de frequência era realizada por meio do 
algoritimo da transformada rápida de Fourier. A partir disso, eram identificadas as 
principais faixas de distibuição da VCa conforme sua frequência: baixas frequências 
(0,1 Hz), altas frequências (0,25 Hz) e muito baixas frequências (menores que 0,1 
Hz).  
 
Figura 8: Avaliação da variabilidade cardiaca durante cinco minutos realizada com paciente 
em repouso. A; paciente saudável. B: Paciente com diagnóstico de polineuropatia 
amiloidótica familiar e comprometimento grave da variabilidade cardiaca por disfunção 
autonômica. (Adaptado de Martinez et al., J Clin Neurophysiol. 2018) (25). 
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A avaliação da VCa no espectro temporal incluiu os seguintes testes: 
respiração profunda, manobra de Valsalva e desafio ortostático. O teste de 
respiração prufunda é realizado com seis ciclos respiratórios com inspiração e 
expiração profundas em 60 segundos. A partir daí como ilustrado na Figura 9, é 
possível a extração de dois índices: o índice expiração:expiração e a amplitude da 
arritmia sinusal.    
 
Figura 9: Variabilidade cardíaca duarante a respiração profunda. A relação 
expiração:inspiração é determinada pela média entre as diferenças de intervalo R-R durante 
expiração e inspiração nos seis ciclos avaliados. Nesse teste teste também é possivel obter 
o valor de amplitude da arritmia sinusal pela fórmula: (B – A) + ( D – C) + ( F – E) + (H – G) 
+ ( J – I) + ( L – K) /6, em que as letras representam a frequência cardíaca nos pontos 
ilustrados. (Adaptado de Martinez et al., J Clin Neurophysiol. 2018) (25). 
 
A razão de Valsalva (RV) foi calculada com a avaliação da frequência 
cardíaca durante a manobra de Valsalva. Essa manobra era realizada com a 
solicitação de que o paciente fizesse expiração forçada com a glote semiaberta até 
que fosse atingida uma pressão de 40mmHg por 15 segundos. Os 45 segundos 
subsequentes eram utilizados como forma de recuperação. A RV propriamente dita, 
era calculada conforme o apontado na Figura 10.     
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Figura 10: Manobra de Valsalva. A razão de Valsalva é dada pela divisão da frequiência 
cardíaca no ponto X pela frequência cardíaca no ponto Y. (Adaptado de Martinez et al., J 
Clin Neurophysiol. 2018) (25). 
 
Por fim, o desafio ortostático era realizado com a solicitação de que o 
paciente passasse da posição de decúbito dorsal para o ortostatismo. A partir disso, 
dois parâmetros era avaliados: a razão 30:15 e a presença de hipotensão 
ortostática. Para a avaliação da razão 30:15 divide-se o intervalo R-R por volta do 
30o batimento pelo intervalo por volta do 15o batimento cardíaco após o paciente 
adotar o ortostatismo. Nessa ocasião do desafio ortostático era avaliada também a 
presença de hipotensão ortostática com aferições da pressão arterial na posição de 
decúbito dorsal, imediatamente após a adoção do ortostatismo e após três minutos. 
A detecção da presença de neuropatia autonômica cardíaca (NAC) se deu 
conforme os critérios propostos por Vinik e Ziegler (26) os quais incluem: poder 
espectral de alta, baixa e muito baixa frequências; índice E:I; razão de Valsalva; 
razão 30:15 e presença de hipotensão ortostática. Alterações em dois dentre esses 
sete fatores indicam NAC incipiente ou limítrofe com especificidade de 98% a qual 
sobe para 100% na presença de três ou mais fatores alterados (26). 
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Avaliação quantitativa do reflexo axonal sudomotor 
A avaliação quantitativa do reflexo axonal sudomotor (QSART) foi realizada 
com o equipamento QSWEAT® (WR Medical Electronics Co, Stillwater, MN, EUA) o 
qual utiliza um software próprio (WR TestWorks Application Software; WR Medical 
Electronics Co) para construção gráfica de uma curva do volume de sudorese pelo  
tempo (Figura 11). 
 
Figura 11: Representações gráficas do exame quantitativo do reflexo axonal 
sudomotor de dois sujeitos. A: Controle saudável com exame normal; B: Paciente 
com neuronopatia sensitiva com exame alterado. 
O protocolo utilizado tomou como base o proposto por Low e colaboradores 
em publicações prévias (27-29). No entanto, pela assimetria característica da NS, 
uma modificação a esse protocolo foi imposta: ao invés de avaliarmos os pacientes 
em apenas um hemicorpo nós realizamos a avaliação bilateral mantendo os sítios 
padronizados: face ventral distal do antebraço (nos 25% distais da distância 
compreendida entre o epicôndilo ulnar e o osso pisiforme), face lateral proximal da 
perna (aproximadamente cinco centímetros distalmente à cabeça da fíbula), face 
medial distal da perna (aproximadamente cinco centímetros proximalmente ao 
maléolo medial) e dorso do pé (próximo ao músculo extensor dos dedos) (Figura 
12). Desta maneira, foram estudados oito pontos por paciente resultando em 400 
pontos avaliados acerca do volume de sudorese. É importante lembrar que o 
posicionamento dos eletrodos meridionais era precedido por limpeza da área  a ser 
examinada. 
	 	 78	
	
 
Figura 12: Locais de avaliação quantitativa do reflexo axonal sudomotor. 1: face 
ventral distal do antebraço; 2: face lateral proximal da perna; 3: face medial distal da 
perna e 4: dorso do pé. 
 
 De maneira resumida, para a avaliação do QSART foram seguidas as 
orientações gerais aos pacientes para o estudo do sistema nervoso autonômico. O 
aparelho QSWEAT® possui um higrômetro (Figura 13 - área demarcada pelo 
retângulo) capaz de detectar as variações de umidade advindas da passagem de ar 
seco pela superfície da pele em avaliação. Para tal, a captação do ar do ambiente é 
realizada por uma bomba que o impulsiona até uma substâcia que age como 
dessecante (#5190, WR Medical Electronics Co., Stillwater, MN) (Figura 13 - área 
demarcada pela elípse). Após essa passagem, uma série de sensores faz a leitura 
da umidade e temperatura do ar que, por sua vez, será impulsionado, a um fluxo 
constante de 60 centímetros cúbicos por minuto, por tubos de teflon até a área de 
pele a ser avaliada.  
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Figura 13: Aparelho QSWEAT®. A área demarcada pelo retângulo mostra o 
compartimento que abriga o higrômetro, sensores e as bombas de captação e 
impulsionamento do ar ambiente. A área demarcada pela elipse vermelha destaca o 
compartimento com a substância dessecante. 
 
 Finalmente, o fluxo de ar chega até os eletrodos meridionais (Figura 14 A) 
que permitem o contato do ar seco vindo do aparelho com o vapor de suor da área 
examinada (aproximadamente 0,3 centimetros quadrados por ponto estudado) 
(Figura 14 B). O ar proveniente das áreas em avaliação e umidificado pelo QSAT 
segue de volta ao aparelho onde são ralizadas novas medidas de umidade e 
temperatura. O resultado dessa leitura comparativa  (umidade do ar seco 
inicialmente impulsionado contra a umidade do ar vindo da área examinada) é dado 
em microlitros de suor. 
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Figura 14: A: eletrodo meridional; B: eletrodo meridional acoplado aos tubos que 
trazem e levam o ar até o higrômetro; C: iontoforizador acoplado ao sistema 
mostrado em B. 
 O racional que permite a avaliação do QSART leva em consideração a 
fisiologia do reflexo axonal sudomotor colinérgico. Para que o mesmo seja obtido, 
além do aparelho e dos componentes já descritos, uma solução de acetilcolina a 
10% é colocada na câmara do eletrodo meridional e, por meio de iontoforese (uso 
de corrente elétrica como método de entrega dérmica de subtâncias), induz-se o 
QSART. Essa indução ocorre na forma das respostas direta (não quantificadas pelo 
QSWEAT) e indireta (quantificáveis pelo QSWEAT) (Figura 15) (30). O aparelho 
utilizado para a iontoforese (Iontophor® II modelo 6111PM/DX) (Figura 14 C) fornece 
uma corrente constante de 2mA durante, cinco minutos (fase ativa da sudorese) e 
nos cinco minutos restantes, ocorre a fase reflexa da sudorese. Dessa maneira, o 
exame tem a duração de 10 minutos para que os quatro pontos de um hemicorpo 
sejam estudados (descontando-se o tempo antes do início da iontoforese necessário 
para que seja alcançada uma linha de base estável para a leitura do volume de 
suorese). Os volumes de sudorese obtidos são graficamente traduzidos em tempo 
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real dando origem às curvas cujas áreas representam o volume total de sudorese 
(Figura 11 A).  
 
 
Figura 15: Representação esquemática do reflexo sudomotor. A esquerda pode-se 
observar a resposra direta de sudorese obtida com a iontoforese de acetilcolina 
(seta verde). Tal resposta ocorre na região da pele em contato com a câmara do 
eletrodo meridional que contém a acetilcolina e não é utilizada para fins 
quantitativos. A despolarização gerada pela acetilcolina gera uma resposta 
antidrômica que atinge as ramificações nervosas e por via ortodrômica estimula as 
glangulas sudoríparas adjacentes. As respostas ssim obtidas são denominadas 
resposta indireta de sudorese, essa sim quantificada pelo QSWEAT. (Adaptado de 
Buchmann et al., Clin Auton Res. 2018) (30). 
  
Avaliação da resposta simpático-cutânea 
 A resposta simpático-cutânea foi realizada nos quatro membros de maneira 
concomitante em aparelho de quatro canais (Nihon Kohden Neuropack M1 
Electromyographer, Nihon Kohden®, Tokyo, Japan). A instrumentação era a 
seguinte: sensibilidade de um mV por divisão; amostragem de 10 segundos e filtros 
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de alta e baixa frequência de 1kHz e 0,5Hz. Os eletrodos G1 e G2  foram colocados 
em palmas e plantas e dorso de mãos e pés respectivamente (Figura 16 A) (31). Era 
feito estímulo elétrico doloroso na topografia do forâme supraorbitário (Figura 16 B).  
 
	
Figura 16: A: Montagem dos eletrodos utilizados na avaliação da resposta simpático-
cutânea. B: Local de estímulo estímulo doloroso utilizado para desencadear a 
resposta simpático-cutânea. 
	
A presença da resposta era acessada visualmente após três estímulos e, 
caso estivessem presentes, suas latências eram aferidas (Figura 17). 
 
 
Figura 17: Exemplos de resposta simpático-cutânea presente (A) e ausente (B) nos 
quatro membros.  
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Erro e atraso diagnóstico 
Nessa frente do trabalho, os pacientes foram convidados a recuperar dados 
acerca do período de início do quadro clínico de NS que incluíam tanto o relato 
pessoal como relatórios médicos, receituários, encaminhamentos prévios além da 
revisão de prontuário médico. Foram então obtidos o tempo de duração da doença, 
idade de início, número de especialistas consultados até o diagnóstico de NS,  
diagnósticos e prescrições equivocadas. 
 
Validação de escala clínica 
Após reunião entre três especialistas em doenças neuromusculares, foi 
elaborada uma série de quesitos que englobam as características clínicas 
fundamentais aos pacientes com NS e que necessitassem de um mínimo de 
instrumentos para o seu preenchimento. Chegou-se então ao instrumento SEARS 
(sensory ataxia rating scale) composto por 10 itens.  
O processo de validação ocorreu em duas etapas: a primeira envolvendo 48 
pacientes e que se prestava à avaliação interobservador na qual dois neurologistas 
avaliavam sequencialmente e de maneira isolada o mesmo paciente e a segunda 
que correspondia a validação intraobservador que envolveu 16 pacientes os quais 
eram avaliados pelo mesmo examinador em um período de até 30 dias entre as 
avaliações. Feita essa etapa, os escores finais foram comparados a instrumentos 
corriqueiros utilizados na avaliação de pacientes com ataxia (SARA - Scale for the 
assessment and rating of ataxia); neuropatia periférica (ISS - INCATT sensory sum 
score) e quedas e equilíbro (EBB – Escala de balanço de Berg) com o objetivo de 
validação do construto em si.  
 
Avaliação do anticorpo anti-FGFR3 
Os anticorpos anti-FGFR3 foram inicialmente descritos no contexto das NS 
em 2015 pelo grupo de pesquisa liderado pelo professor JC Antoine (12). Desde 
então, esforços vem sendo empregados na tentativa de melhorar o delineamento da 
caracterização fenotípica dos pacientes com anti-FGFR3. Nesse sentido, iniciou-se 
um estudo colaborativo entre a Universidade Estadual de Campinas (UNICAMP) e o 
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Centre Hospitalier Universitaire de Saint-Étienne. Os pacientes com NS 
acompanhados no serviço de doenças neuromusculares do Hospital de Clínicas da 
UNICAMP que concordaram em participar eram submetidos à coleta de 10mL de 
sangue periférico. As coletas foram realizadas de maneira consecutiva sendo 
incluídos 42 pacientes com NS. O sangue era então centrifugado para a separação 
entre elementos figurados e plasma o qual era armazenado em freezer em 
temperatura de -80o Celsius. As mesmas foram enviadas ao centro francês onde foi 
realizada a quantificação dos níveis de anti-FGFR3 pelo método ELISA. Os 
resultados obtidos eram confrontados aos obtidos de um grupo de pacientes 
saudáveis a partir do qual os níveis fisiológicos e patológicos foram determinados 
(Figura 18). 
 
 
Figura 18: Representação gráfica dos níveis do anticorpo anti-FGFR3 em dois 
pacientes com o diagnóstico de neuronopatia sensitiva. A: anti-FGFR3 negativo; B: 
anti-FGFR3 positivo.  
 
Sequenciamento Completo do Exoma 
 Os pacientes incluídos nessa avaliação específica possuíam como critério de 
inclusão, além da idade maior que 18 anos, não possuir nenhuma etiologia 
associada à NS, isto é, todos eram idiopáticos. Aqueles pacientes que concordaram 
em participar assinaram o termo de consentimento livre e esclarecido e foram 
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submetidos à coleta de aproximadamente 30mL de sangue periférico. Esse material 
foi processado com o objetivo de extrair o DNA leucocitário. 
 Uma vez extraído e purificado, o DNA foi então utilizado para o 
sequenciamento completo do exoma. As amostras foram fragmentadas e os éxons 
capturados (kit Agilent Sureselect all exon v.6 - Agilent® Santa Clara, CA, EUA) para 
serem, em seguida, sequenciados (Illumina HiSeq 2500®). Depois, os dados foram 
alinhados e a chamada de variantes foi executada.  As filtragens e comparações às 
bases de dados existentes foram realizadas utilizando a plataforma Varstation® 
(www.app.varstation.com), conforme parâmetros descritos na sessão de Resultados 
correspondente (página 121). 
 
Neuronopatia Sensitiva no contexto da hepatite autoimune (HAI) 
 A descrição das NS no contexto da HAI encontra relatos anedóticos de quatro 
casos na literatura (32-35). Dessa forma, com o objetivo de avaliar sistematicamente 
os pacientes com HAI em busca de alterações consistentes com NS, essa frente de 
trabalho foi executada. Aqui, a pergunta principal foi determinar a frequência e as 
características da NS associada à HAI. Os pacientes acompanhados  no ambulatório 
de Gastroenterologia do HC da UNICAMP e que apresentavam o diagnóstico de HAI 
conforme os critérios internacionais (36) foram convidados, de maneira consecutiva, 
a participar dessa avaliação. Aqueles maiores de 18 anos que concordaram em 
participar assinaram o termo de consentimento livre e esclarecido antes de sua 
inclusão no protocolo.  
 Esse protocolo de avaliação era composto por anamnese na qual eram 
obtidos os dados demográficos e acerca das características da HAI, seguido por 
exame físico neurológico e aplicação das escalas INCAT sensory sum score e 
LANSS. Os pacientes em sequência eram submetidos à eletroneuromiografia e 
aqueles que porventura apresentassem o padrão de NS eram também convidados a 
realizar em outra data, a avaliação da variabilidade cardíaca e do reflexo quantitativo 
sudomotor axonal.  
 Incluimos também, na perspectiva de reduzir o fator de confusão inerente à 
lesão hepática,  pacientes com hepatite B crônica. Tais pacientes foram submetidos 
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ao mesmo protocolo de avaliação anteriormente descrito para os pacientes com HAI. 
Somente os pacientes com sinais de lesão hepática de magnitude suficiente para 
que fosse indicado o tratamento antiviral (37) iniciaram o estudo. Tal critério de 
inclusão serviu para que os pacientes classificados como portadores inativos (estado 
de imunotolerância relativa) fossem excluídos uma vez que não têm lesão hepática 
significativa (37). 
   
Análise Estatística  
 A análise estatística foi individualizada para cada estudo, já que cada um 
exigiu um nível distinto de complexidade. Além disso, a abordagem estatística 
empregada é diferente entre os estudos, particularmente no de validação da 
SEARS. Sendo assim, a descrição completa da análise estatística encontra-se nos 
estudos correspondentes presentes na seção “Resultados” (páginas 87 a 192). 
	 	 87	
	
RESULTADOS 
 
	
Estudos 1, 2 e 3: Contribuições ao 
diagnóstico etiológico 
	
	
	
	
	
Sensory neuronopathy heralding human T-cell lymphotropic virus type I myelopathy. 
 
Alberto R. M. Martinez, Raphael F. Casseb, Carlos R. Martins Jr, Anamarli Nucci, 
and Marcondes C. França Jr. 
 
 University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. 
 
Word count: Title: 10, Abstract: 36 Manuscript: 792, References 10, Figures: 1 
Tables: 0 
Keywords: Sensory neuronopathy, ganglionopathy, HTLV, HTLV- myelopathy. 
Running Title: HTLV-1-related sensory neuronopathy and myelitis. 
	 	 88	
	
Funding agencies: Fundação de Amparo à Pesquisa do Estado de São Paulo 
(FAPESP) (Grant #13/01766-7 and #2014/19786-7) and Coordenação de 
Aperfeiçoamento de Pessoal de Nível Superior (CAPES).  
Relevant conflicts of interest/financial disclosures: Nothing to report related to this 
paper. 
Correspondence to: Dr. Marcondes Cavalcante França Jr, Department of Neurology, 
University of Campinas – Rua Tessália Vieira de Camargo, 126. Campinas, SP-
13083-887, Brazil (tel.: +551935219217; fax: +551935217933; e-mail: 
mcfrancajr@uol.com.br 
 
 
Abstract 
Neurological phenotypes of Human T-cell lymphotropic virus type I (HTLV-1) are 
numerous and rarely may not manifest the classic HTLV-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP). We report a case of HTLV-1-
related sensory neuronopathy heralding the classic HAM/TSP. 
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Human T-cell lymphotropic virus type I (HTLV-1) is an endemic retrovirus in 
certain parts of the world (1). Its relationship with humans is traced back to 
thousands of years what may have evolved to a more “harmonious” host/intruder 
interaction (2). Despite the fact that the majority of HTLV-1 carriers are 
asymptomatic, the lifetime risk for a neurological complication varies between 1-
4%(3). The most common neurological phenotype related to HTLV-1 infection is the 
HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or simply 
HTLV-1 myelopathy. Moreover, virtually all components of the nervous system have 
been targeted in the context of HTLV-1 infection leading to several distinct 
phenotypes (1). 
One of these phenotypes is sensory neuronopathy (SN). SN is a rare 
neurological disease, which emerges from the damage of the dorsal root ganglia 
(DRG) leading to asymmetrical non-length-dependent sensory deficits and sensory 
ataxia (4).  
We report here a Brazilian patient who initiated the core features of HAM/TSP 
15 years after coping with HTLV-1-related SN. The overlap between peripheral and 
central impairment in HTLV-1 infected patients is extremely rare and SN heralding 
HAM/TSP has not, as far as we know, been reported before. The research ethics 
committee of the University of Campinas (UNICAMP) approved this study. 
Case Report 
 A 66-year-old woman from Minas Gerais (a southeast state in Brazil) started 
sensory complaints in her right hand when she was 50 years old, described as subtle 
paresthesias and loss of dexterity. These symptoms ascended to the entire limb in 
few weeks. During the next 6 months, she noticed gait imbalance and the 
aforementioned sensory deficits spread first towards the left lower limb and in about 
one month, the left arm and right leg. At this point, mild constipation was present. 
These manifestations progressed from onset up to nadir for 2 years. 
 After six years of the symptoms onset, she was referred to our center, and at 
that time neurological examination demonstrated marked asymmetrical abnormalities 
of sense position and vibration in the trunk and in all limbs, worse in the left lower 
limb and in the right upper limb. She displayed pseudoathetosis in the upper limbs 
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and Romberg sign was identified. Deep tendon reflexes (DTR) were absent and she 
had orthostatic hypotension. Motor functions were unremarkable except for 
pseudoparesis in the left lower limb.  Neurophysiological studies revealed reduction 
of sensory potential amplitudes in both medians, left radial and right ulnar and sural 
nerves. The sensory potentials of right radial, left ulnar and sural nerves were absent. 
Motor conduction and needle EMG evaluation were normal. SN was considered and 
further investigation ruled out the most common metabolic, toxic and rheumatologic 
etiologies including Sjögren syndrome. Infectious workup revealed positive 
serologies for HTLV-1 both in peripheral blood and cerebral spinal fluid. The 
symptoms remained relatively stable until the beginning of 2016 when she 
experienced worsening in the orthostatic hypotension and a noticeable change in her 
gait, which besides the ataxic features had now overt hypertonia of the leg adductors. 
Brisk DTR in the lower limbs and right arm were now noticed. Another important 
symptom was marked worsening of her urinary incontinence.  
 Magnetic resonance imaging was performed and demonstrated symmetric 
pre-central gyri T2-weighted hyperintensities in opposition to a previous normal scan 
4 years ago (Figure 1). Although unspecific, this finding is often found in diseases 
characterized by Wallerian degeneration of the corticospinal tracts (CST) (5). 
 
Discussion 
 We reported this unusual patient who developed two distinct neurological 
phenotypes related to HTLV-1 infection. Her first neurological symptoms were 
sensory ataxia with asymmetric non-length dependent sensory deficits: the hallmarks 
of SN. She indeed fulfilled all the proposed criteria for this disease (6). The classical 
neurological phenotype of HAM/TSP due to CST damage only took place 15 years 
after SN onset. Although SN has already been described in relation with HTLV-1 
infection (7), this is, to the best of our knowledge, the first case describing the 
association of both phenotypes in a single patient and the third description of HTLV-
1-related SN.  
 There are several hypotheses to explain the pathogenesis of neurological 
damage in HTLV-1 infection (2,8). The most comprehensive one takes into account 
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both virological and host factors. Instead of direct viral neuronal damage (9), what 
seems to occur is an exaggerated proinflammatory cellular-mediated immune 
response induced by the virus. This ultimately results in neuronal and glial cell 
damage (1,2,8). 
 A peculiar anatomical feature of the DRG might also help to explain HTLV1-
related SN. The loose blood-neuron barrier due to fenestrated capillaries that supply 
the DRG (10) would make it easy for cytokines and antibodies triggered by the viral 
infection to reach DRG neurons. In conclusion, one should remind of HTLV1 in the 
list of etiologies for SN. It is also important to highlight that SN might herald the onset 
of HAM/TSP for several years as herein described. 
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Figure Legend 
Figura 19: Figure 1: Axial section. T2-weighted brain magnetic resonance imaging 
demonstrating bilateral pre-central gyri hyperintensity (arrows). This finding may 
suggest a pyramidal impairment.
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Neurological disease is one of the major complications of the Zika virus (ZIKV) 
infection, and the peripheral nervous system is one of the main targets (1,2). In fact, 
outbreaks of Guillain-Barre syndrome (GBS) were reported in French Polynesia and 
Latin America soon after ZIKV epidemics (1, 3). Most reported patients had a rather 
typical GBS presentation with rapid ascending paralysis, diffuse areflexia and facial 
diplegia. Recently, atypical phenotypes have been also reported, such as the Miller-
Fisher syndrome (MFS) and small fiber neuropathy (4, 5). 
We now report a Brazilian patient with typical clinical and electrophysiological 
findings of a sensory neuronopathy (SN) that developed weeks after ZIKV infection. 
This description broadens the clinical profile of ZIKV-related neurological disease. 
Case report 
On June 2015, a 42-year old previously healthy woman from Salvador 
(Northeastern Brazil) had a febrile disease accompanied by mild erythematous rash 
and joint pain that lasted 5 days and improved spontaneously. Three weeks later, 
she developed progressive numbness and gait abnormalities. When first seen 5 days 
after the onset of neurological symptoms, she was barely able to walk and required 
bilateral strong support. On examination, she was fully alert, had intact cranial nerve 
functions and preserved muscle strength overall. There were marked deep sensory 
abnormalities in a multifocal pattern (both legs, right arm and truncal region) and 
clear afferent ataxia with positive Romberg sign. Diffuse areflexia. Autonomic 
function remained normal throughout disease course. CSF analysis demonstrated 
protein 10 mg/dL, glucose 69 mg/dL, and <1 white blood cell/µL. MRI of the brain and 
spinal cord had unremarkable findings. Neurophysiology was typical for SN (Table 1). 
Urine PCR reactions were positive for ZIKV RNA. She received IVIg (0.4mg/Kg/day 
for 5 days), but felt no significant improvement and was discharged 10 days after 
admission. Thereafter, she pursued physical rehabilitation and noticed some 
functional gains in the coming months. We were able to evaluate her one year later. 
She is now able to walk, but requires a cane. Sensory ataxia is still severe and 
pseudoathetosis of the upper limbs is now evident. There is definitely no weakness 
or muscle atrophy. 
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Discussion 
This unusual patient presented with asymmetrical and severe deep sensory 
deficits, but with preserved muscle strength - the key criteria of SN (6). Nerve 
conduction studies revealed widespread sensory abnormalities, but interestingly 
sural SNAP amplitudes were not as affected as median or ulnar SNAP amplitudes. 
Moreover, motor nerves and EMG all had normal responses.  
An important differential diagnosis would be MFS. Both SN and MFS share 
ataxia as the core clinical feature. In addition, a pattern of predominant sensory NCS 
abnormalities is common for both disorders. Testing for anti-GQ1b antibodies would 
have been useful, but unfortunately, it was not available at the time. Despite that, we 
strongly believe that this was not MFS, since she did not have cranial nerve 
involvement and especially because of her long-term evolution with persistent deficits 
(with are exceedingly rare for MFS). There is a previous report of ZIKV-related 
sensory polyneuropathy, but in that case deficits followed a symmetric length-
dependent distribution, small fibers were predominantly affected and NCS showed 
exclusive sural abnormalities. 
This seems to be a post-infectious rather than a true direct complication of 
ZIKV infection. First because there was a 3-week delay between infection and SN 
onset (similar to GBS). Second, because CSF profile at disease onset was not 
compatible with active viral infection. ZIKV might have triggered an aberrant immune 
response that inadvertently targeted the dorsal root ganglia. Molecular mimicry may 
play a role in this process (7). In conclusion, ZIKV should be included in the list of 
infectious etiologies that may trigger acute/subacute SN. 
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Tablela 3: Table 1. Motor and sensory nerve conduction studies. 
 
 
 
 
 
 
 
 
 
 
 
- H reflexes were absent on both sides, EMG – No signs of active or chronic 
denervation. 
Sensory nerves Amplitudes (µV) sNCV (m/s) 
Median R / L 3.1 / - 50.4 / - 
Ulnar R / L 1.3 / - 53.0 / - 
Sural R / L 3.8 / 3.6 45.1 / 41.7 
Motor nerves Amplitudes (mV) mNCV (m/s) 
Median R / L 11.2 / 8.4 52.6/48.9 
Ulnar R / L 15.4 / 11.5 52.3 / 54.5 
Peroneal R / L 6.0 / 5.8 46.0 / 42.8 
Tibial R / L 11.2 / 13.1 46.8 / 45.8 
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Abstract 
 
Background: Neurological manifestations have been identified in the context of 
autoimmune hepatitis (AIH). Previous case reports highlighted the association 
between AIH and sensory neuronopathy (SN). Despite that, little is known about the 
frequency of AIH-related SN and its clinical/neurophysiological profile. Moreover, it is 
not clear whether SN is an AIH-specific manifestation or instead related to chronic 
liver dysfunction.  
Methods: We evaluated 70 consecutive patients with AIH and compared their 
findings with 52 patients with chronic active hepatitis B (HepB). All subjects 
underwent extensive clinical and neurophysiological evaluation. We attempted to 
determine risk factors for SN by comparing patients with and without AIH-SN. Group 
comparisons were performed with Student´s t-test and chi-square. P-values < 0.05 
were considered significant.  
Results: Mean ages of patients in the AIH and HepB groups were 42.2±16.3 and 
51.7±13.6, respectively. Gender proportion was slightly different in both groups 
(male: female - 14:56 and 29:23, p<0.01). We found carpal tunnel syndrome, 
radiculopathies and polyneuropathies in the AIH group, but the frequency of each of 
these manifestations was similar to that found in the HepB group.  In contrast, SN 
was only found among patients with AIH (5/70 vs 0/52, p=0.04); the overall 
prevalence of AIH-related SN was 7%. On average, these were women in the 40s 
with asymmetric onset of sensory deficits that evolved over few years to disabling 
proprioceptive ataxia combined with marked dysautonomia. Neurological disability 
and hepatocellular damage did not follow in parallel. Anti-FGFR3 antibodies were 
found in 3/5 (60%) of the patients with AIH-related SN. We could not identify clinical 
or demographic predictors of SN in the context of AIH.  
Conclusion: Sensory neuronopathy, but not other peripheral nervous system 
syndromes, is a specific neurological manifestation of autoimmune hepatitis. It is 
often disabling and, in contrast to hepatocellular damage, does not respond to 
immunosuppression.  
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Background 
 Autoimmune hepatitis (AIH) is a chronic liver disease characterized by 
persisting hepatocellular inflammation and necrosis that often leads to cirrhosis [1,2]. 
The disease typically affects young women (7-8:1) and is more frequent in 
Caucasians. There is a significant overlap between AIH and the other 2 immune-
mediated liver diseases: primary biliary cirrhosis and primary sclerosing cholangitis. 
In addition, several extrahepatic autoimmune disorders associated to AIH have been 
described [3,4]. 
 Neurological manifestations have been identified in the context of AIH [4-8]. 
Most reports described central nervous system diseases, particularly multiple 
sclerosis [9]. Regarding peripheral nervous system (PNS) involvement, there are 
very few studies published so far [8,10]. Despite that, there are 4 independent case 
reports that highlighted the association between AIH and sensory neuronopathy (SN) 
[11-14]. The latter is an uncommon neuromuscular illness with presumed 
autoimmune cause and characterized by primary damage to the cell bodies of 
neurons located in the dorsal root ganglia [15,16]. These data raise the possibility 
that AIH and SN are somehow etiologically associated, since both are rare diseases. 
However, it is also possible that SN emerges because of chronic liver failure rather 
than by a shared immune mechanism. In this context, we designed the current study 
to determine the frequency and the clinical/neurophysiological profile of AIH-related 
SN. We also investigated whether SN is an AIH-specific manifestation by looking at 
its frequency in another cohort of chronic liver disease (active hepatitis B - HepB). To 
accomplish that, we recruited a representative cohort of patients with AIH and 
hepatitis B (HepB) to undergo extensive clinical, immunological and 
neurophysiological studies.  
   
Methods 
Patient Selection  
 The study took place at the neurology, hepatology and infectious diseases 
units at the University of Campinas (UNICAMP) hospital. Data were collected 
between April 2016 and April 2018.  
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 We included consecutive adult patients with AIH regularly followed at 
UNICAMP hepatology clinic. These subjects were diagnosed and classified 
according to the 1999 International Autoimmune Hepatitis Group criteria [17]. 
 The second group consisted of patients with chronic HepB followed at 
UNICAMP infectious disease clinic. We selected only those subjects with active liver 
damage and formal indication to start antiviral treatment according to the current 
recommendations [18]. We excluded those subjects that presented only serological 
evidence of previous HepB exposure or were asymptomatic carriers, conditions with 
no evidence of ongoing hepatocellular damage.  
The Ethical Research Committee of the University of Campinas approved the study 
protocol under the number 25789013.5.0000.5404 and the research took place under 
the recommendations of the 1964 Declaration of Helsinki and its later amendments. 
Before enrollment, all patients agreed and signed an informed consent form. 
 
Study Protocol 
For each patient, we first collected demographic and clinical data, focused in 
the investigation of neurological symptoms. Afterwards, they underwent detailed 
neurological examination. Two scales - the INCAT sensory sum score (ISS) and the 
Leeds assessment of neuropathic symptoms and signs (LANSS) were then 
employed to assess the extent/severity of sensory deficits and the presence of 
neuropathic pain, respectively [19,20].  
Neurophysiological evaluation was performed in a Nihon Kohden 
electromyographer (Nihon Kohden Neuropack M1 Electromyographer, Nihon 
Kohden®, Tokyo, Japan) in a quiet room under controlled temperature (23o Celsius). 
The study protocol included both motor (median, ulnar, tibial, peroneal) and sensory 
nerves (median, ulnar, radial, sural) in both sides. Standard stimulation and recording 
sites were employed [21]. We recorded the amplitudes as well as the conduction 
velocities of SNAP and CMAPs. The USMAR index – a measure of sensory vs motor 
disproportionate involvement in PNS diseases – was then computed [22]. EMG was 
performed using a disposable monopolar needle; the following muscles were 
assessed: first dorsal interosseous, triceps brachii, deltoid, tibialis anterior, 
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gastrocnemius and the vastus lateralis.  Sympathetic skin responses from palms and 
soles were recorded on both sides following supraorbital electrical stimulation [23].   
 Those patients who met the diagnostic criteria for SN [24] underwent 
additional testing. To evaluate autonomic complaints, the scales for outcomes in 
Parkinson’s disease - autonomic dysfunction (SCOPA-Aut) questionnaire was 
employed (range 0 -69; higher scores, more dysautonomia) [25]. Later, we assessed 
the heart rate variability and the quantitative sudomotor axonal reflex test (QSART) 
following previously published guidelines [26,27]. Overall disability was quantified 
using the modified Rankin scale (mRS) [28]. We used the Scale fot assessment and 
rating o ataxia (SARA) to measure the severity of ataxia [29]. Finally, we investigated 
the serum levels of the recently described antibody against fibroblast growth factor 
receptor type 3 (anti-FGFR3). This has been proposed as a marker for immune-
mediated SN [30].  
 
Statistical Analysis  
We employed descriptive statistics to present demographic and clinical data. 
Comparisons between groups were performed by two-sample t test, Pearson's χ2 
and Fisher`s exact tests when appropriate, considering p values <0.05 as statistically 
significant. 
 
Results 
 
 A total of 70 patients with AIH (60 type 1, 4 type 2 and 4 could not be 
classified) and 52 with HepB were enrolled. Clinical and demographic data are 
summarized in Table 1. Considering markers of liver damage, both groups had 
significant alanine aminotransferase (ALT) elevations (upper limit normal (ULN) of 35 
U/L for men and 25 U/L for women); on average, 13 and five times ULN, respectively. 
Both groups had similar proportions of cirrhotic patients (Table1). All HepB patients 
were receiving antiviral therapy (39 with entecavir and 13 with tenofovir disoproxil 
fumarate). 
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 Neurologic symptoms were present in both groups. They encompassed from 
unspecific complaints such as fatigue or paroxysmal paresthesias to more disabling 
manifestations. Indeed, SN was only found among patients with AIH (5/70 vs 0/52, 
p=0.04); in this cohort, the overall prevalence of AIH-related SN was 7%.  Clinical 
examination and nerve conduction studies/EMG revealed other PNS syndromes in 
both cohorts, such as carpal tunnel syndrome, lumbar radiculopathies and 
polyneuropathies (table 1). However, the frequency of each of these syndromes was 
similar in both AIH and HepB groups. None of the patients had clinical evidence of 
central nervous system damage. 
 Detailed demographic, clinical, laboratorial and neurophysiological data of the 
5 patients with AIH-related SN are described in Table 2. On average, these were 
women with asymmetric onset of sensory deficits that evolved over few years to 
disabling proprioceptive ataxia combined with marked dysautonomia.  Three of these 
patients had liver biopsy, the main findings of which are highlighted in Figure 1. 
Three out of the five patients tested positive for anti-FGFR3 antibodies. Interestingly, 
neurological and hepatocellular damage did not run in parallel and had different 
responses to immunosuppressive therapy. The ALT levels and the concurrent mRS 
course over time, for each of these five patients, are displayed in the Figure 2. We 
were not able to identify clinical or demographic factors associated with increased of 
risk of developing SN among patients with AIH. Indeed, demographic data (age, sex) 
and AIH features (age at the disease onset, time since AIH diagnosis, peak ALT and 
liver cirrhosis) were similar between AIH/SN+ and AIH/SN- groups (p>0.05).   
 
Discussion 
 
 AIH-related neurological manifestations have been considered extremely rare 
with prevalence that barely reaches 1% of patients in several cohorts [4-8]. In this 
survey, we performed a comprehensive clinical/neurophysiological investigation and 
found a much higher frequency. Almost half of the patients (34/70) had abnormal 
NCS/EMG. Some of the PNS syndromes identified, such as CTS and 
radiculopathies, are in general age-related phenomena and have no true relationship 
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with AIH. Regarding polyneuropathy, we believe that it may reflect the underlying 
liver dysfunction, rather than immune compromise because its frequency was no 
different between AIH and HepB groups.  
The scenario is different for SN. This disabling neurological condition should 
be considered in the context of patients with AIH. In our cohort, its prevalence 
reached 7%. In contrast to the other PNS manifestations, it was not observed in the 
HepB group. This suggests that the association of AIH and SN in not due to hepatic 
damage per se, but actually because of possible shared autoimmune mechanisms.  
Despite that, the exact shared pathophysiological pathways still remain to be fully 
described. Mutual epitopes in DRG and in hepatocytes may trigger, in different 
periods during the disease course, a specific response that results in one of these 
phenotypes. One possible contributor to this puzzle may rely upon the presence of 
the anti-FGFR3 antibodies; we indeed found high titers in a significant proportion of 
our AIH-SN patients (3/5=60%). FGFR3 is an important protein for neural migration 
signaling in the central nervous system. It is upregulated in the PNS, particularly in 
the DRG, after neural injury and during the regeneration processes [31,32]. Recently, 
Antoine and cols have described the association of anti-FGFR3 antibodies in a 
subset of patients with SN [30]. The Human Protein Atlas [33,34] demonstrated that 
FGFR3 has reduced expression in normal liver, but this expression becomes 
moderate in liver cancer [33-35]. The same might be true for a chronically inflamed 
liver, such as seen in AIH. These data suggest that FGFR3 may be the possible 
shared epitope between AIH and SN. Further studies looking at the expression of this 
protein in AIH liver samples and in patients with AIH/SN- will help to clarify this issue. 
Another major contribution of this study is the phenotypic characterization of 
AIH-related SN. In fact, including the five ones herein reported, a total of nine AIH-SN 
cases have been, to our knowledge, described (three in case reports [11-13] and one 
as part of a SN cohort [14]). Pooled together, the average AIH-SN patient is a woman 
(eight women and one man) whose first symptoms were neurologic or liver-related 
(four neurologic, four liver-related and for one patient it was not clear) in the 4th 
decade. SN-related symptoms follow a chronic course (six chronic, two subacute and 
one acute) with a poor response to immunosuppressive treatment [11-14]. In fact, as 
it may be seen in Figure 2, immunosuppressive treatment has lead to a substantial 
decrease in ALT levels but neurologic impairment, expressed by mRS scores, 
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remained almost stable. This is similar to the results observed in a primary Sjögren 
syndrome-related SN cohort [36]. 
This study, despite the innovation of a systematic neurological and 
neurophysiological approach to AIH, carries some limitations: limited number o AIH 
patients and a possible referral bias due to a facilitated access to the neurologic clinic 
from hepatology clinic and vice-versa. This may have overestimated the frequency of 
AIH-SN probably due to low thresholds of clinical suspicion. The conclusions herein 
presented would benefit from an increase in the number of evaluated AIH patients 
and from a multicentric collaboration. Hence, bearing in mind that SN and AIH are 
both rare conditions, their association seems not to be spurious and should be 
remembered if elevated biomarkers of hepatic aggression are found in a patient with 
SN or if sensory ataxia with asymmetric and non-length dependent sensory deficits 
emerge in a patient diagnosed with AIH. 
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Tables 
Tabela 4: Table 1: Demographics, clinical and neurophysiological characteristics of 
autoimmune hepatitis and hepatitis B groups. 
 
 
Autoimmune 
Hepatitis* 
(N=70) 
Hepatitis B* 
(n=52) 
p 
value
s 
Age (y) 42.2±16.3 51.7±13.6 <0.01 
Gender (M:F) 14:56 29:23 <0.01 
Age at diagnosis (y) 34.1±17 38.2±15.5 0.18 
Disease duration (y) 8.2±5 13.5±9.4 <0.01 
HBV DNA IU/mL n/a 14,173,077±35,790,516	 n/a 
Liver cirrhosis (yes/no) 44/26 27/25 0.26 
Neurologic Symptoms 
(yes/no) 
30/40 21/31 0.85 
Sensory Neuronopathy (%) 5(7.1%) 0 0.04 
CTS¶ (%) 7(10%) 9 (17%) 0.23 
Radiculopathy¶ (%) 20 (28%) 12 (23%) 0.46 
Abnormal SSR 2 (2.8%) 4 (7.6%) 0.39 
Polyneuropathy (%) 2 (2.8%) 2 (3.8%) 1 
* Results expressed by means ± standard deviation. Y: years; M: male; F: female; 
HBV: hepatitis B virus; n/a: not applicable; CTS: carpal tunnel syndrome; SSR: 
sympathetic skin response. ¶ Some patients from the two groups had both diagnosis. 
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Tabela 5: Table 2: Characteristics of the five patients with sensory neuronopathies 
and autoimmune hepatitis. 
 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Age (y) 46 39 61 51 49 
Age at onset (y) 44 32 42 48 29 
SN duration (y) 2 7 19 3 20 
Sex Female Female  Female Female Female 
First clinical 
symptom 
Neurologic Neurologic Hepatic Hepatic Neurologic 
SN evolution Chronic Chronic Subacute Chronic Chronic 
FGFR3 antibody Positive Negative Positive Positive Negative 
Peak ALT U/L 422 231 86 54 340 
AIH diagnosis Definite Probable Definite Probable Definite 
Liver cirrhosis No No  Yes Yes Yes 
Neurological 
findings 
Asymmetric Asymmetric Asymmetric Asymmetric Asymmetric 
Tonic pupils Present Present Absent Absent Present 
SCOPA-Aut 20 16  43 14 
SARA 11.5 12 9 15.5 18 
LANSS 24 0 24 14 7 
USMAR 0 0.45 0.42 0 0 
SSR 
Absent in 
lower limbs 
Normal 
Absent in 
upper limbs 
Absent in all 
limbs 
Absent in 
lower limbs 
and left arm 
Abnormal sweat 
sites (0-8) 
3 2 1 0 8 
CAN Definite Definite Incipient Definite Absent 
Current ALT 
(RV<25 U/L) 
23 5 10 20 74 
Current 
treatment 
Azathioprine 
Prednisone 
+ 
Azathioprine 
None 
Regular 
methylpredni
solone 
Prednisone 
+ 
Azathioprine 
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pulsotherapy  
Neurologic 
improvement 
No No No No No 
 
y: years; SN: sensory neuronopathy; FGFr3: fibroALT: alanine aminotransferase; AIH: 
autoimmune hepatitis; SCOPA-Aut: scales for outcomes in Parkinson’s disease - 
autonomic dysfunction; ISS: INCAT sensory sum score; SARA: scale for assessment and 
rating of ataxia; LANSS: Leeds assessment of neuropathic symptoms and signs; BPI: 
brief pain inventory; BBS: Berg balance scale; USMAR: ulnar sensory and motor 
amplitude ratio; SSR: sympathetic skin response; CAN: cardiac autonomic neuropathy.  
 
 
 
 
Figura 20: Figure 1: Liver biopsies from patients 1, 2 and 3. Patient 1: Chronic 
hepatitis pattern of injury, with periportal interface activity and a dense inflammatory 
cell infiltrates, composed of lymphocytes and plasma cells. (HE, 20x). Patient 2: 
"Postinfantile giant cell hepatitis" characterized by enlarged hepatocytes containing 
numerous nuclei, an indicator of severe hepatocyte injury. (HE, 40x). Patient 3: 
Hepatic fibrosis highlighted in bright blue with trichrome stain. It is possible to 
observe dense septa and nodule outline. (MT, 10x). 
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Figura 21: Figure 2: Alanine aminotransferase (ALT) and modified Rankin scale 
(mRS) evolution of the five patients with autoimmune hepatitis and sensory 
neuronopathy. 
ULN: upper limit of normality. 
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Estudo 4: Contribuições ao diagnóstico 
imunológico 
 
 
Avaliação do anticorpo anti-FGFR3 
 
Introdução 
 Desde a primeira descrição dos primeiros pacientes com neuronopatia 
sensitiva (NS) em 1948 por Derek Denny-Brown (6), o entendimento e a descrição 
das causas associadas ao dano celular aos corpos dos neurônios sensitivos 
abrigados no gânglio da raíz dorsal (GRD) têm sido ampliados. No entanto, a 
despeito desses avanços, aproximadamente metade dos pacientes diagnosticados 
com NS permanecem rotulados como idiopáticos uma vez que uma causa 
subjacente não é identificada (2,4,38-40) Evidências advindas de doenças 
associadas e mesmo de casos idiopáticos sugerem que existam fatores 
relacionados à autoimunidade (2,12,41,42). Nesse sentido, a identificação de 
biomarcadores que possam auxiliar na identificação de formas de NS 
imunomediadas torna-se bastante relevante.  
Os anticorpos anti-receptor tipo 3 do fator de crescimento de fibroblasto (anti-
FGFR3) foram descritos em um subgrupo de pacientes com NS. No entanto, ainda 
não está clara a relevância diagnóstica desses anticorpos (12). Desta maneira, o 
objetivo desse estudo foi avaliar o papel desse anticorpo no diagnóstico etiológico  
das NS e traçar o perfil clinico e neurofisiológico dos pacientes com NS e anti-
FGFR3. 
Métodos 
 Foram incluídos de maneira consecutiva 42 pacientes diagnosticados com NS 
não paraneoplásica conforme os critérios propostos por Camdessanché e 
colaboradores (10). Todos os pacientes eram maiores de 18 anos e assinaram um 
termo de consentimento livre e esclarecido antes de sua inclusão no estudo. A 
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verificação da presença do anticorpo foi realizada em amostra do sangue periférico 
por método ELISA. Os dados clínicos de todos os pacientes foram coletados e 
incluíam além dos dados demográficos os dados relativos ao exame de 
eletroneuromiografia (incluindo o cálculo da razão USMAR (43)), avaliação do 
sistema nervoso autômico (QSWEAT e variabilidade cardíaca) dos pacientes. 
Algumas escalas clínicas como  Leeds Assessment of Neuropathic Symptoms and 
Signs (LANSS) (22) o questionário SCOPA-Aut (23,24) foram empregados para a 
avaliação da presença de dor neuropática e sintomas autonômicos respectivamente. 
Os resultados foram então comparados entre os grupos considerando a presença ou 
ausência do anticorpo anti-FGFR3. Estatística descritiva e testes não paramétricos 
foram utilizados com valores de p <0,05 considerados como significativos. 
 
Resultados 
Dezesseis pacientes (38%) tiveram resultado positivo para o anti-FGFR3, 
sendo 13 mulheres. Nove pacientes com etiologia idiopática, três com síndrome de 
Sjögren, três com hepatite autoimune e um com infecção pelo HTLV. Considerando 
apenas os pacientes soropositivos, 43% apresentavam ataxia e 40% tinham as 
parestesias como sintoma inaugural. A dor está presente no quadro clínico de 81% 
(13/16), fechando critérios para dor neuropática (LANSS>12) em 84% (11/13). A 
escala SCOPA-Aut teve valores médios de 29,5±13,4. O exame de 
eletroneuromiografia mostrou assimetria marcante em 76% (12/16) dos pacientes 
FGFR3 positivos; destes, 87,5%  (14/16) fechavam critérios para neuropatia 
autômica cardíaca. O exame do reflexo axonal sudomotor quantitativo revelou que 
15 dos 16 pacientes com anticorpo anti-FGFR3 apresentavam pelo menos um ponto 
com volume de sudorese anormal, sendo a distribuição de tais pontos ilustrada pela 
figura 22. 
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Figura 22: Representação esquemática dos volumes de sudorese obtidos pela 
avaliação do reflexo axonal sudomotor quantitativo. Os círculos verdes representam 
os pontos com volumes de sudorose normal (entre os percentis 95 e 5); os círculos 
vermelhos representam os pontos com volume de sudorese diminuído (menores que 
o percentil 5) e o círculo azul representa o ponto de sudorese com volume 
aumentado (maior que o percentil 95). 
 
A comparação entre os grupos com a presença e a ausência do referido 
anticorpo montrou que o grupo anti-FGFR3 positivo tinha menor razão entre as 
amplitudes dos potenciais sensitivo e motor do nervo ulnar (0,13±0,2 vs.0,49±0,5, 
p=0,01) refletindo uma maior dissociação sensitivo-motora. Os demais parâmetros 
comparados incluíram: idade, sexo, idade de início, taxa de progressão da escala 
SARA, o tipo de evolução clínica, presença de assimetria, dor, valores de LANSS, 
pseudoparesia, pseudoatetose, etiologia idiopática e neuropatia autonômica 
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cardíaca não demonstraram diferenças estatisticamente significativas (p>0,05) 
(Tabela 6). 
 
Tabela 6: Características dos pacientes com diagnóstico de neuronopatia sensitiva 
quanto a presença ou ausência do anticirpo anti-FGFR3. 
 
Anti-FGFR3 + 
(n=16) 
Anti-FGFR3 – 
(n=26) 
Valor de p 
Idade (anos) 53,3±6,4 50,3±10,7 0,3 
Idade de início 
(anos) 
43,3±6 40,4±9,5 0,3 
Evolução 
(ag/sag+cr) 
5/11 10/16 0,7 
Sexo (M:F) 3:13 8:18 0,4 
Assimetria/simetria 14/2 17/9 0,1 
Pseudoparesia 10 16 1 
Pseudoatetose 13 20 0,6 
Dor (sim/não) 13/3 19/7 0,4 
Etiologia Idiopática 9 16 0,7 
LANSS 14,7±7,3 12,2±6,7 0,2 
SARA 11,8±3,3 12,1±5,8 0,8 
Taxa de 
progressão* 
3,4±4,7 3±4,8 0,8 
CAN 14 20 0,1 
USMAR 0,1±0,2 0,4±0,5 0,02 
*Taxa de progressão dada por valor de SARA dividido pelo tempo de doença em 
anos. 
FGFR3: receptor tipo 3 do fator de crescimento de fibroblasto; Ag: agudo; SAG: 
subagudo; CR: crônico; M: masculino; F: feminino; LANSS: Leeds Assessment of 
Neuropathic Symptoms and Signs; SARA: scale for the assessment and rating of 
ataxia; CAN: neuropatia autonômica cardíaca; USMAR: razão entre as amplitudes 
sensitiva e motora do nervo ulnar. 
	 	 118	
	
Discussão 
 A presença dos anticorpos anti-FGFR3 está relacionada a uma significativa 
proporção dos pacientes com NS dessa coorte (16/42 – 38%). Além disso, mais da 
metade dos pacientes dessa coorte com anti-FGFR3 presente (9/16 – 56%) eram 
encarados como idiopáticos. Embora não saibamos se este anticorpo tem efeito 
patogênico direto, a sua elevada positividade nessa coorte sugere que exista um 
substrato imunomediado. Esses números são consideralvelmente distintos aos 
observados pela coorte francesa, na qual esse anticorpo estava presente em 12,5% 
(9/72) dos pacientes com neuropatias sensitivas adquiridas e também em 12,5% 
(4/32) dos pacientes rotulados como idiopáticos (12). Uma possível explicação para 
estes achados discrepantes reside na seleção mais rigorosa realizada nos pacientes 
brasileiros – todos os pacientes preenchiam os critérios formais para NS (10). Na 
série francesa, foram incluídos também no grupo avaliado pacientes com neuropatia 
sensitiva distal. 
Desta forma, foi possível traçar um perfil médio dos pacientes brasileiros com 
NS e anticorpos anti-FGFR3: mulher por volta dos 53 anos cuja doença se iniciou na 
5a década de vida, com quadro de ataxia sensitiva e dor neuropática. Além disso, há 
marcada cronicidade e significativa desproporção entre o comprometimento 
sensitivo e motor no exame de eletroneuromiografia. Esses dados permitem que 
seja feita a sugestão de incorporação da pesquisa do anticorpo anti-FGFR3 no 
investigação dos pacientes com NS não-paraneoplásica.  
Como perspectivas futuras, cabem a investigação do real papel patogênico 
deste anticorpo e a avaliação de sua especificidade para este tipo de neuropatia. 
Para tanto, esforços multicêntricos vem sendo desenvolvidos na forma de uma 
colaboração entre a UNICAMP e a Universidade de Saint-Etienne. 
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Estudo 5: Contribuições ao diagnóstico 
genético 
  
Introdução 
As neuronopatias sensitivas (NS) representam um fenótipo distinto de 
acometimento do sistema nervoso periférico caracterizado por ataxia sensitiva e 
déficits sensitivos multifocais, assimétricos e que não seguem o padrão de 
comprimento-dependência [1,2]. Esse padrão particular é resultante da lesão aos 
corpos neuronais abrigados nos gânglios sensitivos das raízes dorsais (GRD) 
inicialmente descrita em 1948 por Derek Denny-Brown [3]. Desde então, muitos 
esforços têm sido dedicados à investigação e ao melhor entendimento dos 
mecanismos envolvidos na NS [4]. Uma vez identificado o padrão compatível com 
NS, uma janela de oportunidade se abre para a avaliação de uma série de doenças 
associadas, algumas cujo diagnóstico precoce está diretamente ligado a um melhor 
prognóstico como nas neoplasias, já outras, como a síndrome de Sjögren (SS), 
podem beneficiar-se de tratamento específico [1,2,5,6]. 
A despeito dos avanços recentes, aproximadamente metade dos pacientes 
diagnosticados com NS persistem como idiopáticos [1,2,4,6,7]. NS pode estar 
presente no contexto de inúmeras enfermidades geneticamente definidas, como 
ataxia de Friedreich, algumas ataxias espinocerebelares e citopatias mitocondriais 
[9,10,11]. Nestas doenças, a NS faz parte de um cortejo complexo onde há 
envolvimento de múltiplos sistemas neurais. Acreditamos que variantes patogênicas 
em alguns destes genes poderiam estar relacionadas a fenótipos clínicos mais 
brandos, onde a NS seria a principal ou mesmo única manifestação. Nos dias de 
hoje, o progresso das técnicas de genética molecular e a maior disponibilidade do 
sequenciamento completo de exoma por tecnologia de nova geração (NGS) facilitam 
sobremaneira a investigação de possíveis etiologias genéticas para doenças “ainda 
sem causa”, como as NS [8]. Desta maneira o objetivo desse trabalho é investigar 
possível etiologia genética em pacientes com NS idiopática isolada utilizando 
tecnologia NGS.  
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Método 
Seleção dos pacientes  
 Foram incluídos de maneira consecutiva os pacientes com o diagnóstico de 
NS conforme os critérios diagnósticos propostos por Camdessanché e 
colaboradores [12] e que apresentaram investigação etiológica negativa 
(idiopáticos). Além disso, os pacientes deveriam ser maiores de 18 anos de idade e 
ser acompanhados no ambulatório de doenças neuromusculares do Hospital de 
Clínicas da Universidade Estadual de Campinas. Dentre os exames realizados para 
que a etiologia idiopática fosse considerada, foram incluídos: hemograma, 
eletroforese de proteínas, dosagem sérica das vitaminas B9 e 12, sorologias para 
HIV e HTLV, glicemia de jejum, cobre, anticorpos anti-Ro, anti-La, fator antinúcleo, 
fator reumatóide, transaminases, tomografias computadorizadas de abdome e tórax.  
 O protocolo deste estudo foi aprovado pelo comitê de ética em pesquisa da 
Universidade de Campinas e foi conduzido conforme os preceitos éticos da 
Declaração de Helsinque de 1964 e as suas posteriores emendas. Todos os 
pacientes que desejaram participar desse projeto assinaram o termo de 
consentimento livre e esclarecido antes de sua inclusão no estudo. 
 
Sequenciamento completo do exoma 
Foi realizada a coleta de sangue periférico para a extração do DNA 
leucocitário conforme método fenol-clorofórmio já padronizado no laboratório de 
Genética Molecular da FCM/UNICAMP [13]. Em seguida, as amostras de DNA foram 
fragmentadas sendo realizada a captura de todos os éxons e regiões de transição 
éxon-íntron utilizando o kit Agilent Sureselect all exon v.6 (Agilent® Santa Clara, CA, 
EUA). Com as bibliotecas preparadas, o passo seguinte foi composto pelo 
sequenciamento por NGS no equipamento Illumina HiSeq 2500®. Ao término dessa 
etapa, foi verificada a profundidade do sequenciamento a qual atingiu, em média, 
100x.  
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Análise dos resultados do exoma 
 Os dados originalmente obtidos do sequenciamento foram submetidos a 
controle de qualidade e alinhamento com genoma de referência (Hg 18) utilizando o 
pipeline GATK. A partir daí, foi realizada a chamada de variantes originando os 
arquivos com a extensão .vcf. Realizamos então, as etapas finais de análise 
utilizando a plataforma Varistation® (www.app.varistation.com). De forma resumida, 
filtramos as variantes encontradas utilizando os termos “sensory ataxic neuropathy”, 
“distal peripheral sensory neuropathy”, “sensory neuropathy” e “peripheral 
neuropathy” da plataforma Human Phenotype Ontology (www.hpo.jax.org). Com 
esses parâmetros, analisamos as variantes encontradas em um conjunto de 531 
genes distintos. A seguir, foi empregada nova filtragem considerando apenas as 
variantes estritamente localizadas em éxons ou nas transições éxon-íntron (até 10 
bases). Além disso, priorizamos aquelas variantes cuja frequência foi inferior a 1% 
na população geral tomando por referencia as bases de dados ExAC, GnomAD e 
AbraOM. Finalmente, por meio dos critérios de patogenicidade definidos pelo 
American College of Medical Genetics selecionamos aquelas variantes classificadas 
como patogênicas ou provavelmente patogênicas [14]. 
  
Resultados 
 Foram incluídos 22 pacientes com diagnóstico de NS idiopática. A relação 
entre o número de homens e mulheres foi de 9:13. Os pacientes tinham em média 
50,9 ± 8,3 anos e aos 40,8 ± 8,3 anos iniciaram a doença, a qual tinha uma média de 
duração de 9,5 ± 7,5 anos. Nenhum dos pacientes apresentava antecedentes 
familiares de neuropatia periférica. Os achados de exame neurológico eram 
assimétricos em 77% (17/22) dos pacientes e a instalação dos sintomas relativos à 
NS teve curso crônico, subagudo e agudo em 12, seis e quatro pacientes, 
respectivamente.  
 Em quatro pacientes encontramos variantes suspeitas, mas em nenhum deles 
o diagnóstico conclusivo de uma condição geneticamente determinada pôde ser 
feito. Isto ocorreu na maior parte das vezes porque foi encontrada a variante em 
apenas um dos alelos (Tabela 7).  
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Tabela 7: Descrição das variantes suspeitas encontradas em pacientes com NS 
idiopática. 
Indivíduo Gene Variante/Tipo ACMG Gen 
Frequência 
Alélica 
Mínima 
1 
CUBN 
c.7969_7970insTTAT
ATAA/ 
Frameshift 
PP Het 0,0000325 
CUBN 
c.7969dupT/ 
Frameshift 
PP Het 0,00002031 
POLG c.1174C>G/Missense P Het 0,0018 
2 FXN 
c.499_509del/ 
Frameshift 
PP Het 
0,00000672
6 
3 POLG c.3131T>C/Missense P Het 0,0006 
4 FLVCR1 c.1198C>T/ Missense P Het 0 
 
CUBN: gene cubilin ; POLG: gene DNA polymerase gamma, catalytic subunit; FXN: 
gene frataxin; FLVCR1: gene feline leukemia virus subgroup C cellular receptor 1; 
ACMG: classificação das variantes de acordo com a American College of Medical 
Genetics; P: patogênica; PP: provavelmente patogênica; Gen: genótipo; Het: 
heterozigoto. 
 
Discussão 
 O sequenciamento de exoma por técnicas de nova geração não foi capaz de 
trazer a elucidação diagnóstica para nenhum dos casos de NS idiopática avaliados 
nessa série. Todavia, a análise de algumas variantes encontradas em determinados 
pacientes pode ser de fundamental importância para a formulação de hipóteses 
capazes de auxiliar a descrição de possíveis mecanismos envolvidos nessa doença. 
 Dois pacientes descritos na Tabela 7 possuem variantes no gene POLG. Esse 
gene possui um papel fundamental na replicação do DNA mitocondrial por meio da 
codificação de subunidades da enzima DNA polimerase [15]. As doenças POLG-
	 	 123	
	
relacionadas têm ampla heterogeneidade fenotípica, mas o sistema nervoso é 
frequentemente envolvido [16]. Dentro deste grupo, há NS no contexto do espectro 
de ataxia e neuropatia o qual engloba, mas não se restringe às doenças 
anteriormente conhecidas como SANDO e MIRAS (em tradução livre do inglês: 
SANDO: ataxia sensitiva, neuropatia, disartria e oftalmoplegia; MIRAS: síndrome de 
ataxia sensitiva mitocondrial recessiva). Em ambas as condições, entretanto, são 
necessárias variantes deletérias em ambos os alelos para que o fenótipo seja 
expresso. Nos nossos 2 pacientes identificamos variantes em apenas um dos alelos. 
Outros achados relevantes foram os encontrados no gene CUBN do indivíduo 
1. Esse gene está relacionado à absorção intestinal do complexo “fator intrínseco-
vitamina B12” e, quando mutado, resulta em síndromes carenciais [17]. O déficit da 
vitamina B12 sabidamente é responsável por uma miríade de manifestações 
neurológicas [18].  No contexto das NS, esse quadro carencial pode estar 
relacionado à doença [2] e dessa maneira, por extensão, as mutações no CUBN 
seriam potencialmente relevantes para a fisiopatogênese da doença. No paciente 
em quentão, a investigação complementar não mostrou anemia, nem tampouco, 
macrocitose. Os níveis séricos da vitamina B12 encontravam-se, no inicio da 
investigação diagnóstica, próximos aos limites inferiores de normalidade (186 pg/mL, 
VR: 180-914). Após a reposição parenteral da vitamina B12, não foi observada 
qualquer modificação do quadro neurológico ainda que os níveis de vitamina B12 
permaneçam >500pg/mL pelos menos nos últimos dois anos.  
Por fim, as variantes encontradas nos genes FXN e FLVCR1 também 
merecem atenção. Esses genes relacionam-se respectivamente à ataxia de 
Friedreich e a uma condição caracterizada por ataxia secundária à lesão do cordão 
medular posterior e retinite pigmentosa (PCARP) [19,20]. A ataxia de Friedreich é a 
ataxia autossômica recessiva mais comum no mundo e clinicamente manifesta-se 
por ataxia com componentes cerebelares e sensitivos [21].  Está relacionada à 
redução dos níveis de frataxina normalmente causada pela expansão do tripleto 
GAA na região intrônica do  primeiro íntron do gene FXN [19]. Mutações de ponto no 
FXN também são responsáveis pela doença quando combinadas à expansão GAA 
no outro alelo [19]. Em nossa paciente 2, o triplet-primed PCR não revelou 
expansões anormais GAA. Por sua vez, a PCARP é uma causa rara de ataxia de 
início na infância que cursa com retinite pigmentosa [20]. A ausência do quadro 
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oftalmológico e o início do quadro atáxico na idade adulta (5a década de vida) já 
tornariam tal hipótese diagnóstica pouco provável para a paciente em questão 
(paciente 4). Ademais, a variante deletéria foi identificada apenas em heterozigose 
no nosso caso 4. 
A despeito dessa série não ter sido capaz de identificar de forma definitiva 
pacientes com NS monogênica, acreditamos que hipóteses acerca da fisiopatologia 
da doença podem ser aventadas. Uma possibilidade estaria relacionada ao tipo de 
mutação ligado à doença. O sequenciamento completo do exoma não é capaz de 
avaliar, por exemplo, expansões instáveis e/ou alterações intrônicas como 
recentemente relatado em pacientes com CANVAS [22]. Alternativamente, a 
presença de variantes patogênicas raras em um dos alelos destes genes não seria 
suficiente para determinar a doença, mas tornaria estes indivíduos predispostos ao 
desenvolvimento de NS ao longo da vida. Para tanto, fatores ambientais (como 
exposição ao álcool e outras drogas)  seriam os gatilhos restantes para que o 
fenótipo de NS seja expresso. Neste contexto, as NS idiopáticas de início tardio 
poderiam se comportar como doenças geneticamente complexas, semelhante ao 
que observamos nas formas esporádicas da esclerose lateral amiotrófica 
(associação com expansões intermediárias em ATXN2) ou da doença de Alzheimer 
(associação com o genótipo ApoE ε4) [23,24]. Possivelmente, a expansão da 
casuística ora apresentada poderá, futuramente, auxiliar na resposta a essa 
questão. 
 
Referências 
1- Martinez AR, Faber I, Nucci A, Appenzeller S, França MC Jr. Autoimmune 
neuropathies associated to rheumatic diseases. Autoimmun Rev 2017;16:335-342. 
2 - Gwathmey KG. Sensory Polyneuropathies. Continuum (Minneap Minn) 
2017;23:1411-1436. 
3 - Denny-Brown D. Primary sensory neuropathy with muscular changes associated 
with carcinoma. J Neurol Neurosurg Psychiatry 1948;11:73-87. 
4 - Sghirlanzoni A, Pareyson D, Lauria G. Sensory neuron diseases. Lancet Neurol 
2005; 4:349-361. 
	 	 125	
	
5 - Sheikh SI, Amato AA. The dorsal root ganglion under attack: the acquired sensory 
ganglionopathies. Pract Neurol. 2010 Dec;10(6):326-34. 
6 - Crowell A, Gwathmey KG. Sensory Neuronopathies. Curr Neurol Neurosci Rep 
2017;17:79. 
7 - Martinez AR, Nunes MB, Nucci A, França MC Jr. Sensory neuronopathy and 
autoimmune diseases. Autoimmune Dis 2012;2012:873587. 
8 - Rossor AM, Evans MR, Reilly MM. A practical approach to the genetic 
neuropathies. Pract Neurol. 2015 Jun;15(3):187-98. 
9 - Alix JJ, Alam T, Garrard K, Martindale J, Shanmugarajah P, Ganesh Rao D, 
Hadjivassiliou M. Variable sensory nerve conduction parameters in late onset 
Friedreich ataxia. Muscle Nerve. 2017 Feb;55(2):E7-E8.  
10 - França MC Jr, D'abreu A, Nucci A, Cendes F, Lopes-Cendes I. Prospective 
study of peripheral neuropathy in Machado-Joseph disease. Muscle Nerve. 2009 
Dec;40(6):1012-8. 
11 - Tchikviladzé M, Gilleron M, Maisonobe T, Galanaud D, Laforêt P, Durr A, 
Eymard B, Mochel F, Ogier H, Béhin A, Stojkovic T, Degos B, Gourfinkel-An I, Sedel 
F, Anheim M, Elbaz A, Viala K, Vidailhet M, Brice A, Jardel C, Lombès A. A 
diagnostic flow chart for POLG-related diseases based on signs sensitivity and 
specificity. J Neurol Neurosurg Psychiatry. 2015;86(6):646-54. 
12 - Camdessanché JP, Jousserand G, Ferraud K, Vial C, Petiot P, Honnorat J, et al. 
The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. 
Brain 2009;132:1723-33. 
13 - Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 
2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989. 3-4 p. 
14 - Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde 
M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality 
Assurance Committee. Standards and guidelines for the interpretation of sequence 
variants: a joint consensus recommendation of the American College of Medical 
Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 
2015 May;17(5):405-24. 
	 	 126	
	
15 - Ashley N, O'Rourke A, Smith C, Adams S, Gowda V, Zeviani M, Brown GK, 
Fratter C, Poulton J. Depletion of mitochondrial DNA in fibroblast cultures from 
patients with POLG1 mutations is a consequence of catalytic mutations. Hum Mol 
Genet. 2008;17:2496–506. 
16 - Rahman S, Copeland WC. POLG-related disorders and their neurological 
manifestations. Nat Rev Neurol. 2019;15(1):40-52. 
17 - Aminoff, M., Tahvanainen, E., Grasbeck, R., Weissenbach, J., Broch, H., de la 
Chapelle, A. Selective intestinal malabsorption of vitamin B12 displays recessive 
mendelian inheritance: assignment of a locus to chromosome 10 by linkage. Am. J. 
Hum. Genet. 1995;57: 824-831. 
18 - Kumar N. Nutrients and Neurology. Continuum (Minneap Minn). 2017;23:822-
861. 
19 - Gellera C, Castellotti B, Mariotti C, Mineri R, Seveso V, Didonato S, Taroni F. 
Frataxin gene point mutations in Italian Friedreich ataxia patients. Neurogenetics. 
2007;8:289-99.  
20 - Higgins JJ, Kluetzman K, Berciano J, Combarros O, Loveless JM. Posterior 
column ataxia and retinitis pigmentosa: a distinct clinical and genetic disorder. Mov 
Disord. 2000;15:575-8. 
21 - Abrahão A, Pedroso JL, Braga-Neto P, Bor-Seng-Shu E, de Carvalho Aguiar P, 
Barsottini OG. Milestones in Friedreich ataxia: more than a century and still learning. 
Neurogenetics. 2015;16:151-60. 
22 - Cortese A, et al. A Novel Recessive Pentanucleotide Repeat Expansion is a 
Frequent Cause of Late-onset Sensory Ataxic Neuropathy. Abstract presented at the 
Peripheral Nerve Society Annual Meeting (Baltimore, 2018).  
23 - Tavares de Andrade HM, Cintra VP, de Albuquerque M, Piccinin CC, Bonadia 
LC, Duarte Couteiro RE, Sabino de Oliveira D, Claudino R, Magno Gonçalves MV, 
Dourado MET Jr, de Souza LC, Teixeira AL, de Godoy Rousseff Prado L, Tumas V, 
Bulle Oliveira AS, Nucci A, Lopes-Cendes I, Marques W Jr, França MC Jr. 
Intermediate-length CAG repeat in ATXN2 is associated with increased risk for 
	 	 127	
	
amyotrophic lateral sclerosis in Brazilian patients. Neurobiol Aging. 2018;69:292.e15-
292.e18. 
24 - Mahoney-Sanchez L, Belaidi AA, Bush AI, Ayton S. The Complex Role of 
Apolipoprotein E in Alzheimer's Disease: an Overview and Update. J Mol Neurosci. 
2016;60:325-335. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 	 128	
	
 
Estudo 6: Avaliação das queixas álgicas dos 
pacientes com neuronopatia sensitiva  
	
Estudo submetido à análise para publicação em periódico indexado. 
Pain is frequent and disabling in non-paraneoplastic sensory neuronopathy.  
Alberto Rolim Muro Martineza, M.D.; Thiago Junqueira Ribeiro de Rezendea, PhD; 
Fabricio Diniz de Limaa, M.D.; Felipe Franco da Graçaa, M.D.; Anamarli Nuccia, M.D. 
PhD; Marcondes Cavalcante França Jra, M.D. PhD. 
 
a- Neurology Department – Neuromuscular Division, University of Campinas 
(UNICAMP), Campinas, Sao Paulo, Brazil. 
 
Word count: Title: 5, Abstract: 198, Manuscript: 2027, References 20, Figures: 1 
Tables: 1  
Funding agencies: This study was supported by Fundação de Amparo à Pesquisa 
do Estado de São Paulo (FAPESP) (Grant #13/01766-7 and #2014/19786-7) and 
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). 
Declarations of interest: none. 
Running Title: Pain in non-paraneoplastic sensory neuronopathy 
Correspondence to: Professor Marcondes Cavalcante França Jr;  
Department of Neurology, University of Campinas; 
Address: Rua Tessália Vieira de Camargo, 126.  
Campinas, SP, Brazil; ZIPCODE:13083-887 
Tel.: +551935219217; fax: +551935217933;  
e-mail: mcfrancajr@uol.com.br 
	 	 129	
	
Abstract  
Introduction: Dorsal root ganglia (DRG) damage result in sensory neuronopathies 
(SN), classically dominated by sensory ataxia, non-length sensory deficits and also 
pain-related complaints. Pain complaints in SN clinical picture date back to its first 
descriptions in 1948. However, there were no studies, which addressed this symptom 
especially out of the paraneoplastic SN forms. That said, our objectives were to 
investigate pain characteristics in non-paraneoplastic SN.  
Methods: Fifty-six non-paraneoplastic SN patients were consecutively enrolled from a 
tertiary neuromuscular clinic. All patients were examined and questioned about the 
presence and localization of pain complaints. Besides the neurologic examination, 
we also assessed clinical scales, the prescribed treatments, and outcomes.  
Results: There were 38 women. The mean age, age at diagnosis and the disease 
duration were 50.46±10.56, 41.69±9.39 and 8.66±7.21 years respectively. Fourteen 
patients had pain as the first SN manifestation, and 43/56 had pain as part of their 
clinical pictures, being asymmetric in 24/43 and neuropathic in 31/43. Most patients 
(80%) could not achieve satisfactory pain control through usual pain-relief drug 
regimens.  
Conclusion: Pain is a frequent and relevant symptom for non-paraneoplastic SN 
patients. It brings significant impact on daily activities, and the usual drug 
prescriptions fail to control it adequately. 
 
Keywords: Sensory neuronopathy; ganglionopathy; sensory ataxia; pain; 
neuropathic pain. 
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1. Introduction 
Dorsal root ganglia (DRG) represent a paramount structure in the peripheral 
nervous system architecture. Several conditions may include the DRG damage as 
part of their pathophysiology, and nearly in half of the cases, its affection seems to be 
primary [1,2]. Regardless of which is the underlying etiology of the DRG destruction, 
the resultant clinical picture is mainly composed of, but not restricted to, asymmetric 
sensory deficits and sensory ataxia, hallmarks of the sensory neuronopathies (SN) 
[3].  
It is not hard to guess that, being SN a sensory nervous system impairment 
condition, pain might play a role in this multiple symptoms spectrum. The presence of 
pain is acknowledged since the first Derek Denny-Brown`s sensory neuronopathies 
first descriptions in 1948 [4]. One of the two SN patients firstly described suffered as 
said by professor Denny-Brown from: " an ache in his right ear radiating into the right 
side of the neck." [5] Despite that, to the best of our knowledge, there are no papers 
devoted to specifically address pain and its characteristics as part of the clinical 
picture in SN cohorts.  
Considering the scenario as mentioned above, our objectives with this paper 
were to describe the "pain profile” of non-paraneoplastic SN patients and also to 
report its response to the available drug regimen. 
 
 
 
DRG: Dorsal root ganglia; SN: sensory neuronopathies; LANSS: Leeds assessment 
of neuropathic symptoms and signs; BPI: brief pain inventory;iBPI:Brief Pain 
Inventory Interference Scale; SARA: assessment and rating of ataxia; INCATSS: 
inflammatory neuropathy cause and treatment sensory sum score; BSS: Berg 
balance scale; VAS: visual analog scale; CP: Chronic pain. 
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2. Methods 
 
2.1 Subjects’ selection and clinical evaluation 
 We enrolled consecutively all patients diagnosed with non-paraneoplastic SN 
accordingly the Camdessanché and cols proposed criteria [6].  All patients are 
followed in a tertiary referral outpatient neuromuscular clinic of the University of 
Campinas hospital, São Paulo, Brazil in the period between 2015 and 2017. Besides 
that, all enrolled patients were above the age of 18 years old and signed an informed 
consent form. We retrieved information regarding the demographics and symptoms 
at the disease onset. 
At last, we have assessed the presence of pain and its characterization towards 
topography description and through clinical scales all validated for Brazilian 
Portuguese, such as the Leeds assessment of neuropathic symptoms and signs 
(LANSS) score [7], the brief pain inventory (BPI) [8] and the Brief Pain Inventory 
Interference Scale (iBPI) [9]. A human figure was shown to all patients who 
complained about pain, and they should check all the pain sites. We compared 
patients with and without pain complaints through their scores in different scales such 
as the scale for the assessment and rating of ataxia (SARA), the inflammatory 
neuropathy cause and treatment sensory sum score (INCATSS) and the Berg 
balance scale (BBS). Drug regimens prescribed for pain management were recorded 
as well, and patients should report on a visual analog scale (VAS) the percentage of 
pain control for their actual prescription. Percentages below 50% were considered as 
"insufficient control," those between 50 and 90% as "unsatisfactory control" and 
those rates above 90% as "good control”. 
 
2.2 Statistical analyses and Ethical Considerations 
We used descriptive statistics to clinical and demographic data presentation. 
Group comparisons were performed with exact Fisher’s, Pearson's χ2 and 2-sample 
t-tests when appropriated. P values < 0.05 considered significant.  
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The Ethical Research Committee of the University of Campinas (UNICAMP) 
approved this study protocol, which was carried out under the 1964 Declaration of 
Helsinki and its later amendments. All patients agreed with and signed an informed 
consent statement form before enrollment. 
 
3. Results 
 
3.1 Demographics and clinical characteristics 
 A total of fifty-six SN patients were enrolled, 18 were men, and there were 38 
women. Mean age at evaluation and the symptoms onset were 50.46±10.56 years 
(ranging from 26 to 74 years old) and 41.69±9.39 years (range 20-63) respectively. 
Disease duration was in average 8.66±7.21 years (range 1-25 years). Table 1 
summarizes demographic and clinical data. Most patients, 32/56 (57%), had 
idiopathic forms whereas the remaining 24 patients had SN in the context of other 
diseases (18 in dysimmune conditions, three in infectious context, two with B12 
vitamin deficiency and one in monoclonal gammopathy of undetermined 
significance). The pain was the debut symptom of one of every four patients (14/56). 
Nearly half of the patients, 27/56 (48.21%) had negative sensory symptoms, 13/56 
(23.21%) had gait ataxia, and 2/56 (3.57%) had pruritus as the main symptom in the 
disease onset. 
 
3.2 Pain profile in sensory neuronopathies 
 Overall, the pain was part of the clinical picture in 43 out of 56 patients with SN 
(76.78%) being the first symptom for 25% (14/56) of the patients in this series. Sixty-
one percent of men (11/18) and 84.2% of women (32/38) had pain as part of their SN 
clinical picture (p=0.09). For those patients that reported pain, the mean BPI score in 
the previous 24 hours before the evaluation was 6.58±2 (range 3-10) and the mean 
value for the iBPI score (composed by a mean value from seven different categories 
each of them ranging from 0 to10, where a value of 10 is a total interference with the 
proposed category) was 7.28±1.65 (range 4-10). For most patients (24/43), the 
	 	 133	
	
painful sites were asymmetric. Considering the body sites which patients pointed as 
being involved with their pain complaints, hands (62% each), right foot (60%) and left 
foot (57%) were the most frequently marked. Figure 1 highlights the anatomical 
distribution of pain and shows a frequency bar to stress how frequently a site is 
involved.  
 
Figura 23: Figure 1: Pain distribution as a frequency heat map in sensory 
neuronopathy patients. 
 
Thirty-one subjects (72%) had neuropathic pain; defined as LANSS scores ≥ 
12 [7] and allodynia/hyperalgesia was present in 15 out of the 43 (35%) patients that 
reported painful complaints. There were no differences (p>0.05) between those 
patients with pain when compared to those without pain regarding SARA, INCATSS 
and BBS scores, associated diseases, disease course, gender, age at the disease 
onset and the disease duration (Table 1). However, for the forty SN patients whose 
diagnostic delay times are known, those patients whose SN clinical pictures included 
pain had longer diagnostic delays when compared to those without pain (7.14±6.3 vs. 
3.44±2.77 years respectively, p=0.026).  
	 	 134	
	
Tabela 8: Table 1: General demographics and clinical data about pain in non-
paraneoplastic sensory neuronopathy. 
Sensory Neuronopathies Patients (N= 56) 
 Pain (n=43) No Pain (n=13) p-values 
Age (years±SD) 51.56±10.42 46.85±10.62 0.16 
Male:Female ratio 11:32 7:6 0.08 
Age at disease onset (years±SD) 42.58±8.82 38.77±10.99 0.20 
Disease duration (years±SD) 8.84±7.17 8.08±7.65 0.74 
Mean iBPI (mean±SD) 7.28±1.65 n/a n/a 
SARA (mean±SD) 11.19±5.19 11.11±4.66 0.96 
INCATSS  (mean±SD) 16.50±4.15 13.92±5.0 0.07 
BBS (mean±SD) 28.35±14.24 28.42±19.09 0.98 
Delay in SN diagnosis (years±SD) 7.14±6.3 3.44±2.77 0.02 
iBPI : Brief Pain Inventory Interference Scale; SARA: scale for the assessment and 
rating of ataxia; INCATSS: inflammatory neuropathy cause and treatment sensory 
sum score; BSS: Berg balance scale; SN: sensory neuronopathies; n/a: not 
applicable. 
 
Several drug regimens were prescribed for 36/43 patients to relieve pain. They 
included as one drug or multiple-drug regimens, the usual options for neuropathic 
pain, for instance: gabapentin, carbamazepine, duloxetine, pregabalin, amitriptyline, 
venlafaxine, nonsteroidal anti-inflammatory drugs or opiates. Seven out of 36 
patients who received a drug prescription (19.4%) achieved good pain control (90-
100% of pain relief in VAS). The remaining 80.6%(29/36) failed to achieve pain relief 
at all (47.2% - 17/36) or have reached inadequate pain control (33.3% - 12/36).  
 
4. Discussion 
 Chronic pain (CP) is prevalent and frequent in non-paraneoplastic SN patients. 
For instance, pain complaints are present in 77% of the patients in this cohort. 
Population-based studies worldwide, have described CP in 2 to 40% of the general 
population [10-13]. In the context of previous SN studies, CP may be present 
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between 50 and 80% of the cases [6,14]. This data is in line with our findings; 
however, there are two relevant differences between this report and the previous 
ones. Firstly, in these previous studies information regarding pain was restricted to its 
frequency, and secondly, the SN cohort profile was slightly different for the one 
herein described since there was a significant proportion of paraneoplastic/toxic 
related-SN in these previous papers (44/78 and 20/20 respectively). Following the 
same path, Mori and cols reported similar frequencies (50%) for pain in Sjögren 
syndrome-related SN patients [15]. 
 The pathogenesis of chronic pain in SN may be multifactorial; all mechanisms 
together reach a common final result: the degeneration of small and medium neurons 
[16]. Even the DRG`s Aβ and Aδ fibers destruction being responsible for the classic 
ataxic symptoms of the SN, the 60-70% of the DRG`s cells are the origin of 
unmyelinated C fibers which are intimately linked to sensory functions and once 
damaged are related to neuropathic pain [16]. Distally to the DRG, Oki and cols have 
demonstrated by histopathologic sural nerve studies in two groups of patients with 
paraneoplastic neuropathy, that the painful group, when compared to the ataxic 
group, had a trend towards a more intense small myelinated fibers loss over the large 
myelinated fibers reduction [17]. These destructive mechanisms seem to take place 
randomly during the SN course since there was no statistically significant relationship 
between the disease duration and the presence of pain. That said, the 
abovementioned factors may be responsible for the modest treatment response 
observed, what endorses previous works and guidelines [1,18,19]. 
 Although the presence of pain did not reach the statistical requirements to take 
place in the current diagnostic criteria [6], addressing pain in SN patients is 
paramount to good clinical practice. Besides the ominous influence in daily life 
activities described as an average iBPI score higher than seven, patients whose SN 
clinical picture encompasses pain, tend to have more extended periods between the 
disease onset and the SN diagnose. One possible explanation is that ¼ of the non-
paraneoplastic SN patients display pain complaints before the classic sensory ataxia 
take place, another explanation may rely on the fact that many other different 
conditions are ranked first when one less “neurologically experienced” evaluates a 
patient with painful conditions. In order to establish a red flag for SN, accordingly to 
our findings, an average profile may be outlined to describe the SN patient who 
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suffers from pain. This average profile would be a middle-aged woman who has an 
idiopathic form of SN, fulfilling neuropathic pain criteria and complaints mainly on her 
extremities but in an asymmetrical fashion, the pain significantly impacts on her daily 
life activities and has an unsatisfactory outcome with the usual pain-relief drug 
regimens for treating the neuropathic symptoms.  
A significant clue to raise suspicion for diagnosing a possible SN when one is 
evaluating a patient with a similar profile relies upon the presence of asymmetries 
and a non-length dependent pattern that are in line with the known pathophysiology 
of SN. Overall, this described pain profile is different from other peripheral nerve 
disorders in which pain is part of the clinical picture as well. A meaningful example is 
the painful diabetic neuropathy present in 11 to 25% of the diabetic patients, 
manifested with symmetric length-dependent distribution and generally satisfactorily 
treated with an aggressive glycemic control [20]. 
Overall this study suggests that pain, especially neuropathic pain, is frequent 
and induces a significant impact on the quality of life of non-paraneoplastic SN 
patients. Knowing how pain-related symptoms and complaints behave in this 
subgroup is essential to improve the general care of these patients. However, there 
are some limitations for this study that deserve a careful discussion. This study was a 
single neuromuscular referral center study that included, even being this primary 
inclusion criterion related to our objectives, only a SN subgroup. Even being this 
issue limited by the fact that our center is the reference for all neuromuscular cases 
in a two and a half million people region with extra-patients from Countrywide, a 
referral bias could have taken place. Afterward, further studies are needed not only to 
increase the studied population but also to address, for each SN etiology, specific 
mechanisms involved in pain leading to better tailored pain-relieve options amenable 
to future treatment trials. 
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LEGENDS 
Table1: General demographics and clinical data about pain in non-paraneoplastic 
sensory neuronopathy. 
Figure 1: Pain distribution as a frequency heat map in sensory neuronopathy 
patients. 
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ABSTRACT 
  
Introduction: Sensory neuronopathy (SN) represent a particular peripheral nerve 
system disorder which clinical picture seems to be more than the classical 
asymmetric non-length dependent sensory deficits and sensory ataxia. Autonomic 
dysfunction symptoms are described since the 1948`s first descriptions however they 
were not yet adequately evaluated regarding their frequency and characteristics and 
also their relationship to sensory deficits. To address these issues, we performed a 
comprehensive clinical and neurophysiological evaluation of a large cohort of non-
paraneoplastic SN.  
Methods: We included consecutive patients with non-paraneoplastic SN followed in 
a university hospital and age/sex-matched healthy controls. They were clinically 
evaluated and underwent to autonomic evaluation that included: clinical scale, 
quantitative sudomotor axon reflex test, heart rate variability and sympathetic skin 
response. 
Results: SN patients had significantly more complaints regarding autonomic 
dysfunction reflected by higher SCOPA-Aut scores (26.63±12.72 vs. 12.66±9.11, 
p<0.001) than controls. Clinical (Adie's more frequent in SN patients p=0.009) and 
neurophysiological evaluations helped to restate this difference. QSART evaluations 
displayed abnormalities in 91% of the SN patients and lower sweat volumes in all 
examined sites (p<0.001). Cardiac autonomic neuropathy was more frequent as well 
in these patients (p<0.001).  
Conclusions: Autonomic dysfunction in distinct domains is frequent in non-
paraneoplastic SN patients and the care of these patients should regularly address it. 
Altogether the results herein described suggesting that the clinical picture of non-
paraneoplastic SN is related to a double autonomic and sensory neuronopathy. 
 
KEYWORDS: Sensory neuronopathy; Autonomic dysfunction; non-paraneoplastic; 
quantitative sudomotor axon reflex test; heart rate variability 
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INTRODUCTION 
In the 70th anniversary of the first sensory neuronopathy (SN) description 
made in 1948[1,2], its full clinical and neurophysiological characterization is still 
pursued. The hallmark of the disease is sensory ataxia with a multifocal non-length-
dependent sensory impairment[3-5]. However, patients frequently present a more 
variable clinical picture[6], and non-sensory symptoms received little attention.   
The very first SN description made by Professor Denny-Brown had 
acknowledged autonomic manifestations in the SN context. The patient from the 
"Case 1" of his pivotal report had transient urinary retention during the SN course[2]. 
Our group[7] and others[8-10] have already reported autonomic dysfunction in the 
context of SN, but essential questions on this topic remain unsolved. For instance, 
the frequency, clinical relevance, and pattern of autonomic signs in SN are still not 
precise. Moreover, how autonomic and sensory deficits correlate remains to be 
investigated. To address these issues, we performed a comprehensive clinical and 
neurophysiological evaluation of a large cohort of non-paraneoplastic SN.  
 
METHODS  
Patients 
 We prospectively invited all non-paraneoplastic SN patients from 2015 to 2017 
followed at the University of Campinas (UNICAMP) hospital, Sao Paulo, Brazil, to 
undergo this study protocol. As inclusion criteria, all patients should be older than 18 
years, fulfill the current SN diagnostic criteria proposed by Camdessanché and 
cols[3] and sign an informed consent form. 
Our study protocol encompassed an interview and a chart review to gather data 
regarding the general demographics, age at disease onset and possible SN-
associated diseases. All subjects underwent a detailed neurological examination. 
The Scale for the assessment and rating of ataxia (SARA), Berg balance scale (BBS) 
and INCAT sensory sum score (INCATSS) were also employed to quantify the SN 
severity.   
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In parallel, a group of age and sex-matched healthy individuals were invited to 
undergo the same study protocol. Most of them were husbands or spouses of the 
patients. 
Our local Institutional Review Board/Ethical Committee (Comitê de Ética em 
Pesquisa – UNICAMP) approved this study under number #25789013.5.0000.5404. 
Autonomic Evaluation 
We performed a comprehensive autonomic evaluation that included: the filling 
of the Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms (SCOPA-
Aut)[11,12], the assessment of the heart rate variability (HRV), quantitative 
sudomotor axon reflex test (QSART) and sympathetic skin response (SSR). All 
autonomic data were acquired in an interval shorter that one month and during the 
morning hours (8 am until 11 am) in order to equalize the subjects’ circadian cycle 
variations. All patients were also required to avoid smoke and physical activities 
during the preceding hours of the tests, make light caffeine and chocolate-free 
breakfast and when possible, all the potential autonomic-interfering drugs were 
suspended for at least two half-lives before the evaluation.  
During the examination period, the patients were oriented to assume dorsal 
decubitus and rest for at least 10 minutes before the beginning of the tests. The room 
was quiet, lights dimmed and with controlled temperature (23oC). The following 
sequence of tests was adopted: HRV, QSART, and SSR.  
 
Heart Rate Variability  
The HRV was assessed using the Poly-Spectrum-8/E digital system® 
(Neurosoft Ltd., Ivanovo, Russia). R-R interval data were acquired with EKG 
electrodes placed in the four limbs and processed by the software Poly-
Spectrum.NET® (Neurosoft Ltd., Ivanovo, Russia). We performed frequency and time 
domain analyses of the HRV with a standard protocol. For the frequency domains 
analysis, the patient laid down after a rest period, for another 5 minutes. The fast-
Fourier transformation algorithm converted the time domain data into the frequency 
domain spectrum, which allowed the identification of high frequency  (0.15–0.4 Hz), 
low frequency (0.04–0.15 Hz) and very low frequency (0.0033–0.04 Hz) bands. Their 
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relative distribution in percentage and the LF/HF ratio were then computed. Detailed 
mathematical workflow of these analyses was described elsewhere[13-15]. The time 
domain analyses represented by the cardiovagal tests included deep breathing, the 
Valsalva maneuver as well as the heart rate and blood pressure response to the 
orthostatic position tests. These cardiovagal tests were analyzed accordingly to the 
cutoff values stated by Ravits[16]. 
Moreover, we assessed a few more time domain data that included the 
average heart rate, maximum and minimum RR intervals, mean RR normal-to-normal 
intervals, also called NN intervals (RRNN); mean of the standard deviations of all the 
intervals without artifacts (RRNN) and the percentage of successive RR intervals that 
differ by more than 50ms (pNN50). One of the authors (ARMM) reviewed all series 
seeking for gross errors and artifacts.  
Deep Breathing: patients were instructed to inhale and exhale accordingly to a 
metronomic ten-second interval during one minute. The deep breathing index or the 
expiration/inspiration index (E:I) was defined as the mean of the ratios between the 
higher and the lowest R-R intervals for each of the six respiratory cycles[16]. In an 
analog way, respiratory sinus arrhythmia (RSA) was calculated as the sum of the 
differences between the heart rate in the inspiration and the expiration peaks for 
each respiratory cycle[16]. 
Valsalva maneuver: subjects were told to exhale after a full inhale process 
forcedly. The acquisition started after reaching a 40cmH2O pressure, and this was 
the target pressure for 15 seconds. The remaining 45 seconds were for recovery. 
Patients did another two trials with a 3-5 minute interval between them. The Valsalva 
ratio (VR) was calculated using the longest and the shortest R-R interval[16]. 
Blood pressure and heart rate variability after orthostatic challenge: the blood 
pressure measurements were performed with the patient in decubitus and one, three 
and five minutes after active orthostatic posture was adopted. Orthostatic 
hypotension (OH) adopted criteria was a drop in the systolic blood pressure or the 
diastolic blood pressure of 20 and ten mmHg respectively [17]. The 30:15 ratio, also 
obtained through this maneuver, was calculated after the division of the R-R interval 
around the 30th heartbeat by the R-R interval around the 15th heartbeat counted after 
the orthostatic position was reached [16]. 
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Cardiovascular autonomic neuropathy 
Cardiovascular autonomic neuropathy (CAN) definition encompassed the 
criteria proposed by Vinik and Ziegler[18]. These criteria include RR intervals in the 
HF, LF and VLF bands, VR, 30:15 ratio, E:I index and systolic blood pressure 
response to the orthostatic position. Two or more abnormal criteria were used to 
define CAN with 98% of specificity[18]. 
We have also performed a comparison between SN patients considering 
those with and those without a CAN taking into account demographic characteristics 
(age, sex, age at onset and disease duration) and the presence of a dysimmune 
context (Sjögren syndrome, autoimmune hepatitis and systemic lupus 
erythematosus). 
 
Quantitative Sudomotor Axon Reflex Testing 
The commercially available device QSWEAT® (WR Medical Electronics Co, 
Stillwater, MN, USA) evaluated the quantitative sudomotor axon reflex which was 
graphically displayed in a computer screen after being processed by a specific 
software system (WR TestWorks Application Software; WR Medical Electronics Co). 
We employed a slightly modified version of the protocol reported by Low et al.[19-22]: 
SN patients underwent the Q-sweat examination in both body sides resulting in eight 
points examined per patient instead of the original four. In summary, the QSART 
represents a postganglionic sympathetic evaluation test and is elicited in a small area 
(0.119 in2) at these four described sites. The QSWEAT hardware contains a 
hygrometer, which detects small increments in the dry air received from the sweat 
cells placed in these points. The source of this dry air is the room air after passage 
through a desiccant pack (#5190, WR Medical Electronics Co., Stillwater, MN). 
Examination on each side had duration of 10 minutes. All tests were initiated 
after reaching a stable baseline, in the first five minutes a two mA current 
iontophoresis using the Iontophor® II (Model 6111PM/DX) of a 10% acetylcholine 
solution was followed by a rest interval for another five minutes. The sweat volume 
resultant from the sudomotor reflex was acquired in a multicompartmental sweat cell 
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and displayed in nanoliters per minute. The area under the resulting curve expressed 
the total sweat volume.  
We qualitatively searched, considering sweat volume and the ipsilateral (ulnar 
or sural nerves) sensory nerve action potential amplitude (SNAP), for the presence of 
concordant results (normal SNAP and abnormal sweat volume and vice versa). We 
later explored the eventual correlation between SNAPs and sweat volumes in the 
upper (ulnar plus radial SNAP amplitudes vs. sweat volume of the forearm) and the 
lower (sural SNAP amplitude vs. the lower limb sum of sweat volumes).  
 
Sympathetic Skin Response 
SSR was obtained simultaneously in the four limbs with a 4-channel Nihon 
Kohden Neuropack M1 Electromyographer (Nihon Kohden®, Tokyo, Japan) with the 
following setup: sensitivity one mV/division, the sampling time of 10 seconds and low/ 
high-frequency filters of 1kHz and 0.5Hz respectively[23]. The G1 and G2 electrodes 
were placed in the palm/plant and the hand/foot dorsum respectively. Patients were 
positioned in a supine position and were told to close their eyes and try to relax. A 
random 20 mA electrical stimulus (single 0.2 ms square pulse) was given in the 
glabella. All patients underwent this procedure two more times. The presence of SSR 
was visually assessed and their onset latencies recorded. 
 
Statistical Analysis 
Descriptive statistics were used to represent the demographic, autonomic and 
neurophysiologic data. Comparison of means was made with Mann-Whitney U test or 
Kruskal–Wallis when appropriate. Groups correlations were performed with 
Pearson`s or Spearman`s Correlation Coefficient calculation when appropriate. A 
p<0.05 was considered significant. Statistical analyses of the autonomic metrics were 
done using Prism® (GraphPad Software, Inc., San Diego, CA) or the Matlab® (v. 
R2017b).  
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RESULTS 
 
Study Population 
We enrolled 56 SN patients and 32 healthy controls. Briefly, 50 patients 
underwent QSART and SSR testing, whereas 44 accomplished the HRV exam. 
Figure 1 shows a flowchart detailing the patient recruitment process, the number of 
SN patients that underwent each exam and the reasons for the dropouts on each 
study step. Considering only those patients that were evaluated, patients and 
controls had similar age (50.9±10.3 years vs. 47±12.3 years, p=0.1) and gender 
proportion (male: female ratio of 18:32 vs. 12:20, p=1). Disease onset and disease 
duration were 41.3±9.3 and 8.6±7.2 years, respectively. Two-thirds of the patients 
had asymmetric sensory symptoms. Tonic pupils (Adie’s pupil) were present in nine 
SN patients, but none of the control subjects (p=0.009).  
 Twenty-eight patients had idiopathic SN, and 22 had SN in the context of 
other conditions (ten Sjögren syndrome, five autoimmune hepatitis, two B12 vitamin 
deficiency, one systemic lupus erythematosus, one infection of human T-cell 
lymphotropic virus type 1, one hepatitis C virus, one toxic and one monoclonal 
gammopathy of undetermined significance). Five patients were taking medications 
that could interfere with the autonomic evaluations. These patients had their 
medications suspended a few days before the exams. Two patients had 
hypothyroidism under medication with physiologic hormonal rates during the past five 
years. 
  
SCOPA-Aut 
SN patients had significantly higher SCOPA-AUT scores when compared to 
controls. This result holds not only for total scores (25.68±12.89 vs. 12.16±8.12, 
p<0.001) but also for all subdomain scores (Table 1). The sexual dysfunction in 
women was an exception since it did not reach statistical significance (1.84±2.49 vs. 
1±1.49, p=0.17). 
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Tabela 9: Table 1: Comparison of SCOPA-Aut total scores and its subdomains for 
sensory neuronopathy patients and healthy controls. 
 
 SN patients (n=50)* Controls (n=32)* p value 
Gastrointestinal 
dysfunction 
6.2±4.9 3.41±2.89 0.005 
Urinary dysfunction 8.14±4.7 3.75±3.3 <0.001 
Cardiovascular 
dysfunction 
3.14±2.3 0.59±0.95 <0.001 
Thermoregulatory 
dysfunction 
5.11±3.04 3.03±2.97 0.003 
Pupillomotor dysfunction 1.23±0.91 0.63±0.83 0.004 
Sexual dysfunction (SxD) 1.86±2.36 0.75±1.3 0.01 
SxD men 1.92±2.07 0.25±0.45 0.01 
SxD women 1.84±2.49 1±1.49 0.17 
Total 25.68±12.89 12.16±8.12 <0.001 
* Results expressed by mean ± standard deviation. SN: sensory neuronopathy; SxD: 
sexual dysfunction 
 
Heart Rate Variability 
 Frequency domain 
 High (0.15–0.4 Hz), low (0.04–0.15 Hz) and very-low-frequency bands 
(0.0033–0.04 Hz) had the same proportions and total distributions between patients 
and controls. The LF/HF ratio had no significant difference between groups as well 
(Table 2). Eleven patients had 18 abnormal parameters in the frequency band 
distribution (six on HF, five on LF and seven on the VLF) whereas it was abnormal in 
four control subjects (one in HF, two in LF and one in VLF). 
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Tabela 10: Table 2: Frequency and time domain parameters of sensory 
neuronopathy patients and controls. 
 SN (n=44) Controls (n=32) p value 
Frequency Domain 
High frequency 
(HF) 
(mean±SD, 
ms2) 
730.6±1566.6 609.3±881.4 0.72 
Low frequency 
(LF) 
(mean±SD, 
ms2) 
540.5±659.9 685.3±550.4 0.36 
Very low 
frequency 
(VLF) 
(mean±SD, 
ms2) 
887.6±1239.5 840.8±574.7 0.86 
LF/HF 
(mean±SD) 
1.89±1.89 1.95±1.64 0.89 
%HF/%LF/%V
LF (mean±SD) 
27±21.9/27.6±12/45.7±1
8.4 
24.1±15/31.1±12.2/44.1±1
4.7 
0.56/0.26/0.
71 
Time Domain 
Average HR 
(mean±SD,bp
m) 
70.34±11.83 67.31±8.96 0.27 
RR max 
(mean±SD,ms) 
1027.77±197.8 1140.73±277.53 0.04 
RR min 
(mean±SD,ms) 
683.53±164.2 759.18±153.13 0.04 
RRNN 
(mean±SD,ms) 
870.51±147.1 918.76±155.07 0.17 
SDNN 46.67±30.55 49.43±23.18 0.66 
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(mean±SD,ms) 
pNN50 
(mean±SD,%) 
7.96±12.6 9.29±12.96 0.67 
Valsalva ratio 
(mean±SD) 
1.3±0.21 1.63±0.45 <0.001 
30:15 ratio 
(mean±SD) 
1.07±0.08 1.24±0.18 <0.001 
RSA 
(mean±SD,bp
m) 
12.86±7.09 20.6±8.84 <0.001 
E:I (mean±SD) 1.2±0.12 1.39±0.2 <0.001 
SN: sensory neuronopathy; HR: heart rate; max: maximum,; min: minimum; RRNN: 
mean RR normal-to-normal intervals; SDNN: Mean of the standard deviations of all 
the intervals without artifacts (NN intervals); pNN50: percentage of successive RR 
intervals that differ by more than 50ms; RSA: respiratory sinus arrhythmia; bpm: 
heartbeats per minute; E:I : expiration/inspiration ratio. 
 
 Time domain 
 Patients had shorter means of maximum and minimum resting RR intervals as 
well as all the cardiovagal tests (Valsalva ratio, 30:15 ratio, respiratory sinus 
arrhythmia, and the inspiration/expiration ratio) (Table 2). Mean RR normal-to-normal 
intervals (RRNN), the mean of the standard deviations of all the intervals without 
artifacts also called NN intervals (SDNN), and the percentage of successive RR 
intervals that differ by more than 50ms (pNN50) were similar for both groups (Table 
2). Accordingly to the reference values[16], 68%(30/44) of SN patients had abnormal 
VR, 54%(24/44) had abnormal 30:15 ratio and 13% (6/44) had abnormal E:I. 
 
Cardiovascular autonomic neuropathy 
 Thirty-one SN patients had two or more abnormal tests indicating CAN, 
whereas five controls fulfilled CAN criteria (p<0.001). There was not a specific 
characteristic associated to CAN, including gender proportion, age at the autonomic 
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evaluation, age at the SN onset, SN duration and the SN in a dysimmune context 
(Sjögren syndrome, autoimmune hepatitis and systemic lupus erythematosus)  (p-
values: 0.727, 0.141, 0.85, 0.541 and 1 respectively).  
 
Orthostatic Hypotension 
 Twenty-seven patients and four controls reached the criteria for OH  
(p<0.001). Despite that, only four of the SN patients and none of the controls had 
symptomatic hypotension with mild complaints of dizziness and blurred vision.  
 
Sudomotor function   
 Quantitative sudomotor axon reflex was assessed bilaterally (four standard 
sites per side) in SN patients resulting in eight points per patient whereas controls 
followed the standard four-point assessment. Total sweat volume was significantly 
lower in the SN group for all sites evaluated (Table 3 and Figure 2). At least one 
abnormal site was present in 92% of the patients (46/50), and from the total of 400 
assessed sites, 212 (53%) had a sweat volume under the 5th percentile for their age 
and sex. This proportion was significantly higher the one observed in controls, which 
had six points under the 5th percentile out of 128 assessed, p<0.001. In 38 points 
from 17 different SN patients (range: 1-7 sites) the sudomotor reflex was absent 
(anhydrosis) and two sites, from two different patients, had sweat volumes in the 
forearm over the 95th percentile (hyperhidrosis). Asymmetric findings and non-length 
dependent sweat impairment were present in two-thirds and in half, respectively, of 
the SN patients. Figure 3 summarizes the absolute number (Figure 3A) and the 
distribution (Figure 3B) of abnormal sweat sites in SN patients.  
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Tabela 11: Table 3: Sweat volume and response latencies for each standard site. 
 SN patients (n=50) Controls (n=32) p value* 
Right forearm (µL) 0.80±0.76 
1.22±0.65 
0.011 
Left forearm (µL) 0.71±0.93 0.008 
Latency right/left (s) 107.6±58.57/107.02±47.44 95.03±33.53 0.27/0.21 
Right proximal leg 
(µL) 
0.53±0.54 
1.04±0.42 
<0.001 
Left proximal leg 
(µL) 
0.61±0.52 <0.001 
Latency right/left (s) 94.24±50.79/106.06±81.29 78.06±35.86 0.12/0.07 
Right distal leg (µL) 0.41±0.53 
1.08±0.54 
<0.001 
Left distal leg (µL) 0.50±0.57 <0.001 
Latency right/left (s) 104.02±54.98/105.04±50 85.91±33.48 0.1/0.06 
Right foot (µL) 0.3±0.43 
0.75±0.42 
<0.001 
Left foot (µL) 0.22±0.29 <0.001 
Latency right/left (s) 144.56±56.09/152.73±75.0
6 
133.28±55.66 
0.38/0.22 
SN: sensory neuronopathies; µL: microliters; s: seconds; * significant differences are 
in bold. 
 
A comparison made with the nerve conduction studies revealed that the sweat 
volumes were normal whereas the SNAP amplitudes were abnormal in 32 patients in 
the right upper limb, five in the right lower limb, 29 in the left upper limb and nine in 
the left lower limb. Five patients (three in the left sural nerve, one in the right sural 
nerve e one in the left ulnar nerve) had normal SNAPs amplitudes and abnormal 
sweat volumes in the ipsilateral limb. Only two patients (one for the left ulnar nerve 
and one for the right sural nerve) had normal SNAPs and sweat volumes in the 
examined limb. No correlation between SNAPs amplitudes a sweat volume was 
obtained in the upper (right: R= -0.01 p=0.9; left: R= -0.145 p=0.31) or in the lower 
(right: R=0.04 p=0.77; left: R= -0.01 p=0.94) limbs. The same was true for the 
analysis of the total sweat volume and the disease duration, SARA, BBS and 
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INCATSS and SCOPA-Aut (R= -0.21 p=0.14; R= -0.04 p=0.76; R = -0.02 p= 0.88; R= 
0.07 p=0.62; R= 0.009 p=0.95, respectively). 
 
Sympathetic Skin Response 
 SSR was absent in at least one point in 30 (60%) SN patients while it was 
present in all points of the controls (left hand: p<0.001; right hand: p<0.001; left foot: 
p<0.001 and right foot: p<0.001). For ten patients, SSR was absent in all limbs, and 
for eight SN patients, a non-length dependent patter was present (SSR present in at 
least one foot and absent in an upper limb). Upper limbs SSR latencies were similar 
for both groups (left:  1440.67±382ms vs. 1317.14±259 ms p= 0.2; right: 
1369.55±453.62 vs. 1299.76±290.37 p= 0.53) whereas in the lower limbs latencies 
were significantly longer in the SN group (left:  2143.18±478.44ms vs. 
1765.71±353.93ms p= 0.005; right: 2193.63±571.44ms vs. 1856.19±270.03ms p= 
0.01). 
 
DISCUSSION 
  
 Non-paraneoplastic sensory neuronopathies are considered rare diseases and 
many aspects of the phenotype still deserve investigation, such as autonomic 
nervous system involvement. In this study, we recruited a large cohort of patients 
with npSN and performed a comprehensive clinical and neurophysiological 
evaluation of the autonomic function. As a group, patients had frequent and severe 
clinical manifestations of autonomic failure, such as postural hypotension. The more 
detailed neurophysiological assessment revealed combined dysfunction of both 
sympathetic and parasympathetic divisions in a remarkable proportion of patients.  
 Complaints related to the autonomic dysfunction were assessed through the 
SCOPA-Aut questionnaire since it is a comprehensive autonomic symptom survey. 
Even though it was designed to address autonomic symptoms in Parkinson’s disease 
(PD), it is the only Brazilian Portuguese validated instrument to address the 
autonomic system clinically[12]. Lately, this instrument has been used successfully in 
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different conditions other than PD[24-26]. It was able to demonstrate that npSN 
patients’ complaints extended to all autonomic subdomains in a pattern similar to 
other peripheral neuropathies[27-29]. Autonomic signs were also conspicuous in this 
cohort, such as OH.  Such postural drop in blood pressure, when combined with 
sensory ataxia, may result in an increased risk of falls adding significant hazard for 
these individuals. Tonic pupils were also a routine finding - present in one out of five 
npSN patients. This latter finding may reflect damage to the ciliary ganglion, which is 
in accordance with previous descriptions in SN[7] and case reports of other 
autoimmune conditions, such as Sjögren syndrome[30,31]. 
 Analysis of time-domain parameters of HRV revealed parasympathetic 
dysfunction in many patients with npSN. On the other hand, OH is a sign of 
sympathetic failure. Our group[7] and others[32] have already described 
parasympathetic impairment in SN. However, the original contribution of this study 
refers to the comprehensive clinical and neurophysiological evaluation of a larger 
npSN cohort. This approach enabled, for example,  the accurate assessment of 
npSN-related CAN. Our results indeed demonstrated definitive CAN in almost three-
quarters of SN patients.  
Interestingly, individual analysis of specific subjects brings exciting insights 
into how this impairment takes place. Three patients, for instance, had OH but no 
cardiovagal abnormalities. These findings are in striking contrast to those found in 
the diabetic CAN, where vagal dysfunction appears long before signs of sympathetic 
failure[29,33]. Much like somatic diabetic neuropathy, the diabetic CAN is a length-
dependent phenomenon, which explains why the vagus nerve is preferentially 
affected.  These considerations taken together, suggest that at least for some 
patients npSN-related CAN is a non-length dependent process.  
A significant finding in this study is the description of the pattern of sudomotor 
abnormalities in npSN. QSART analyses revealed that sudomotor dysfunction was a 
seemingly universal feature of the disease. Moreover, most patients had an 
asymmetric and non-length dependent pattern of sweat loss. Interestingly, the 
distribution of areas of sudomotor and sensory deficits over the body surface was 
mostly non-overlapping. Many subjects indeed had dramatically reduced sweat 
responses in limbs where clinical and sensory NCS were normal. These results 
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suggest that sudomotor dysfunction in npSN cannot be attributed to damaged 
sensory fibers per se. There must direct involvement of sympathetic cholinergic post-
ganglionic fibers. Besides, the multifocal rather than ‘polyneuropathic” pattern of 
sweat loss raises the hypothesis that autonomic ganglia, not distal autonomic axons 
are the actual target of the lesion. In such a scenario, many patients would indeed 
have a double neuronopathy – sensory and autonomic. This mechanism agrees with 
the experimental study of Collins and Weiner who could not elicit a sweat response in 
a cat’s pad after stimulating its dorsal roots proximal to the DRG[34]. A possible 
explanation for this double neuronopathy hypothesis lay in the functional and 
structural characteristics shared by both sensory and autonomic neurons. Evidence 
may be found in animal models[35-37] and confirmed by the existence of a group of 
hereditary neuropathies, such as the hereditary sensory and autonomic neuropathies 
(HSANs), that target selectively autonomic and sensory neurons.  
  Another argument towards the simultaneous sensory and autonomic 
neuronopathy emerges from the lack of association between sweat volumes and 
severity of ataxia/sensory deficits. Despite a tendency towards an inverse correlation 
between the total sweat volume and the disease duration, this was not statistically 
significant (p=0,14). This lack of correlation was also true for the CAN. Patients with 
and without criteria for CAN had similar ages, disease duration, gender, and 
associated etiologies. These data suggest that the random DRG destruction that 
takes place not only by the time of disease onset but also during its course also 
happens in the autonomic structures.  
 Overall, this study suggests that non-paraneoplastic SN has sympathetic and 
parasympathetic dysfunction as part of the clinical disease phenotype. Overall, 
dysautonomia was rather frequent and sometimes severe; it included both 
Sudomotor and cardiac abnormalities. This study has some limitations. Our cohort 
size of 47 patients is reasonably large for such a rare disease but precludes analysis 
of etiology-defined subgroups of npSN. One certainly needs to move towards 
multicentric studies in order to fully appreciate how frequent and severe autonomic 
dysfunction is in distinct subtypes of npSN, such as Sjogren's or toxic-related. The 
natural history of these abnormalities should also be pursued in prospective surveys. 
Another significant limitation is that we did not include data from paraneoplastic SN 
patients, who had already been evaluated before[38] with a result of 30% of the 
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patients with autonomic neuropathy. Neurologists should be aware of autonomic 
dysfunction not only in paraneoplastic but also in npSN since this is frequent, often 
disabling but a potentially treatable manifestation.  
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FIGURES: 
 
Figura 24: Figure 1: Flowchart of the inclusion process and the performed 
evaluations. The dropouts of each step are justified.  
SN: Sensory neuronopathy; QSART: quantitative sudomotor axon reflex test; HRV: 
heart rate variability; SSR: sympathetic skin response.  
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Figura 25: Figure 2: Box-plot of sweat volumes for each standard point of sensory 
neuronopathy patients and healthy controls.  
§: p= 0.011; ¶: p=0.008 ; * p<0.001. SN: sensory neuronopathy; µL: microliters.  
 
 
 
Figura 26: Figure 3: Absolute number per examined site (A) and the distribution (B) 
of abnormal sweat volumes.  
Red circles: sweat volume < 5th percentile; Blue circles: sweat volumes > 95th 
percentile; Green circles: > 5th percentile and < 95th percentile.  
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Abstract 
 Introduction: Sensory neuronopathies (SN) are characterized by multifocal 
non-length dependent sensory deficits and sensory ataxia. Its early recognition is 
essential for proper management and allows associated conditions investigation. Our 
objectives were to characterize the diagnostic odyssey for non-paraneoplastic SN 
(npSN) patients and to identify possible factors associated with delayed diagnosis. 
 Methods: We enrolled consecutively 48 npSN patients who were instructed to 
retrieve their previous medical records, and then we collected the data about their 
demographics, disease onset, previous incorrect diagnoses, and the recommended 
treatments.  
 Results: There was a male:female ratio of 14:34 and the mean age at the 
diagnosis was 41.4±10.5 years. Negative sensory symptoms were the heralding 
symptoms of SN in 25/48 patients (52%), and 28/48(58%) had idiopathic forms. The 
mean interval until the proper diagnose was 5.45±5.39 years with an average of 
3.08±1.4 wrong diagnosis.  
 Discussion: These results suggest that diagnostic delay and misdiagnosis are 
frequent in npSN.  
Keywords: Sensory neuronopathy, ganglionopathy, misdiagnosis, diagnostic delay, 
non-paraneoplastic, sensory ataxia.  
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Introduction 
 
Sensory neuronopathy (SN) is characterized by primary dorsal root ganglia 
damage and typically manifests as sensory ataxia with multifocal non-length 
dependent sensory deficits 1,2. First described in 1948 by Dr. Derek Denny-Brown 3, 
the full phenotypic characterization of the disease and its etiology is still pursued 4. A 
precocious detection of SN may provide, in a way rarely seen in neurology, a window 
of opportunity for the assessment of related conditions. For some of those, early 
identification may improve the prognosis of the underlying disorder, as it is the case 
of lung cancer for example, and for others, such as Sjögren syndrome or 
autoimmune hepatitis, it allows the start of effective treatment 4.  
Camdessanché and cols proposed in 2009 a set of diagnostic criteria that 
includes clinical features, electrodiagnostic and neuroimaging data 5. These criteria 
have been validated and are helpful for clinical practice. Despite that, diagnosis of 
SN is still challenging for both specialists and non-specialists for several reasons. 
This scenario is especially critical for non-paraneoplastic forms of the disease 
(npSN). Cancer-related SN often has an abrupt onset and somewhat stereotyped 
presentation, which is not the case for the remaining subtypes of SN 6. First, npSN is 
a rare disease, and medical awareness becomes a significant issue 6. Besides, the 
clinical picture of npSN is far from homogeneous and may recapitulate other 
neurological as well as non-neurological illnesses. Some patients have predominant 
small fiber-related symptoms, whereas others essentially present large fiber-related 
symptoms 7. Disease course is also highly variable, ranging from acute to chronic 
progression. Take together; these conditions increase the likelihood of misdiagnosis 
or delay in diagnosis of npSN.  
Thereby, our objectives were to investigate the diagnostic odyssey of patients 
with npSN, with a particular interest in the identification of incorrect diagnoses 
performed, duration of the diagnostic delay and possible predictive factors for this 
delay. 
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Methods 
 
Subjects’ selection and clinical evaluation 
 We consecutively included patients diagnosed with npSN according to the 
criteria proposed by Camdessanché and cols 5, followed in a tertiary referral 
outpatient neuromuscular clinic of the University of Campinas hospital, São Paulo, 
Brazil in the period between 2016 and 2017. One of the authors (ARMM) interviewed 
all patients focusing on the disease onset, symptoms at that time and the entire 
“health services pathway” until the diagnosis was finally reached, including the 
number and the specialties of the consultant physicians and eventually the 
suggested treatments. Before this active inquiry, all patients were informed about 
what SN-related signs and symptoms are to avoid misinterpretations regarding the 
appointments that were not related to the SN clinical picture. Furthermore, all 
patients were encouraged to retrieve all available information about their medical 
care since the disease onset. These included but were not restricted to, quondam 
disease reports, referral forms, therapeutic plans, previous prescriptions and 
eventually a copy of the medical records from the former clinics. Given the 
heterogeneity of the patients referred to our center, we have reviewed the outside 
medical records to ensure accurate conclusions. In addition to the crude description 
of the diagnostic odyssey, we looked for factors associated with the diagnostic delay 
trying to delineate possible milestones involved in this process.  
 
Statistical analyses 
Demographic and clinical data are presented with descriptive statistics 
(measures of central tendency and dispersion) and 2-sample t-test, Pearson's χ2 test 
or exact Fisher’s test were applied to compare groups when appropriate, with p 
values < 0.05 considered significant. Groups were compared considering gender, 
associated etiologies, heralding symptom (negative and positive sensory complaints 
and ataxia), asymmetric symptoms at the onset and the evolution course. All 
included patients agreed with and signed an informed consent statement form. This 
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study was approved by the local Ethical Committee and was carried out following the 
1964 Declaration of Helsinki and its later amendments.  
 
Results 
 
Demographics and clinical characteristics 
 A total of 48 npSN patients were enrolled. Mean age at evaluation was 
51±11.3 years (range 26-72) and the male: female ratio was 14:34. The age at the 
disease onset was 41.4±10.5 years (range 20-63), and the mean age at the 
diagnosis was 45.9±12.2 years. Considering specifically the gender, men and women 
had similar ages at onset: 43.1±11.1 and 40.7±10.3 years, respectively (p=0.48).  
Gait ataxia was the debut symptom in 11 patients (22.91%) whereas negative 
and positive sensory symptoms were the inaugurating symptoms of npSN in 25 
(52%) and 12 (25%) patients, respectively. Interestingly, 2 patients (5%) had pruritus 
as the first symptom. These initial symptoms were asymmetric in 36 (75%) and 
symmetric in 12 (25%) of the npSN patients. Symptoms evolved in a chronic fashion 
in 34 patients (70%) whereas for 14 patients (30%) the disease had an 
acute/subacute onset.  
Twenty-eight patients (58.3%) had idiopathic or primary SN, for 11 patients 
(23%) SN was related to Sjögren Syndrome, 4 (8.3%) had associated autoimmune 
hepatitis, and the latter 5 (10.4%) had other associated diseases, which included 1 
HTLV infection, 1 Zika virus infection, 1 hepatitis C virus infection, 1 monoclonal 
gammopathy of undetermined significance and 1 patient with systemic lupus 
erythematosus. Bearing in mind only the group of patients that have SN related to 
another disease, in 12 out of 20 (60%) SN was the first clinical manifestation 
enabling a posterior recognition of the underlying disease during the work-up. The 
mean disease duration by the time of this evaluation was 9.0±7.4 years. Table 1 
summarizes the general demographics and information about the disease onset and 
diagnostic delay/misdiagnoses. 
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Diagnostic delay and misdiagnosis 
Concerning the diagnostic delay, an average patient from this group had a 
5.4±5.3-year interval between the disease onset and the correct diagnosis (range 1-
21). None of these patients had the first evaluation made in our clinic. Their path 
throughout the health system due to SN-related symptoms included appointments 
with a mean of 4.3 ± 2.4 (1-10) physicians that included general practitioners, 
orthopedic surgeons, general and vascular surgeons, psychiatrists, neurosurgeons, 
neurologists, and others. Each patient received an average of 3.5 ± 1.5 incorrect 
diagnoses (ranging from 1-7) (Table 1). Table 2 lists the incorrect diagnoses given 
after an appointment for SN-related symptoms and signs.  Based on these 
misdiagnoses, in 64 occasions a prescription was made (mean of 1.3 per patient) 
being non-steroidal anti-inflammatory drugs the most frequently recommended 
(23%). Besides the incorrect diagnoses and treatments, more than half of these 
patients (27/48) refer that they have stopped their working activities since the disease 
onset.  
 
Factors associated with the diagnostic delay 
Group comparisons were made considering different characteristics such as 
gender, associated etiologies, heralding symptom (negative and positive sensory 
complaints and ataxia), asymmetric symptoms at the onset and the evolution course. 
A disease onset before forty years of age (n=27) was associated with a smaller 
diagnostic delay when compared to those patients (n=21) with a disease onset over 
the 40 years old (3.7±3.4 vs. 7.8±6.7 years, p=0.01). All the remaining characteristics 
were not significantly associated with longer diagnostic delays or to a higher number 
of misdiagnoses (p>0.05).  
Discussion 
 This is the first study specifically devoted to investigating the diagnostic 
odyssey of npSN; herein we were able to show that misdiagnoses with consequent 
diagnostic delay were a significant issue in this cohort. Our data reveal that on 
average, patients receive 3 incorrect diagnoses before SN recognition. The whole 
process takes more than 5 years and appointments with at least 4 physicians up to 
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the proper diagnosis. Such delay has clear implications for affected individuals, such 
as the exposure to inadequate therapeutic regimens and in the end, economic/social 
hazard related to unemployment (more than half of the patients lose their jobs along 
the process). Such numbers are similar to other rare neuromuscular disorders, where 
the diagnostic delay is also a problem 8-15. This delay also takes place, for example, 
in hereditary transthyretin amyloid neuropathy (150 patients: 46.4±25.4 months of 
delay) 13 and myotonic dystrophy type I (679 patients: 7.3±8.2 years of delay) 10. 
Taken together these data suggest that lack of awareness may be the fundamental 
cornerstone for all these disorders. 
 Several factors may have influenced our results. Even though a large 
European cohort has placed SN as the most common paraneoplastic syndrome 16, it 
is overall considered a rare condition 4,7,17. However, we did not include the 
paraneoplastic forms of SN, which may resemble a more aggressive symptom 
settlement when compared to the non-paraneoplastic forms. Therefore our results 
should be considered only for this latter subgroup.  
Another possible explanation for our results is the remarkable phenotypic 
heterogeneity that characterizes the SN. Besides classic sensory ataxia, positive 
symptoms related to small fiber damage frequently take part in the clinical picture. 
Additionally, some features, such as pseudoathetosis and pseudoparesis, that 
emerge from severe proprioceptive deafferentation present in SN could be 
considered as bizarre or even resultant from a psychiatric condition to less 
experienced physicians 1,5,6,7,18. However, since none of these distinct complaints of 
the SN patients were related to shorter delay in diagnosing or to fewer misdiagnoses, 
it seems that SN may not be part of the “average physician’s” diagnosis list. This 
issue has become even more relevant since Antoine and cols have published a 
study, based on electrodiagnostic tests, that argues in favor of an eight-month 
window from the disease onset as the ideal period for starting therapy to achieve SN 
stabilization 19.  
These results are particularly worrisome considering how the Brazilian`s 
health system is structured. Patients that rely on the public system, which are the 
vast majority of this cohort, are preliminarily evaluated in the primary care. After that, 
a limited workup may take place and then those patients who fulfill specific referral 
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criteria are forwarded to a tertiary clinic what may add extra time to the delay in the 
SN diagnosis.  Since the present study is a tertiary center-based, there might also be 
a referral bias towards more severely affected subjects. In this scenario, we 
hypothesize that estimates for diagnostic delay would be even higher considering the 
general population. In our opinion, subjects with few or even milder symptoms would 
suffer from long delays, because of the less severe phenotype that may easily 
resemble other long-standing peripheral nerve disorders. Nevertheless, it is 
imperative to increase the awareness for the disease recognition to achieve an 
earlier diagnosis. To accomplish that, besides a prompt recognition of clinical signs 
and symptoms, complementary exams assume a helpful role and include both simple 
techniques such as an electrodiagnostic index 20 and more complex ones, such as 
spinal cord magnetic resonance imaging 21,22.  
Considering this “everybody loses” scenario, an average SN patient suffers 
not only with inappropriate treatments but also with longer and costly diagnostic 
workup; on the other hand, physicians enter in the trend of increasing numbers of 
malpractice claims 23. To recognize the weaker points in the whole diagnostic 
process is extremely important to set strategies for better outcomes. Instead of 
pointing fingers, it is paramount to remember a pioneer in the study of misdiagnosis 
in medicine, Dr. Richard Cabot, who said: “Reform, not blame” as a guideline to 
improve not only SN neurological care but also the general health services 24. 
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Tabela 12: Table 1: General demographics and clinical data of the recruited cohort of 
patients with non-paraneoplastic SN. 
Sensory Neuronopathies Patients (N= 48) 
Age (years±SD) 51±11.3 
Male:Female ratio 14:34 
Age at disease onset (years±SD) 41.4±10.5 
Disease duration (years±SD) 9.02±7.42 
Diagnostic Delay (years±SD) 5.45±5.39 
Number of misdiagnosis (±SD) 3.5±1.5 
Number of Consulted Physicians (±SD) 4.35±2.46 
 
Tabela 13: Table 2: List of incorrect diagnoses given for patients with non-
paraneoplastic SN. 
Wrong Diagnosis for sensory neuronopathies Patients (N= 167) 
Neuropathy 
Radiculopathy 
18 
18 
Polyneuropathy 11 
Ostheoarticular 11 
Psychiatric 10 
Demyelinating neuropaties (GBS/CIDP)  9 
Toxic/Metabolic 
Central Nervous System* 
Carential 
Others 
9 
8 
8 
19 
No hypothesis made 46 
* Wrong central nervous system-related diagnosis included: 2 spinal cord damages, 
2 multiple sclerosis, 2 autosomal recessive ataxias, 1 cerebellar impairment, 1 
stroke.   
GBS: Guillain-Barre syndrome; CIDP: chronic inflammatory demyelinating 
polyneuropathy.  
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Abstract 
 
Background: Sensory neuronopathies (SN) result from dorsal root ganglia damage 
and manifest with a combination of sensory deficits and proprioceptive ataxia. 
Characterization of the natural history and development of therapeutic trials are 
hampered by the lack of clinical scales that capture the whole spectrum of SN-related 
manifestations. In this setting, our objective was to propose and validate a rating 
instrument devoted to assess afferent ataxias, especially SN. 
Methods: Three experienced neuromuscular specialists developed items to rate 
sensory ataxia. The resultant instrument was later validated by the assessment of the 
intraclass correlation coefficient, for iterrater validity in 48 SN patients  and later in a 
smaller subset of 16 patients to assess its intrarater validity. Standardized 
Crombach`s alpha and Oblimin rotation analysis were performed to verify internal 
consistency and items’ relationship respectively. The following step was the 
evaluation of SEARS’s external validity when it was compared to different scales: 
scale for the assessment and rating of ataxia (SARA), Beck balance scale (BBS) and 
INCAT sensory sum score (ISS). 
Results: A 10-item scale with an intraclass correlation coefficient >.95 for intra and 
interrating measurements with a good internal consistency (standardized Cronbach’s 
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alpha of 0.83) were observed. There was a normal distribution of the scores without a 
floor or ceiling effect. A moderate to good correlation between SEARS and SARA, 
BBS and ISS was also observed. 
Conclusions: SEARS is a reliable, easy-to-perform and consistent instrument to rate 
sensory ataxia. Larger cohorts and multicentric studies are needed to validate its 
usefulness towards possible treatment trials. 
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Introduction 
  
 Sensory neuronopathies (SN) represent a distinct phenotype of peripheral 
nervous system impairment. The clinical picture is the reflex of the dorsal root ganglia 
(DRG) damage and is composed by non-length dependent and asymmetrical 
sensory deficits alongside sensory ataxia [1-3]. Besides these classic and sometimes 
straightforward symptoms, unusual ones may arise, such as pseudoathetosis and 
pseudoparesis [1,4].  Despite the presence of well-defined diagnostic criteria [5], 
seventy years after Denny-Brown’s first SN report in 1948 [6], there are still no 
validated instruments to capture and quantify the whole spectrum of SN-related 
manifestations. Its relatively low prevalence [1-3,7,8] probably may have contributed 
to this scenario. 
 The urge for such rating instruments has earned even higher importance since 
the recently published paper by Antoine and cols describing a therapeutic window 
beyond which there is a modest neurophysiological recovering of nerve parameters 
in SN patients [9]. Therefore, measuring the disease severity is paramount for the 
design of clinical trials. There are several instruments devoted to rating symptoms in 
conditions that may resemble SN, however, their items have heavier weights for 
cerebellar ataxia signs [10-12], length-dependent sensory deficits [13] or motor 
symptoms [14]. These are all rather unusual for the typical subject with SN. Taking 
these facts into account, we conceived the Sensory Ataxia Rating Scale (SEARS) 
that is a semiquantitative instrument specifically designed to assess SN-related 
manifestations. We herein describe the results of its validation in a representative 
patient cohort with SN. 
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Methods 
Scale conceiving  
SEARS was first designed in 2014 when three board certificated neurologists 
(AN, MCFJ, and ARMM) with 30, 15 and four years of experience in the care of SN 
patients have figured out the core features of physical examination during the 
disease course that encompass both mild and severe SN presentations. Ideally, the 
individual items should also, when possible, include the evaluation with eyes closed, 
which is a hallmark in sensory ataxia. A minimal set of specialized gadgets required 
for SEARS execution was also intended, however, since it includes the evaluation of 
the sensory system a tuning fork, a reflex hammer, and a pinprick tool are needed. 
Examiners were both neurologists and the first seven patients they performed the 
evaluations together reaching a consensus for the different items. 
 
 
Scale description 
 A full-scale description is available in the supplemental data (Appendix 1). The 
neurological examination includes gait (0-6), balance (0-7), appendicular coordination 
for upper (0-3) and lower limbs (0-3), pseudoathetosis (0-4), pseudoparesis (0-4), 
tactile sensation (0-5), sense position (0-2) and vibratory (0-5) senses and deep 
tendon reflexes (0-2). Its scores vary from 0 (no impairment) to 41 (maximal 
impairment). Gait, balance and appendicular coordination include performances both 
with eyes open and closed. Careful  supervision was done especially for attempts 
done with eyes closed; no accidents were recorded due to these tests. 
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Study population 
 All enrolled patients fulfilled SN diagnostic criteria [5] and are regularly 
followed at UNICAMP neuromuscular outpatient clinic. Two experienced neurologists 
conducted the interrater evaluations that took place in the same morning, after or 
before, the regular outpatient clinic appointments between 2015 and 2017. After the 
interrating process took place, a subset of 15 patients was consecutively evaluated 
twice by one of the authors in a maximal interval of 30 days between them to assess 
intrarater reliability. Our local Ethics committee (Comitê de Ética em Pesquisa – 
UNICAMP) approved this study under number #25789013.5.0000.5404, and all 
patients signed an informed consent form before the enrollment. 
 
Construct validation 
 In addition to the SEARS, all patients were also evaluated under three 
different scales for external criterion validation purposes. Correlation between 
SEARS and the scale for the assessment and rating of ataxia (SARA) [15], INCAT 
sensory sum score (ISS) [16], Berg balance scale (BBS) [17] and the disease 
duration was examined. 
 Scale scores and their meaning are summarized as follows: 
- SARA: scale initially designed to assess ataxic features in spinocerebellar 
ataxias, ranges from 0 (no ataxia) to 40 (severe ataxia);  
- ISS: instrument validated in sensory-motor immune-mediated 
polyneuropathies with scores ranging from 0 (normal) to 16 (the worst 
scenario);  
- BSS: evaluates the functional balance performance. The possible scores 
range from 0 (worst performance) to 56 (no balance issues). 
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Statistical analyses 
  Statistical analyses were performed using SPSS v22 , MATLAB r2017b and 
Free Statistics Software (v1.2.1) [18]. Descriptive statistics were used to express 
general demographic and the scales scores. The intraclass correlation coefficient 
(ICC) was calculated to demonstrate the agreement between each examiner 
(interrater evaluation) and also the intrarater concordance for each item and the final 
score. Assuming that SEARS scale is reproducible, we use the principal component 
analysis (PCA) to assess its reliability in each modality (inter and intrarater). In this 
scenario, we expect that for a given individual will be closer to him/herself rather than 
to someone else.  Cronbach’s α coefficient was used to evaluate internal 
consistency. To determine items’ relationship we used exploratory factor analysis 
with Oblimin rotation. Item-to-total correlations and floor and ceiling effects assessed 
clinimetric properties. SEARS external validity was further investigated by the 
determination of Pearson`s coefficient considering SARA, ISS and BBS scores and 
also to the disease duration.  
 
 
Results 
 Forty-eight patients with SN were consecutively enrolled and evaluated to 
assess interrater characteristics. A smaller subset of these patients (16 patients) was 
later evaluated to gather the intrarater properties.  Demographic and clinical data of 
these groups are shown in Table 1. There was somewhat expected etiology 
heterogeneity since no underlying SN-related disorder was selected. Among the 
observed etiologies, there were subjects with Sjögren syndrome, autoimmune 
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hepatitis, vitamin B12 deficiency, HTLV1 infection, monoclonal gammopathy of 
undetermined significance and idiopathic cases.  
The SEARS feasibility was acceptable and although time measurement was 
not formally done, a 15 to 30-minutes total time was required to administer it. Reflex 
hammer, tuning fork, and a pinprick tool are the only devices needed to perform 
SEARS; all of them are part of the everyday carry-on items of an average 
neurologist.  
 Considering the patient population described herein in Table 1, mean scores 
for SEARS were 23.1±5.8 (range 8-39). All items had a wide range of scores and 
only two of them, static balance and vibration sensation, did not reach the minimum 
score in this SN population (all subjects had scores ≥1 in each of these items). 
Overall, there was a normal distribution of SEARS scores, without floor or ceiling 
effect. 
 SEARS’s interrater and intrarater evaluation showed an excellent agreement 
with ICC of 0.96 and 0.98 respectively. SEARS’s characteristics and scores for inter 
and intrarating correlations are summarized in Table 2. Interater and intrarater 
reliabilities had a good result overall and are displayed graphically in the Figures 1 
and 2, respectively. Individual items also had ICC>0.8 emphasizing a definite 
agreement alongside all the scale`s items. A standardized Cronbach’s alpha of 0.83 
denoted an excellent internal consistency, which was not significantly affected when 
single items were deleted.  
All the ten SEARS items reached the item-to-total correlations scores higher 
than the criterion 0.3 (Table 2) [19]. None of the patients reached the minimum or the 
maximum values for SEARS and most sub item scores spread from zero to the 
maximal score (exception for static balance and sensory testing as previously 
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mentioned). Exploratory factor analysis with Oblimin rotation indicates that two 
factors may explain 51.7% of the SEARS variance. These factors were related to 
ataxia and sensory evaluation. This implies that sensory ataxia is the primary 
measurement underlying the final SEARS scores. 
 External construct validation demonstrated that SEARS have a moderate 
correlation to SARA (r= 0.64, p<0.001), ISS (r= 0.51, p<0.001) and BBS (r= - 0.57, 
p<0.001) with non-significant correlation with disease duration (r= 0.07, p=0.6). 
 
 
 
Discussion  
  
The absence of validated instruments capable of providing reliable endpoint-
measurements represents one of the multiple barriers for the development of 
treatment trials directed towards several orphan diseases, such as SN. Specifically 
for patients with SN, these difficulties are combined with the lack of specific 
biomarkers for both early diagnosis and follow-up [2,5,7]. Therefore, another clear 
benefit from a rating instrument is the possibility to gather follow-up data useful to 
delineate SN natural history. 
SEARS represent the first instrument specifically designed to evaluate 
sensory ataxia. Its conceiving took place with a selection of the main clinical features 
of a typical patient with SN. The resulting ten items had good inter and intrarater 
agreement highlighted by ICC values. In this easy-to-perform clinical scale, a short 
time interval and a neurologist everyday-carry set of equipment are the only 
requirements for its fulfillment. For non-specialists, some training is required to 
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become familiar to some different clinical findings such as pseudoathetosis and 
pseudoparesis. Initially described by Oppenheim as “useless hand” in the context of 
multiple sclerosis patients with a severe proprioceptive loss, the phenomenon of 
pseudoparesis, which is not restricted to the hands, refers to an apparent weakness 
when the motor function in intact [20]. In other words, patients with SN may seem to 
be weak in the physical examination, however since they have, by definition, a 
preserved motor function, this pseudoparesis is the result of the DRG damage that 
leads to impaired proprioception. This is what explains a better performance of the 
strength exam when a SN patient is told to look straight to the examined muscle 
being tested. 
The Oblimin rotation alongside the Cronbach’s α coefficient highlighted a 
reliable general neurological measurement underlying the SEARS. Indeed, two 
factors related to ataxia and sensory evaluation items encompassed more than 50% 
of the variance. Additionally, SEARS scores had a moderate and statistically 
significant correlation with different constructs that evaluate ataxia (SARA), balance 
(BSS) and sensory neuropathic signs (INCATSS). Conversely, there was no 
correlation between SEARS scores and disease duration. SN are rather 
heterogeneous in terms of etiology and this leads to dramatic variation in the rates of 
disease progression. For instance, autoimmune SN often has acute or subacute 
onset, whereas idiopathic and inherited subtypes evolve slowly along several years. 
Such discrepancies may explain the lack of correlation between SEARS scores and 
disease duration. 
The central role of SEARS as another rating instrument in a universe of 
clinical scales, many of them focused on ataxias and peripheral neuropathies, is the 
fact that it was specifically designed to capture and quantify distinctive features of 
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sensory ataxia. The inclusion of the eyes closed during several items, the Romberg 
sign, pseudoathetosis and pseudoparesis are paramount for afferent ataxias. On the 
other hand, the presence of items devoted to characteristics rarely seen in SN such 
as speech evaluation [11-13], swallowing, cough, strength, muscle wasting [12,14], 
make parts of the existing instruments not suitable to the afferent ataxias. Moreover, 
a specific rating process for the items 7 and 9 helped to balance eventual non-length 
dependent deficits since a deficit in proximal limb segments in the context of sparing 
more distal ones would bring a ceiling effect in the item score such as the one 
observed in the INCATSS scores. No floor or ceiling effects were indeed seen in 
SEARS.  
Some limitations, however, may be acknowledged. First of all, these 
evaluations included only adults harboring sensory neuronopathies. Second, this was 
a cross-sectional evaluation, One still needs to assess the validity of this tool for 
children and how sensitive it is to track disease progression. Therefore, longitudinal 
studies with larger cohort sizes are the next step needed. Considering the rarity of 
SN, multicentric efforts will be needed to reach this goal.  
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Tabela 14: Table 1: Demographics and clinical characteristics of the sensory 
neuronopathy patients. 
 
 Interrater (N=48) Intrarrater (N=16) 
Age (average ± SD) 
years 
50 ± 10.8 53.8 ± 11 
Sex M:F 13:35 4:12 
Disease onset (average 
± SD) years 
41.4 ± 9.3 42.2 ± 8.3 
Disease duration 
(average ± SD) years 
8.5 ± 7 11 ± 7.8 
Idiopathic etiology 26/48 8/16 
Sjögren syndrome-
related 
11/48 4/16 
Other etiologies* 11/48 4/16 
* Other etiologies include: autoimmune hepatitis, HTLV infection, monoclonal 
gammopathy of undetermined significance and B12 vitamin deficiency. 
 
 
 
 
	 	 186	
	
Tabela 15: Table 2: SEARS items and the respective interrater, intrarater and Item-
to-total correlations. 
 
ITEM 
IE ICC 
(n=48) 
IA ICC 
(n=16) 
Item-to-total correlation 
(Spearman rho) (n=48) 
1 0.92 0.96 0.71 (p<0.001) 
2 0.93 0.97 0.63 (p<0.001) 
3 0.85 0.94 0.54 (p<0.001) 
4 0.93 0.96 0.48 (p<0.001) 
5 0.93 0.93 0.67 (p<0.001) 
6 0.91 0.91 0.52 (p<0.001) 
7 0.92 0.92 0.31 (p = 0.02) 
8 0.93 0.92 0.51 (p<0.001) 
9 0.94 0.94 0.52 (p<0.001) 
10 0.96 1 0.53 (p<0.001) 
SEARS final score 0.96 0.98 n/a 
IE ICC: interrater intraclass correlation coefficient; IA ICC: intrarrater intraclass 
correlation coefficient; n/a: not applicable. 
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Figura 27: Figure 1: Heat map: matrix of ranked distance between subjects. Test-
retest pairs that scored as 1 (dark blue) represent individuals closer to him/herself. 
Test-retest pairs that scored higher than 1 show individuals closer to individuals other 
than him/herself. SEARS performance demonstrates short distances (represented by 
color differences) between test-retest scores in the individuals. 
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Figura 28: Figure 2: Principal component analysis plot created with the scores of 
each item of the SEARS scale. Individuals are color-coded and the same color 
represents a test-retest pair of the intrarater evaluation.   
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Supplement  
 
Sensory ataxia rating scale (SEARS) 
1. Static balance: the patient is asked to stand for fifteen seconds in three positions: 
1: natural position; 2: with feet together (halluces together); 3: heel-to-toe position. 
The patient ideally is barefooted. All positions must be evaluated with opened and 
closed eyes. Three trials are allowed, and the best performance is recorded. The 
patient can: 
0 – Stay in the heel-to-toe position with eyes closed >10 seconds (normal); 
1 – Stand with the feet together and eyes closed with minimum balance >10 
seconds; 
2 – Stand in the natural position and eyes closed >10 seconds; 
3 - Stand in the natural position >10 seconds with opened eyes but not with closed 
eyes; 
4 – Stand in the natural position >10 seconds with intermittent support and opened 
eyes; 
5 - Stand in the natural position >10 seconds with constant support and opened eyes; 
6 – Unable to stand in the natural position >10 seconds even with constant support 
and opened eyes. 
 
2. Gait: the patient is asked to perform an 8-meter (approximately 8.5 yards), with a 
turn in the halfway, ideally next to a wall and with an examiner to eventual support. 
Patients are evaluated with a natural gait, gait with eyes closed and heel-to-toe gait: 
0 – Normal gait even with eyes closed; 
1 – Slightly difficulties present only with eyes closed; 
2 – Severe gait abnormalities with eyes closed and/or gait impossible in the heel-to-
toe; 
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3 – Unable to walk with closed eyes and/or with significant difficulties in the turn but 
still able to walk unassisted with opened eyes; 
4 - Severe unsteadiness with difficulties during the turn or eventual support in the 
wall; 
5 – A constant need of a cane or one arm of the examiner; 
6- Gait only possible with opened eyes and constant strong support (canes, walker or 
a person); 
7- Unable to walk. 
 
3. Upper limbs coordination: a three trial finger-nose evaluation is performed with 
eyes opened and three with eyes closed. The evaluation is considered abnormal if 
two or three movements miss the target. The final score is reached by the average of 
the scores of each arm separately. 
0 – Normal (even with eyes closed); 
1- Normal with eyes opened but abnormal with eyes closed; 
2 – Abnormal even with eyes open; 
3- The patient is unable to perform the task. 
 
4. Lower limbs coordination: the evaluation is made with a five-trial with eyes opened 
and five trials with eyes closed. The patient is required to touch the heel in the 
midpoint of the anterior leg followed by a leg extension in which a minimal distance of 
0,5foot is reached. The evaluation is considered abnormal if three or more 
movements miss the target. The final score is reached by the average of the scores 
of each leg separately. 
0 – Normal (even with eyes closed); 
1- Normal with eyes opened but abnormal with eyes closed; 
2 – Abnormal even with eyes open; 
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3- The patient is unable to perform the task. 
 
5. Pseudoathetosis: may be determined in all limbs separately if the patient is unable 
to perform the task by any reason it is considered present. 
0 - Absent in all limbs; 
1 – Present in 1 limb; 
2 – Present in 2 limbs; 
3 – Present in 3 limbs; 
4 – Present in 4 limbs. 
 
6. Pseudoparesis: may be determined in all limbs separately if the patient is unable 
to perform the task by any reason it is considered present. 
0 - Absent in all limbs; 
1 – Present in 1 limb; 
2 – Present in 2 limbs; 
3 – Present in 3 limbs; 
4 – Present in 4 limbs. 
 
7. Sensory testing: Pain is tested in the following sites: second finger, wrist, elbow 
and shoulder in the upper limbs and hallux, ankle, knee, and hip bilaterally. Each side 
is evaluated separately, and the final score is the average between the numbers of 
abnormal points on each side. 
0 – Final mean is zero; 
1 – Final mean is 1; 
2 - Final mean is 2 or 3; 
3 - Final mean is 4 or 5; 
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4 - Final mean is 6 or 7; 
5 - Final mean is 8. 
 
8. Sensory testing: sense position. This sensory modality is evaluated in both 
halluces and the distal phalanges of the 2nd fingers. 
0 – Normal sense position; 
1 – Sense position is impaired in the fingers or the halluces; 
2 – Sense position is impaired in both fingers and halluces. 
 
9. Sensory testing: vibration sense is tested in the following sites: second finger, 
wrist, elbow and shoulder in the upper limbs and hallux, ankle, knee, and hip 
bilaterally. A length dependent criterion is defined if the impairment is more severe in 
the proximal than in the distal sites of a limb. Twenty and fifteen seconds are 
considered normal for upper and lower limbs respectively. 
0 – No abnormalities; 
1 – Abnormalities restricted to the distal sites; 
2 – Proximal abnormalities more severe than proximal in a single limb; 
3 – Diffuse hipopalestesia but following the length-dependent criteria; 
4 - Diffuse hipopalestesia NOT following the length-dependent criteria; 
5 – Global apalestesia. 
 
10. Deep tendon reflexes. Biceps, brachioradialis, knee and ankle reflexes. 
0 – Normal reflexes; 
1 – Absent reflexes in upper or lower limbs; 
2 – Global areflexia. 
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DISCUSSÃO 
 
	 Na tese ora apresentada buscamos ampliar o conhecimento acerca das 
etiologias imputadas como responsáveis pelos quadros de NS, melhorar o 
delineamento da sintomatologia clínica inclusive com o suporte de técnicas 
neurofisiológicas, identificar pontos relevantes  no que tange ao atraso e o erro 
diagnóstico desses pacientes os quais uma vez diagnosticados podem, agora, ter 
quantificados os seus sinais e sintomas por  meio de instrumento puramente clínico. 
Desta forma, podemos dizer que os resultados expostos expandiram o 
universo de doenças relacionadas às NS, chamam a atenção para sintomas comuns 
porém por vezes negligenciados em um contexto clínico dominado pela ataxia 
sensitiva e fornecem meios para que os pacientes possam ser objetivamente 
acompanhados. Sendo assim, a atenção a esses pacientes, feita não somente por 
neurologistas como por diversas especialidades, foi diretamente impactada por 
novas informações a respeito da fisiopatologia da doença e da formação de um 
alicerce para possíveis estudos que envolvam a evolução natural da NS. 
 
Contribuições ao diagnóstico etiológico 
 A primeira contribuição de nosso trabalho para a literatura foi a identificação 
de uma nova etiologia para a NS. A epidemia vivida por nosso país a partir de 2015 
com um aumento significativo do número de casos de infecção pelo vírus Zika 
(ZIKV) e de maneira associada de suas complicações neurológicas (44), fez emergir 
uma série de manifestações ainda não descritas assiciadas ao ZIKV (45,46). Nesse 
contexto, tivemos a oportunidade de descrever, a até então inédita associação entre 
NS e ZIKV. A paciente em questão, apresentou quadro clínico pós infeccioso 
exclusivamente sensitivo com estudo neurofisiógico do sistema nervoso periférico 
corroborando os achados clínicos ao demonstrar um nítido acometimento dos 
nervos sensitivos que não obedecia aos critérios de comprimento-dependência 
(amplitude do potencial de ação sensitivo do nervo sural com um menor 
acometimento em relação aos nervos mediano e ulnar). Os possíveis diagnósticos 
deferenciais poderiam incluir uma polineuropatia sensitiva associada ao ZIKV ou 
ainda a síndrome de Miller-Fisher (SMF). A polineropatia associada ao ZIKV já foi 
	 	 194	
	
descrita. No entanto, clinicamente e neurofisiologicamente o caso descrito 
diferencia-se do primeiro pois este apresentava achados clínicos associados ao 
acometimento simétrico e comprimento-dependente predominantemente associado 
à lesão de fibras neurológicas finas e um padrão de lesão pelos estudos de 
condução nervosa restritos aos nervos surais (47). Quanto à discussão diagnóstica 
de uma possível SMF, a ausência de anticorpos anti-GQ1B poderia ser útil (48), no 
entanto a indisponibilidade do mesmo tornou a discussão semiológica mais 
relevante. A resposta incompleta à infusão de imunoglobulina humana e a 
inexistência do acometimento dos nervos cranianos associdos ao curso prolongado 
e persistente dos déficits torna menos provável o dignóstico de SMF. Outro ponto 
relevante que fala em favor ao quadro pós-infeccioso de NS associado ao ZIKV é o 
fato de que os GRD são particularmente vulneráveis a ação de fatores externos 
(2,3,38) colocando-os em risco especialmente na presença de agentes 
neurotrópicos com potencial lesivo como é o caso do ZIKV (49). De fato, a avaliação 
pacientes por técnicas de neuroimagem com infecção pelo ZIKV e outro fenótipo 
neurológico, demonstrou o acometimento tanto das raízes neurais como também 
dos GRD (50).  
 Uma outra adição importante às doenças associadas a NS foi a descrição de 
um caso de NS associada ao HTLV-1 e que posteriormente iniciou quadro de 
liberação piramidal e sinais de paraparesia. Trata-se do primeiro caso de um 
fenótipo neurológico composto por essa associação. Nesse caso específico, o início 
dos sintomas com NS permitiu o dignóstico da infecção pelo HTLV-1 pelo protocolo 
de triagem de doenças associadas disparado pelo reconhecimento de NS. Dois 
casos da possível associação entre NS e HTLV-1 foram previamente descritos (51), 
todavia  a possível associação com síndrome de Sjogren de ambos os pacientes 
torna difícil a exclusão etiológica e ainda assim, não apresentavam o fenótipo 
combinado como o da paciente em questão. Desta maneira, o reconhecimento do 
HTLV-1 como etiologia associada à NS ganha relevância na avaliação desses 
pacientes assim como a possibilidade da associação entre NS e a clássica 
paraparesia por HTLV demanda uma investicacao clínica e neurofisiológica 
cuidadosa. 
 A investigação da presença de anticorpos anti-FGFR3 como parte de um 
estudo colaborativo com o grupo francês trouxe resultados interessantes. A 
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descrição de anticorpos anti-FGFR3 no contexto das neuropatias sensitivas 
(incluindo as NS) foi feita em 2015 por Antoine e colaboradores (12). Quando os 
resultados apresentados pelo grupo francês  em 72 pacientes com diagnóstico de 
NS são colocados em perspectiva com os resultados dos 42 pacientes brasileiros 
testados, identificamos uma positividade de 12,5% (9/72) contra 38% (16/42) na 
coorte nacional (12). Quando consideramos apenas as formas idiopáticas de NS a 
positividade dos pacientes franceses era de 12,5% (4/32) e  a dos pacientes 
brasileiros de 37,5% (9/24). A partir dos dados dos 42 pacientes com NS testados 
para a positividade dos anticorpos anti-FGFR3 foi possível a delineação do paciente 
médio com NS e esse perfil imunológico: mulher, na sexta década de vida com início 
dos sintomas relativos à NS na quinta década de vida cuja a evolução da NS 
mostrou-se crônica, marcadamente assimétrica, de etiologia idiopática para as 
tradicionalmente investigadas e com uma marcada desproporção sensitivo-motora 
nos estudos de condução nervosa. 
 Seguindo as contribuições ao diagnóstico etiológico das NS, procedemos ao 
melhor delineamento da NS associada à hepatite autoimune (HAI). Na coorte 
estudada, observamos cinco pacientes com a associação HAI-NS, atingindo uma 
prevalência de 7%. Essa proporção é significativamente maior que a frequência de 
maniestações neurológicas  encontradas em outras séries de pacientes com HAI 
(52-58). Um possibilidade para tal associação, poderia estar na presença da 
hepatopatia como fator causal da NS. Todavia, ao observarmos que na coorte 
paralela de pacientes com hepatite B crônica não houve qualquer paciente com 
critérios de NS. Desta forma, podemos inferir que a associação NS-HAI 
provavelmente deve surgir de um contexto imunológico compartilhado ainda por ser 
identificado entre as duas condições e não ao dano hepático em si. A presença do 
anti-FGFR3 em 3/5(60%) dos pacientes com HAI-SN pode auxiliar na resposta a 
essa questão. Os anticorpos anti-FGFR3, foram descritos no contexto das NS, 
conforme o acima mencionado, em um subgrupo de pacientes franceses com 
neuropatia sensitiva adquirida (12). Em condições fisiológicas, o FGFR3 tem funções 
de migração neuronal no sistema nervoso central, sofrendo um upregulation nos 
GRD quando há lesão dos nervos periféricos (59,60). Apesar de sua baixa 
expressão no fígado normal (61,62), em condições patológicas, como no carcinoma 
hepatocelular, há um aumento da expressão do FGFR3 hepático (63) o que 
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possivelmente, também possa ocorrer na HAI. Considerando o conjunto de 
pacientes aqui descritos e os quatro pacientes descritos previamente (32-35), é 
possível traçar um “perfil médio” dos pacientes NS-HAI. Este seria o de uma mulher 
que na 4a década de vida desevelve anormalidades neurológicas ou hepáticas. A NS 
tem seu curso crônico com pouca resposta à terapia imunossupressora. De fato 
esses dados de tratamento parecem similares aos observados em uma coorte 
retrespectiva de pacientes com síndrome de Sjögren (17). 
 Por fim, nós verificamos o valor do sequenciamento completo do exoma por 
tecnologia de nova geração em 22 pacientes com NS idiopática. Nenhum dos 
pacientes avaliados foi diagnosticado do ponto de vista das doenças genéticas 
monogênicas. Todavia, 4 pacientes apresentavam variantes em heterozigose  em 
genes capazes de levar, dentre outros sintomas, à ataxia sensitiva (POLG, CUBN, 
FXN e FLVCR1) (64-67). Sendo assim, hipóteses sobre a fisiopatologia das NS 
podem ser encontradas em condições não passiveis de avaliação pelo 
sequenciamento do exoma (expansões instáveis e/ou alterações intrônicas). Ou 
ainda, considerando-se a NS como doença geneticamente complexa – onde existem 
genes de predisposição, mas não causais - a exemplo de outras associações já bém 
documentadas como na esclerose ateral amiotrófica e expansões em ATXN2 ou 
ainda na doença de Alzheimer e o genótipo ApoE ε4 (68,69). 
 
Contribuição para Caracterização Fenotípica e Fisiopatologia da 
Neuronopatia Sensitiva 
 A menção a sintomas relativos à dor como constituintes do quadro clínico das 
NS remonta à descrição inicial feita por Derek Denny-Brown (6). Nela, foi descrito o 
paciente do caso 1 cuja apresentação inicial da NS se deu por meio de dor 
neuropática envolvendo a face. No entanto, não havia uma abordagem sistemática 
dos sintomas dolorosos no contexto das NS. Isto se mostrou relevante uma vez que 
77% dos pacientes de nossa coorte apresentavam queixas dolorosas. Séries 
anteriores se ativeram à descrição da presença ou não de dor entre os pacientes 
com NS que atingia valores entre 50-80% (10,70). Outro ponto de diferenciação é o 
de que tais coortes apresentavam significativo  número de pacientes com NS no 
contexto de síndrome tóxicas ou paraneoplásicas (56% e 100% respectivamente). 
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Outra série envolvendo exclusivamente pacientes com Sindrome de Sjögren 
encontrou dor crônica em 50% dos mesmos (71). Deve-se ressaltar, entretanto, que 
tanto paraneoplasias quanto a síndrome de Sjögren podem causar dano aos axônios 
das fibras finas, de modo que o substrato da dor nestas duas condições pode 
permanecer incerto.  
 O contexto de lesão dos GRDs tem como fator relevante a própria população 
neuronal que os integra. Aproximadamente 60-70% das fibras que compõe os GRD 
são compostas por fibras C não-mielinizadas as quais, quando danificadas, 
possuem ligação estreita com os quadros de dor neuropática (3,38). De fato, tal 
mecanismo pode ser o responsável pela baixa responsividade dos regimes 
teraupêuticos empregados nos pacientes avaliados.  Tal dado é colocado ainda em 
maior foco quando observamos que mais de dois terços dos pacientes com NS 
possuem critérios para dor neuropática (LANSS>11) (22). 
 Ainda no plano que objetiva a melhor caracterização fenotípica dos pacientes 
com NS foi realizada a investigação de possíveis danos ao sistema nervoso 
autonômico. Os resultados obtidos demonstraram que existe dentre os pacientes 
com NS uma dupla neuronopatia: a clássica sensitiva e a autonômica. De fato, 
grande parte dos pacientes monstrou alterações clinicas e neurofisiológicas 
consistentes com disfunção autonômica em ambas as suas divisões: simpática e 
parassimpática.  
 A investigação focada em sinais e sintomas clínicos por meio da escala 
SCOPA-Aut (23,24) demonstrou que em todos os domínios examinados, os 
pacientes com NS pontuam de maneira mais significativamente alta, denotando 
disfunção autonômica nesse grupo. O passo seguinte se deu com a investigação 
complementar neurofisiológica na tentativa de promover a localização de possíveis 
lesões autonômicas. 
 A avaliação da variabilidade cardíaca demonstrou alterações significativas em 
todos os testes cardiovagais (razão expiração:inspiração, razão de Valsalva, 
índice 30:15 e variação da arritmia sinusal respiratória) além de uma maior 
proporção de pacientes com hipotensão ortostática. Tais resultados denotam já aí 
disfunção em ambos os braços autonômicos. Outro fator relevante e, de certa forma 
inesperado, foi que ¾ dos pacientes com SN fecham critérios para uma neuropatia 
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cardíaca autonômica. Esse dado demanda cautela e ainda necessita ser colocado 
em perspectiva clínica no que tange ao impacto de tal neuropatia na sobrevida 
desses pacientes. A análise individual de alguns pacientes pode ser útil para o 
fornecimento de pistas que auxiliem no esclarecimento da fisiopatologia do 
acometimento autonômico das NS e no seu diagnóstico diferencial com condições 
que também cursem com lesão autonômica. Nesse sentido, três pacientes puderam 
ser identificados com hipotensão ortostática, volume de sudorese reduzidos e sem 
critérios para neuropatia autonômica cardíaca. Tais achados apontam para um dano 
à subdivisão simpática dos sistema nervoso autonômico sem o acometimento 
parassimpático concomitante. Esse padrão auxilia na diferenciação entre os 
pacientes com NS e os pacientes diabéticos nos quais, habitualmente o cortejo de 
lesão autonômica cardíaca passa pelo dano parassimpático antes que se instale a 
lesão ao simpático (26,72).  
O teste quantitativo do reflexo axonal sudomotor identificiou alterações em 
92% dos pacientes. O padrão observado era assimétrico e não comprimento-
dependente. Deste modo, consideramos provável um sitio de lesão no corpo celular 
dos neurônios autonômicos periféricos, e não nas suas extensões distais.  
 
Contribuição para o seguimento clínico da neuronopatia sensitiva 
 A despeito do fato de que um consórcio europeu que estudou manisfetações 
paraneoplásicas terem colocado as NS como a principal paraneoplasia neurológica 
(73), essas ainda são consideradas como uma manifestação rara de disfunção do 
sistema nervoso periférico (2,39,40). Todavia, os resultados descritos acrescentam 
uma variável nessa equação: estaria a afirmação de que as NS são doenças raras 
ligadas ao erro diagnóstico ao qual estão submetidas? Considerando o viés de 
encaminhamento inerente a um estudo que ocorre em níveis terciários de atenção à 
saúde que leva casos menos graves a provavelmente persistem sem o diagnóstico 
apropriado, observa-se que os pacientes que conseguem ter sua doença 
diagnosticada apresentam um atraso médio de mais de 5 anos. Colocado em 
perspectiva, esse atraso impõe aos pacientes possíveis impactos na qualidade de 
vida e na sobrevida em si, uma vez que condições passiveis de tratamento 
apropriado como é o caso das doenças reumatológicas associadas à NS ou ainda 
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condições em que o inicio do tratamento é fundamental como é os casos das 
neoplasias, também tem o seu diagnóstico atrasado. As razões envolvidas nesse 
cenário passam não somente pela relativa raridade das NS mas também pela 
heterogeneidade fenotípica das mesmas, a qual pode incluir além da clássica ataxia 
sensitiva, quadros clínicos dominados por sintomas sensitivos positivos , a presença 
de sinais pouco frequentes como é o caso da pseudoatetose e pseudoparesia e 
ainda o fato de que possivelmente a NS não integrar o rol de diagnósticos 
diferenciais da grande parte dos profissionais responsáveis pela atenção à saúde. 
Dessa maneira, a difusão desse fenômeno e da própria eduacacao continuada em 
neurologia em si, seriam fatores importantantes para que esse cenário seja 
revertido. 
 Passada a odisseia até a identificação adequada da NS, outros pontos 
importantes no seguimento desses pacientes são a falta de dados que auxiliem na  
compreensão do comportamento da doença em termos de historia natural e ainda a 
ausência de estudos metodologicamente robustos que auxiliem nas opções 
terapêuticas. Nesse sentido, foi proposto um instrumento clínico que visa 
acrescentar informações quantitativas ao seguimento dos pacientes com NS e 
representar um possível método para a avaliação dos resultados atingindos em 
futuros estudos envolvendo o tratamento da doença.  
 A escala SEARS mostrou-se um instrumento de relativa simplicidade para 
aplicação sem a necessidade de material pouco usual. A validação do construto 
mostrou também correlação moderada com os instrumentos vigentes com a ressalva 
de que a inexistência de instrumentos específicos à avaliação de quadros 
compostos exclusivamente por ataxia senitiva, torna difícil uma correlação mais 
robusta. O construto interno mostrou boa correlação denotada pelo alfa de Cronbach 
associado aos altos (>0,95) coeficientes de correlação intraclasse para as 
avaliações inter e interobservadores, tornam sólido o instrumento. Outro fator 
relevante verificado foi a análise fatorial com modelo de rotação que indicou que 
mais da metade da variância foi devida a somente dois fatores os quais englobam 
medidas envolvendo a ataxia e o exame de sensibilidade. 
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PERSPECTIVAS FUTURAS 
 
A exploração de doenças associadas às NS é um fator relevante e que 
encontra ressonância com a descrição de novos autoanticorpos relacionados à 
doença como é o caso do anti-FGFR3. Essa afirmação se justifica pela ampliação da 
compreensão do fatores envolvidos na fisiopatogenia da doença visto que alvos 
antigênicos podem ser melhor avaliados e, por conseguinte, novas abordagens 
terapêuticas podem vir a ser propostas. 
 Para tal, é necessária a existência de instrumentos capazes de avaliar 
variações clínicas da doença uma vez que as alterações neurofisológicas parecem 
ser irreversíveis após um curto intervalo de tempo após o início da doença (41). 
Nesse sentido, a SEARS destaca-se ao possibilitar tanto estudos futuros envolvendo 
a história natual da doença bem como o planejamento de estudos envolvendo o 
tratamento da doença. 
 Há ainda a necessidade de se estabelecer fluxos de colaboração e 
cooperação nacionais e internacionais para que, além do incremento no número de 
pacientes estudados, abordagens em paralelo possam ser mais facilmente 
executadas.  
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CONCLUSÕES 
 
1. O Zika vírus e o HTLV-1 devem ser considerados na investigação etiológica 
de NS. 
2. O anticorpo anti-FGFR3 está presente em parcela significativa dos pacientes 
com NS (idiopáticos), especialmente no Brasil. 
3. O sequenciamento completo do exoma pode contribuir para o entendimento 
etiológico das NS. 
4.  Dor é frequente na NS, está localizada principalmente nas extremidades e 
tem padrão neuropático, sendo refratária ao tratamento usual. 
5. Disfunção simpática e parassimpática são frequentes nas NS. Pacientes com 
NS apresentam dano às fibras finas colinérgicas pós-ganglionares num 
padrão não comprimento-dependente. 
6. Pacientes com NS tem em média cinco anos de atraso diagnóstico, passam 
por quatro médicos diferentes e recebem três diagnósticos errados; 
7. A escala SEARS mostrou ser um intrumento útil capaz de avaliar e quantificar 
a ataxia nos pacientes com NS. 
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Abstract 
The cranial nerves (CN) IX and X emerge from medulla oblongata and have 
motor, sensory and parasympathetic functions. Some of these are amenable to 
neurophysiological assessment. It is often hard to separate the individual contribution 
of each nerve; in fact, some of the techniques are indeed a composite functional 
measure of both nerves. The main methods are the evaluation of the swallowing 
function (combined IX and X), laryngeal EMG (predominant motor vagal function) 
and heart rate variability (predominant parasympathetic vagal function). This review 
describes, therefore, the techniques that best evaluate the major symptoms 
presented in IX and X CN disturbance: dysphagia, dysphonia and autonomic 
parasympathetic dysfunction.  
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Introduction 
 
Historical Considerations 
The intimate anatomic and functional relationship between the cranial nerves 
(CN) IX and X was first described by Galen (AD 130-200). At that time, anatomists 
believed that there were only six CN, but Galen noticed that the CN VI in fact was 
divided into three parts, each one with a distinct course (this CN VI was described 
later as being the IX, X and XI nerves). Avicenna, the Persian (AD 980-1036), more 
than 800 years later, was the first to report that from the three CN emerging from the 
same foramen, one innervates the tongue and the throat (IX nerve). Since that, many 
other anatomists and physicians described the relationship between the IX and X 
CN.1 From the simple observation that it innervates the tongue (from the Greek, 
glossus) and the throat (from the Greek, pharynx) comes the name glossopharyngeal 
nerve to the CN IX. Due to its long course through the body, giving branches to the 
thoracic and abdominal organs, the CN X was named first as pneumogastric, and 
nowadays it is known as the vagus nerve (from the Latin, vagus means wandering, 
straying). 
 
Anatomical and Functional Considerations 
Both CN IX and X originate from nuclei located at the dorsolateral aspect of 
the medulla oblongata, emerging side by side at the sulcus between the olive and 
inferior cerebellar peduncle. They also leave the skull together through the jugular 
foramen. Both nerves have similar functional components: general and special 
visceral efferent fibers (GVE and SVE), general and special visceral afferent fibers 
(GVA and SVA), and general somatic afferent fibers (GSA). The GVE fibers of the 
CN IX originate from the inferior sallivatory nucleus and those of the CN X originate 
from the vagal dorsal motor nucleus. The GVE fibers are the pre-ganglionic fibers of 
the parasympathetic nervous system. The SVE fibers of CN IX and X emerge from 
the nucleus ambiguous to innervate the pharynx and larynx muscles. The major 
component of the IX and X afferent fibers is visceral. The visceral general (GVA) 
sensation from thoracoabdominal organs and carotid sinus and the special gustatory 
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(SVA) fibers ends together at the nucleus of the solitary tract (NST). Finally, the 
(GSA) fibers that comes from the tympanic membrane, upper pharynx and posterior 
third of the tongue (IX nerve) and from the external auricular meatus (auricular 
branch of the X nerve) ends at some trigeminal nuclei.2 This historical known 
anatomic and functional relationship lead us to approach them together again in this 
review. 
Impairment of each of the above-mentioned functional components may lead 
to a myriad of signs and symptoms, the most frequent of which are: dysphagia, 
dysphonia (Table-1)3 and autonomic parasympathetic dysfunction.  
Dysphagia is specially related to the involvement of the IX nerve, the main 
responsible for triggering the swallowing reflex, but also to the X nerve due to the 
motor innervation of the pharynx, larynx and esophagus; one must remember that 
some other nerves are related to the swallowing process like the hypoglossus and 
trigeminal nerve. Dysphonia is mainly attributed to the involvement of the X nerve, its 
branches and consequently the pharyngeal and laryngeal muscles it innervates. 
Autonomic-related manifestations often go unnoticed and are only identified through 
additional testing. However, in some specific clinical scenarios, these are 
troublesome. For example, in some cases of glossopharyngeal neuralgia, patients 
have bradycardia and syncope in addition to pain, suggesting that CN IX may also be 
involved with cardiac frequency control through NST and the glossopharyngeal-vagal 
reflex arc.4,5 For that reason and for a better comprehension of the text, the 
electrophysiological techniques will be described in relation to the clinical symptom 
and not the CN.  
Although dysphagia, dysphonia and autonomic disturbances are common in 
neurological practice, these symptoms are not routinely evaluated under a 
neurophysiologic point of view. There are no electrophysiological techniques to 
evaluate separately the CN IX. In contrast to the usual neurophysiological methods 
that are largely topographic, the techniques available for the assessment of CN IX 
and X evaluate function as a whole, and do not enable precise localization of the 
damage. This holds true for swallowing function tests and autonomic 
parasympathetic tests. The only notable exception is laryngeal EMG; this test can 
identify lower motor neuron damage and therefore localize lesions at the motor nuclei 
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of the CN X (or its descending fibers).6-9 Considering the above-mentioned 
difficulties, we will describe the known electrophysiological techniques we have to 
study dysphagia, dysphonia and the autonomic parasympathetic dysfunction. 
 
Neurophysiology Approach 
 
A) Dysphagia: 
The neurophysiology of swallowing (SW) involves the complex sequence of 
voluntary and involuntary movements of the oropharynx, larynx, esophagus and 
respiratory muscles.10 SW can be subdivided into two phases: the oropharyngeal 
and the esophageal. CN IX and X-related dysphagia compromises the oropharyngeal 
phase .8 
Oropharyngeal SW starts at the end of mastication, when the alimentary bolus 
is ready and it can be understood as a reflex phenomenon triggered at the 
oropharynx by the bolus. The afferent loop reaches the brainstem through the IX and 
X nerves and the efferent loop leaves the brainstem through the V, VII, IX, X and XII 
nerves, resulting in a complex and coordinated motor sequence: the elevation and 
closure of the larynx and soft palate for airway protection, together with the 
contraction of the suprahyoid/submental muscles situated under the chin;8 the 
propulsive, pumping forces of the tongue; the sweeping function of the pharyngeal 
constrictor muscles and, finally, the relaxation and opening of the cricopharyngeal 
muscle of the upper esophageal sphincter, which is normally closed at rest.  As a 
result, the bolus is delivered into the esophagus.8,11   
In general, the routine SW neurophysiology demands a stimulus, triggered by 
a bolus with some known properties, the EMG recording of some of the involved 
muscles, and the recording of the movement of the larynx. The methods of “Single 
Bolus Analysis” and “Dysphagia Limits” are the first step to study neurogenic 
dysphagia 
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1. SINGLE BOLUS ANALYSIS (SBA) 
The onset and duration of oropharyngeal SW can be evaluated recording 
suprahyoid/submental muscles EMG (SM-EMG). SM-EMG is recorded with bipolar 
silver-chloride EEG electrodes placed side by side at the midline over the submental 
muscle complex under the chin. Signals are filtered (bandpass 100Hz – 10kHz), 
amplified, rectified and integrated.  Since the submental muscles fire simultaneously 
to initiate a swallowing (pulling the larynx upward), SM-EMG gives considerable 
amount of information about the onset and duration of the oropharyngeal SW. The 
normal movement of the larynx upward forwards the bolus safely to the pharyngo-
esophageal segment, preventing aspiration. SM-EMG activity continues until the 
oropharyngeal SW is completed. 
The Movement of the Larynx can be monitored using a simple piezoelectric 
wafer sensor with 4 x 2.5 mm rubber bung fixed at the midline, between the thyroid 
and cricoid cartilages. Its output signal is filtered (bandpass 0.001 – 20 Hz) and fed 
into one of the channels of the EMG apparatus. The sensor allows the time analysis 
of the laryngeal elevation during pharyngeal phase of SW and the amplitude of the 
upward and downward laryngeal movements.  The laryngeal sensor output originates 
two deflections during SW. Using delay line technique, all electromechanical events 
are displayed synchronously. The interval between the onsets of both deflections is 
thought to reflect the time necessary for the elevation, closure and relocation of the 
larynx.11 The time frame to record the single bolus analysis must be adjusted 
between 2-5 sec and at least five traces should be recorded.  The individual traces 
are examined, superimposed and then averaged. 
Cricopharyngeal EMG (CP-EMG) is recorded with a concentric needle 
electrode inserted percutaneously at the level of cricoid cartilage approximately 1.5 
cm lateral to its palpable lateral border in the posterior-median direction.12 Because 
the peripheral facial muscles are the first to be activated, as mouth closes before the 
oropharyngeal phase, it is recommended to record their EMG activity simultaneously 
with surface electrodes placed bipolarly on the upper and lower lips near the corners 
of the mouth.13  Tongue and pharyngeal constrictor muscle activity, associated with 
bolus propulsion and laryngeal adductor muscle activity, associated with laryngeal 
closure, can also be recorded with needle EMG.14,15 Deviation of these parameters 
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from normal values exposes the differences in the pathophysiology of four groups of 
neurogenic diseases with dysphagia but only the group enrolling the direct 
involvement of CN IX and X and nuclei will be considered in this review. 
The clinical conditions in which CN IX and X are involved are summarized in 
Table 1. Among such rare conditions, the commonest is the “Wallenberg Syndrome” 
or lateral medullary infarction (LMI), in which the swallowing centers of Nucleus 
Tractus Solitarii and Nucleus Ambiguous are partly injured due to occlusion of the 
vertebral artery, basilar artery (BA) or the posterior inferior cerebellar artery (PICA). 
Dysphagia is found in 51 to 94 % of the patients with Wallenberg syndrome.16 
Oropharyngeal phase of SW is predominantly impaired and extremely slow, whereas 
the oropharyngeal phase of SW reflex remains within normal limits in patients with 
unilateral peripheral IX and X CN palsies. Although LMI may be ipsilateral, the 
deleterious effect on the oropharyngeal SW is bilateral, so that we may conclude that 
the damage of premotor neurons at unilateral swallowing center may result in a 
failure to project to bilateral motor neuron pools and the contralateral nucleus 
ambiguous due to disconnection between each medullary SW center. This bilateral 
representation of pharyngeal dysphagia in unilateral LMI may also play a role in 
recovery of function.16 
 
2. DYSPHAGIA LIMIT (DL) 
DL is a sensitive and specific screening test for the detection of neurogenic 
dysphagia and may be useful to follow the course of dysphagia objectively.10,17 
Normal individuals can swallow boluses of 20 ml of water at once.  Individuals with 
impaired SW may be unable to do so and will need two or more swallows for a bolus 
of less than 20 ml. When an oral bolus of large liquid volume is divided into two or 
more parts swallowed successively we call it “Piecemeal Deglutition” (PD). The 
volume at which a second swallow becomes necessary is known as the “Dysphagia 
Limit” (DL).  The same electrophysiological recording methods described for the SBA 
are used for DL, but with the sweep duration settled at 10 sec. and the delay line 
starting at 2 sec. The effect of the bolus is followed for 8 sec. The patients are given 
3, 5, 10, 15 and 20 ml of water and the sweep is initiated at the examiner’s order to 
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swallow. The laryngeal sensor signals and the integrated activity of the SM-EMG are 
recorded from the beginning of these long sweeps of EMG screen.  It is requested 
that the patient swallows all the liquid at once. As each volume of liquid is swallowed, 
laryngeal sensor and SM-EMG signals are usually observed at the onset of the 
recording. The recurrence of two or more signals within 8 sec. period of the recording 
is accepted as piecemeal deglutition, and indicates one is reaching the DL for that 
specific subject. DL is found to be a very useful test for objective diagnosis of 
neurogenic dysphagia.  The diagnostic value and sensitivity of DL is around 90 % in 
dysphagic patients.10  
Some technical details must be observed for the DL method: 
1- The piezoelectric laryngeal sensor should be used to record the 
laryngeal movements during SW. This sensor can be found commercially; 
2- The amount of water must be delivered into the mouth behind the 
incisors with a graduated syringe. 
3- Fast backward directed flush of water must be avoided because it 
increases the chance of an early escape to the pharynx and the possibility of gag 
reflex. 
4- If there is a suspicion of DL at a certain water volume, the procedure 
must be repeated twice or thrice with the same volume of water to confirm it is 
consistent. 
5- Subjects were instructed to speak at rest between each water volume. 
6- If you don’t have a laryngeal sensor, you may use the orbicularis oris 
muscle EMG (ORI-EMG) as the indicator of the onset of SW, together with the SM-
EMG. In this case the delay line would be used on ORI-EMG at the first channel.8 
DL seems to be more specific in demonstrating oropharyngeal SW disorders 
in symptomatic patients than those with subclinical neurogenic dysphagia.  However, 
the subclinical dysphagia can also be diagnosed by DL.10 
 
3. SEQUENTIAL WATER SWALLOWING (SWS) 
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In humans, SWS has been recognized as the best approach to evaluate the 
physiology of SW and its coordination with respiration. For that reason, it is the 
method of choice to evaluate aspiration problems .18-20   SWS is considerably 
different from DL test from technical and physiological points of view.  SWS consists 
of drinking 50 or 100 ml of water continuously and successively from a cup or straw 
without any cessation. Recording of respiration is essential to understand the 
relationship between SWS and apnea periods of breathing. SWS is useful to detect 
subclinical dysphagia and even the risk of aspiration accurately.18 Although SWS 
begins with the cortical drive, consecutive swallows can be partly regulated by the 
NTS at the medullary level.21 SWS studies should use at least a 2 channel-EMG 
apparatus to record the SM-EMG, and one of them must be the nasal airflow 
(bandpass 0,2 to 20Hz). Total analysis time is adjusted to 20 seconds for each set of 
SWS. After a command, normal adults swallow successively and regularly in a 
rhythmic fashion, and, simultaneously, apnea period is also recorded. SWS traces 
are recorded rhythmically except for the last inter swallow interval which is prolonged 
in comparison to the previous intervals. At the onset of SW, apnea is initiated by 
often inspiration/expiration.  When the last inter-swallow interval is longer than 1 
second, the sudden 2nd short respiratory cycle with inspiration and expiration occurs 
before the last SW. The number of swallows and duration of SWS increased 
significantly from 50 to 100 ml.  There are two interesting phenomena in SWS 
investigation. One is that the first SM-EMG burst almost always appears just before 
or during the last respiratory cycles and before the SW apnea, different from the SM-
EMG following swallow. It is called “foreburst SWS” and is found in 86 % of normal 
adult subjects during SWS.22 The other is the “Compensatory Respiration Cycle” 
with inspiration/expiration during apnea periods while participants are sequentially 
swallowing. It is not uncommon to record the compensatory respiratory cycle 
between the last inter swallow interval, as we just mentioned above. However, in 
neurogenic dysphagia, compensatory respiration can also be recorded in the middle 
of SWS during apnea. Compensatory respiratory cycle during apnea periods are 
often recorded once. In aging, the SWS duration and apnea periods are longer than 
those of young and middle-aged people.22   
	 	 218	
	
	
	
SWS has been studied in patients with neurogenic dysphagia due to various 
etiologies.9  Patients with brainstem infarction but mildly affected were investigated 
during the first week of stroke. The number of swallows and the duration of SWS 
were significantly increased (p < 0.02). However, their SW apnea periods were even 
more significantly prolonged (p < 0.001). These abnormalities can demonstrate that 
some electrophysiological abnormalities of oropharyngeal SW take place even in 
subjects with no dysphagic complaints.9 
 
4. POLYGRAPHIC / EEG STUDIES: Evaluation of Spontaneous 
Swallowing (SS). 
All the above tests are performed voluntarily after a “swallow” command but 
also spontaneous swallowing (SS) of saliva can be recorded. This can be done 
during 24hours recording or, according to a recently proposed technique, using one-
hour polygraphic recording.13 The rate of SS can be variable due to many factors 
and, in general, both techniques are not often used for clinical purposes.  
 
The electrophysiological methods above described are summarized in Figure 
1. All the described techniques can be easily performed in an EMG laboratory, 
demanding some training. They are safe, repeatable and suitable for longitudinal 
studies of chronic neurogenic dysphagia or to follow the treatment, and even for 
detecting subclinical dysphagia. But when silent aspiration needs to be proven, 
invasive approaches such as video fluoroscopy and fiber optic endoscopy must be 
considered. 
 
B) Dysphonia 
 
Dysphonia can be recognized by hearing the voice of the patient; hoarseness, 
loss of volume, vocal fatigue and loss of upper vocal register can be caused by vocal 
fold paralysis.23 Laryngeal endoscopic examination can confirm a mobility disorder 
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but laryngeal EMG (LEMG) becomes the ideal technique to complement the 
investigation and to identify true neurogenic dysphonia.6,24-26  
Vocal fold paralysis can be the result of peripheral nerve injuries (vagus nerve 
damages by trauma, tumor or axon neuropathy) or central disorders such as 
laryngeal motor neuron death or brain stem stroke.27 LEMG is capable of making 
this distinction and also to differentiate vocal fold paresis/paralysis from other factors 
producing vocal fold disturbance such as presbilarynx or arytenoid joint 
disease.28,29  Furthermore, this technique is able to show acute denervation, signs 
of early and late reinnervation and, in some cases, aberrant reinnervation leading to 
synkinesis.30,31  
 
• Anatomic and physiological aspects 
The larynx is formed by three unpaired cartilages (cricoid, epiglottis and 
thyroid) and three paired cartilages (cuneiform, corniculate and arytenoids). Two of 
them allow the identification of surface landmarks:  the thyroid cartilage has a 
palpable projection in the midline called laryngeal prominence and the cricoid has an 
arch that is equally palpable right below. Between them there is a structure called 
cricothyroid membrane that allows the introduction of the needle electrode to 
evaluate the larynx intrinsic muscles.32 For details on surface landmarks, please 
read Kimaid et al., 2015.6  
The larynx intrinsic muscles that are relevant to EMG are thyro-arytenoideus 
(TA), crico-arytenoideus lateralis (CAL), crico-arytenoideus posticus (CAP) and crico-
thyroideus (CT), all existing in pairs. The first three, when activated, lead to adduction 
of vocal folds. From these muscles, CAP is the only one responsible for the 
abduction of the vocal folds.32-34 
All the muscles described are innervated by branches of the vagus nerve and 
all but one are innervated by the ipsilateral recurrent laryngeal nerve. The CT is the 
only muscle innervated by the external branch of the ipsilateral superior laryngeal 
nerve.  
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• LEMG Technique 
Many techniques to insert electrodes into laryngeal muscles were 
described.35-40 Despite that, the technique that best fits current clinical practice 
uses percutaneous insertion of the needle electrode guided by the surface landmarks 
of the larynx.41-43 In a recent review, we detailed the technical aspects and the 
utility of LEMG.6 We will summarize here the critical features of this technique.  
Equipment required 
A two-channel equipment is sufficient for LEMG (one required for EMG trace 
recording and the other for voice signal). The recording parameters are the same for 
conventional EMG examination with a sweep speed of 5ms/cm and a sensitivity of 
100uV/cm in order to enable more accurate analysis of motor unit potentials (MUP) 
(shorter duration and smaller amplitude). One can use for routine studies both 
monopolar or concentric needle electrodes; 26,44,45 in our practice, concentric 
needles provide more stable background activity related to the small recording area 
and, because they are also a little harder than the monopolar needle, the insertion 
through the membranes and cartilages is easier.46-49  
 
Electrode Insertion  
It is very important to explain in detail the whole procedure to the patient and 
reassure him/her about potential safety concerns. This will guarantee an ideal 
activation of the muscles analyzed. The LEMG requires great collaboration from the 
patient and in general neither sedation nor anesthesia are needed. There are 
basically two relative contraindications of LEMG that must be taken into account: 
patients with bleeding disorders/ taking anticoagulant drugs and patients with 
bilateral adduction paralysis - edema or hematoma can obstruct the airflow.27,43,49 
If the benefits of the exam are predicted to be higher than the risks, the procedure 
must be done with all the necessary care and precautions.  
 For the purpose of better exposing the surface landmarks, the patient is 
asked to lay down at the supine position with a cushion under the dorsal region. 
Right after the insertion, we can confirm the correct electrode position asking the 
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patient to perform specific vocal tasks that activate the target muscle.27,43,49 
Insertion techniques are summarized in the Figure 2. For additional details, please 
refer to Kimaid et al, 2015.6 
 
• Recurrent laryngeal nerve study: 
  Thyroarytenoid Muscle (TA) 
This muscle can be assessed by two techniques: through the cricothyroid 
membrane – the most commonly used - and through the thyroid cartilage.43 In the 
first one, we insert the electrode in the midline in sagittal direction trough the 
cricothyroid membrane, 45 degrees upward in the vertical plane and 30 degrees 
laterally in the horizontal plane (Figure 2A). In the second technique, the electrode is 
inserted directly through the thyroid cartilage in the level of the TA origin, in the 
midway point of the vertical limits of the cartilage, 0,5-0,8 cm laterally from the 
midline in women and 0,8-1 cm in men (Figure 2B). This technique is restricted to 
young patients – in whom cartilages are not yet calcified.43 In order to activate the 
TA we can ask the patient to say the phoneme \e\ ([ε:]) and for its relaxation we 
request a brief inspiration (sniff). Inverted muscle activation suggests synkinesis.  
Lateral Cricoarytenoid Muscle (LCA) 
The are several ways to assess the LCA. We prefer to insert the electrode 
through the cricothyroid membrane in the lower border of the thyroid cartilage, 30 
degrees laterally in the horizontal plane, straight or at a maximum 20 degrees 
upward in the vertical plane (Figure 2D).43 As well as in TA study, the activation of 
the CAL can be done by asking the patient to say the phoneme \e\ ([ε:]).  
The anatomic limits for insertion of TA and LCA are quite similar and because 
of that it is often difficult to reliably differentiate them. In clinical practice, such 
distinction generally does not matter because both are innervated from the anterior 
branch of the recurrent laryngeal nerve.49 
Posterior Cricoarytenoid Muscle (PCA) 
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There are basically two techniques and both require a challenging approach: 
the first one requires the larynx to be rotated in the vertical axis and the electrode 
should be inserted in the horizontal plane in the inferior third of the lateral border of 
the larynx (Figure 2E); 43,49,50 the second technique – only amenable to young 
patients -  consists in inserting the electrode anteriorly, in the midline, through the 
cricothyroid membrane, laterally in the horizontal plane by 15 degrees, through the 
laryngeal lumen and reaching the CAP after passing through the posterior lamina of 
the cricoid cartilage (Figure 2F). 43,49,50 To activate the CAP, the patient must do a 
brief and intense inspiration (sniff) and to relax it the patient is asked to say the 
phoneme \e\ ([ε:]). Inverted muscle activation suggests synkinesis as well. 
 
• External branch superior laryngeal nerve study: 
Cricothyroid Muscle (CT) 
The techniques vary from the authors and the access of this muscle is easier 
than the others discussed above; we commonly insert the electrode 1,5 cm laterally 
from the midline in the upper border of the cricoid arch, in the horizontal plane (90 
degrees with vertical line) directly within the muscle (Figure 2C). 43 To activate the 
CT, the patient must say the phoneme \i\ ([i:]). 
 
The physician needs to be aware that cough beginning during examination 
indicates misplacement of the needle (often located at the laryngeal lumen).26,43,45 
Whenever that happens, one should immediately remove the electrode up to the 
cricothyroid membrane and reintroduce it with another angle. 
• LEMG findings 
The LEMG study follows the same steps for the conventional EMG: 1) 
insertion activity analysis; 2) rest activity analysis; 3) slight voluntary muscle 
contraction; 4) maximum voluntary muscle contraction. The interpretation of 
neurogenic, myopathic and central nervous system dysfunction is similar, either. 
There are, however, some caveats.  
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1) Insertion activity: LEMG insertion activity is considered normal if there is 
a burst of MUP with at least 300 ms duration.  
2) Rest activity analysis: There is a “tonic” activity of laryngeal muscles at 
rest and the absence of such rest activity is considered pathologic.49 The MUP 
increases and reduces its firing rate while breathing, in contrast to the spontaneous 
activity of fibrillation potentials, for instance.   
3) Slight voluntary muscle contraction: It’s known that MUPs are most 
accurately assessed during slight muscle contraction, but it is very difficult for the 
patient to control the intensity of laryngeal muscle activation; so, in order to properly 
analyze the MUPs we suggest that this should be done during rest. Normal laryngeal 
MUP parameters previously reported are summarized on Table 2.39,45,51,52 
4) Maximum voluntary muscle contraction: LEMG interferential activity can 
be graduated from 1+ to 4+. Special EMG softwares can quantify the MUP more 
precisely like Multi-MUP analysis52 or softwares that procedure quantitative EMG, 
for example.53,54 
 
Although LEMG is a demanding neurophysiologic test, it can be safely 
performed in most EMG laboratories by a trained team.  
 
C) Autonomic parasympathetic dysfunction 
 
Heartbeat Variability Evaluation 
The human cardiac rate is physiologically characterized by an intrinsic and 
subtle beat-to-beat interval variation. Changes in the intrathoracic pressure, such as 
the ones caused by deep breathing or by a Valsalva maneuver, are physiological 
examples of factors that influence the time interval between the heartbeats.55,56 The 
interplay of parasympathetic and sympathetic cardiac innervation is the main 
determinant of this heart rate variability.56,57  
Cardiac Innervation 
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The heart innervation is derived from the cardiac plexus. It is a complex 
structure formed by the sympathetic and parasympathetic nerve ends.58 This 
peculiar interaction controls the excitability, the contractility and also rate of 
contraction of the myocardium. The sinoatrial node is the primary cardiac pacemaker, 
an structure under vagus nerve control. Thereafter, the heart rate is ultimately 
modulated by CN X stimulation or inhibition, leading to a beat-to-beat control. Once 
CN X is inhibited, the sympathetic influence in the heart (heart rate increasing) takes 
place.57 Whereas the parasympathetic cardiac innervation is restricted to sinoatrial 
and atrioventricular nodes, the sympathetic cardiac innervation has a widespread 
distribution. Evidence from myocardial scintigraphy with MIBG (a sympathetic tracer) 
uptake has demonstrated a dispersed distribution of sympathetic nerve ends in the 
cardiac muscle.59 
This beat-to-beat control is mediated by chemo and baroreceptors placed in 
the aortic arch and in the carotid bulb, which send information through CN IX and CN 
X to the nucleus of the solitary tract.60 This is the structure that mediates the 
cardiovagal reflexes by sympathetic and parasympathetic efferent innervation.61 
Cardiovagal reflexes are triggered by a number of daily activities including the 
breathing cycles, standing position and Valsalva maneuver-like activities, such as 
coughing and sneezing.1,57,60,62,63  
Neurophysiological Evaluation 
The heartbeat variability is essentially under parasympathetic control mediated 
through CN X with a contribution of both CN IX and X by cardiovagal reflexes.57,61 
This fact opens a window of opportunity for the assessment of these nerves through 
neurophysiological techniques. Three of them will be herein better described: the R-R 
variability during Deep breathing, during the Valsalva maneuver (VM) and power 
spectral analysis. 
 
• Deep breathing: 
The evaluation of the heartbeat variability during sequential deep breathing is 
an extremely sensitive method to evaluate CN X influence on heart rate.57,64 After 
the placement of the electrodes in a precordial EKG derivation (usually D2), the 
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patient is placed in the supine position and instructed to perform 6-8 breathing cycles 
(5 seconds for inspiration and 5 seconds for expiration). This is the recommended 
strategy to obtain better test reproducibility. It is critical to instruct the patient not to 
hold the breath in the end of the inspiration, since this attitude would cause a 
significant and unexpected intrathoracic pressure variation. After a period of 3-5 
minutes of rest, a novel protocol is started with another 6-8 breathing cycles, 10 
seconds each.  
At the end of the 6 cycles acquisition, in healthy individuals it may be possible 
to visually recognize, in a graphic representation of the plotted heartbeats, the sinus 
arrhythmia.65,66 It is defined as heart rate acceleration during the inspiration and a 
slowing during the expiration phase of the breathing cycle (Figure 3).67 The 
respiratory sinus arrhythmia amplitude (RSA) is determined by the difference 
between the higher and the lower frequencies for each breathing cycle divided by the 
total of cycles analyzed (usually six).66 The range of RSA may be adjusted 
according to the patient age as shown in the Table 3.64,66  
Even though this is a reliable test for the cardiovagal function, a series of 
conditions may influence the R-R interval analysis and its interpretation. Age and 
obesity are some of those that cannot be modified.63,66 It is recommendable that 
before starting the test, the patient is placed in a comfortable and quiet place and rest 
in the supine position for at least 20 minutes .63 Other desirable recommendations 
are avoidance of drinks containing caffeine in the hours preceding the examination, 
emptying the bladder before the examination and if possible, a washout period of 
drugs that may interact with the cardiac function, such as beta-blockers.68 There are 
specific situations that preclude adequate evaluation of heart rate variability, such as 
cardiac arrhythmias (especially atrial fibrillation) and the use of pacemaker. Technical 
limitations due to increased distance between the signal generator (heart) and the 
surface electrodes, as is the case of obesity and chronic obstructive pulmonary 
disease, may hamper the heartbeat signal detection.  
 
• Valsalva Maneuver: 
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Named after the Italian physician Antonio Valsalva (1666-1723), the VM is a 
complex-multiphase process that begins with increasing intrathoracic pressure 
against the closed glottis followed by the releasing of the pressure.69 There are four 
distinct phases identified during the VM: 
 
- Phase 1: increase of the intrathoracic and aortic pressure as the subject 
starts to blow, consequently the preload is reduced, blood pressure rises and by a 
baroreflex, the heart rate decreases; 
- Phase 2:  as the intrathoracic pressure is kept elevated, a reduction of 
the systemic blood return and decrease of the cardiac output take place. As a result, 
the blood pressure is reduced and the baroreceptor reflex once again is activated 
reducing the vagal stimuli over the sinoatrial node and stimulating the sympathetic 
activity. As result of these changes, the heart rate raises, the R-R interval reduces 
and the blood pressure faces a slight increment; 
- Phase 3: pressure releasing and the cardiac preload increases; this 
phase is purely mechanic as is phase 1 and lasts 1-2 seconds only; 
- Phase 4: the cardiac output increases and so the blood pressure 
(overshoot), activating the baroreflex that reduces the heart rate (increasing the R-R 
interval). As time passes the blood pressure and heart rate reach the normal status.  
 
Considering these physiological events, the evaluation of the cardiovagal 
function is particularly amenable during phases 2 and 4.64 In order to obtain a 
reliable measurement, the patient is instructed to perform a forced expiration at 40 
mmHg pressure during 15 seconds followed by a 45 second period of regular 
breathing.63,70 The maintenance of the 40mmHg pressure is achieved with a 
blowing tube connected to a manometer with a clear mark in the target pressure.66 
Alternatively, the patient may be instructed to blow on the open side of a 10cc plastic 
syringe for the same 15 seconds.66,71 As in the deep breathing evaluation, the 
patient may be rested and positioned in a recumbent or semi-recumbent position 
before the test starts.  
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Once the test is performed, it is recommended a second trial after a 3-5-
minute interval. Figure 4 shows the normal pattern of R-R interval variation in a 
healthy subject. The division of the maximum heart rate by the minimum heart rate 
within the 30-second interval defines the Valsalva Ratio (VR).63,64,72 Normal values 
vary according to sex and age (Table 4).66 
Most protocols of autonomic evaluation include beat-to-beat blood pressure 
monitoring during the VM test. This combined evaluation is particularly important if 
one wants to pharmacologically assess the different phases of the VM. However, 
since the scope of this paper is the evaluation of the CN IX and X, their role in the 
VM is restricted to the analysis of the R-R interval and thereafter linked to the VR. 
 
• Power Spectral Analysis 
Another useful neurophysiological test for CN IX and X function is power 
spectral analysis (PSA) of resting heart rate variability. This is usually done on 
continuous D2 EKG tracings obtained during short periods of 2-5 minutes (figure 5). 
In specific situations, 24-hour acquisition tracings may be employed as well. 
Heart rate variability may be evaluated under time and frequency domain 
analyses.62,73 The two techniques previously described (Deep breathing and 
Valsalva maneuver) are examples of time domain short-period measurements 
analyzed through statistical methods. Still, time domain HRV is amenable to be 
evaluated through a more complex method which by a long-period acquisition, 
explore the geometric patterns of the heartbeats plot, reason why this was named the 
geometric method of time domain analysis.57,74  
In contrast, PSA depends on frequency domain analyses. These take into 
account that variations between the heartbeats occur according to discrete 
oscillations of different frequency bands.75 To obtain the central frequency in which 
the heartbeats are distributed in, various mathematical algorithms may be applied; 
the most frequent are the fast Fourier transformation and the autoregressive 
approach.75 These procedures try to place a complex biological system on a 
stationary condition leading to a simplification of the involved variables. Thereafter, 
three major components have been identified: low frequencies (0.1 Hz), high 
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frequencies (0.25 Hz) and the very low frequencies (lower than 0.1 Hz).57,76,77 
Classically, low frequency (LF) is related to baroreflex activity towards the vasomotor 
activity and the high frequency (HF) is related to the respiratory activity. Moreover, 
HF components are traditionally interpreted as a vagal activity biomarker what may 
be seen as a physiological correlate of the parasympathetic HR control in the 
sinoatrial node that is faster than the sympathetic influence.57 Low frequencies, on 
the other side, are related to a sympathetic shift in the sympatho-vagal system 
confirmed by a series of experimental data.76 However, more comprehensive 
concepts have stated that neither low nor high frequency components are specific of 
a singular neural circuit.78 They recommend a practical approach considering the 
LF/HF ratio that may reflect more properly the sympatho-vagal interaction.60,78,79 
Conclusion 
The evaluation of CN IX and X is clinically relevant for several clinical 
conditions, where dysphagia, dysphonia and autonomic parasympathetic dysfunction 
are the heralding manifestations. It is crucial that clinical neurophysiologists 
understand, at least the basic concepts of swallowing testing techniques, laryngeal 
EMG and heart rate variability analysis, to enhance and ultimately improve patient 
care. 
Table 1: Syndromes with IX and X cranial nerve involvement, their symptoms and 
etiology (modified from Gorlin et al., 2001).  
 
Syndrome Lesion CN IX and X 
Manifestations 
Additional Neurologic 
Manifestations 
Etiology 
Wallenberg Lateral medulla Ipsilateral paralysis and 
anesthesia of the pharynx, and 
larynx. Results in dysphonia 
and dysphagia. 
Ipsilateral loss of corneal reflex, loss of pain 
and temperature sensation. Ipsilateral Horner’s 
Syndrome. Contralateral loss of pain and 
temperature sensation on trunk and extremities. 
Infarction, 
neoplasm 
Cestan-
Chenais 
Lateral/medial 
medulla 
Ipsilateral paralysis and 
anesthesia of the pharynx, and 
larynx. Results in dysphonia 
and dysphagia. 
Manifestations associated with Wallenberg’s 
Syndrome, with the addition of contralateral 
hemiplegia. 
Thrombosis of the 
vertebral artery 
proximal to PICA 
origin 
Vernet Jugular foramen Ipsilateral paralysis and 
anesthesia of the pharynx, and 
larynx. Results in dysphonia 
and dysphagia. 
Ipsilateral paralysis of CN XI resulting in 
paralysis of the sternocleidomastoid and 
trapezius muscles. 
Neoplasm, 
infection, skull 
base fractures 
Collet-Sicard Extra cranial at the 
jugular foramen 
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Garcin Jugular foramen, 
skull base 
Ipsilateral paralysis and 
anesthesia of the pharynx, and 
larynx. Results in dysphonia 
and dysphagia. 
Progressive involvement of multiple cranial 
nerves. 
Neoplasm, 
infection, trauma. 
Villaret Parapharyngeal space Ipsilateral paralysis and 
anesthesia of the pharynx, and 
larynx. Results in dysphonia 
and dysphagia. 
Ipsilateral paralysis of CN XI, XII resulting in 
paralysis of sternocleidomastoid, trapezius, and 
muscles of the tongue. 
Neoplasm, 
infection 
Tapia Intersection of CN X 
and XII below the 
nodose ganglia 
Ipsilateral paralysis and 
anesthesia of the pharynx, and 
larynx. Results in dysphonia 
and dysphagia. 
	
Ipsilateral paralysis of CN XII, resulting in 
paralysis of the muscles of the tongue 
Neoplasm, trauma 
 
 
 
 
 
Table 2: LEMG Normal Motor Unit Potential Duration and Amplitude 
Author (year)  Parameters TA CT PCA LAC 
Faaborg-andersen (1957) 
Duration (Mean±SD, ms) 3,5 (SD=0,1) 5,3 (SD=0,1) 4,4 (SD=0,2) ___ 
Amplitude (µV) 224-358 224-358 ___ ___ 
Rodriguez et al. (1990) 
Duration (Mean±SD, ms) 3,5 (SD=1,0) 4,4 (SD=1,6) ___ ___ 
Amplitude (µV) 426( SD=194) 500 (SD=224) ___ ___ 
Lovelace et al. (1992) 
Duration (Mean±SD, ms) 3-6 3-6 ___ ___ 
Amplitude (µV) 100-400 100-400 ___ ___ 
Koivu et al (2002) 
Duration (Mean±SD, ms) 4,5 (SD=0,6) 4,6 (SD=0,7) ___ ___ 
Amplitude (µV) 349 (SD=100) 282 (SD=86) ___ ___ 
Kimaid et al. (2004) 
Duration (Mean±SD, ms) 3,8 (SD=0,4) 4,9 (SD=0,6) 4,5 (SD=0,5) 4,1 (SD=0,4) 
Amplitude (µV) 413 (160-630) 585 (360-780) 475 (373-610) 388 (256-580) 
CT : crico-thyroideus ; LAC :lateral cricoarytenoid ; PCA : posterior cricoarytenoid ; TA : thyro-
arytenoideus. 
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Table 3: Normal values for the respiratory sinus arrhythmia amplitude (RSA) according to 
age. 
 
Age range (years) 10-29 30-39 40-49 50-59 60-69 
Normal RSA values (beats/min) ≥ 14 ≥ 12 ≥ 10 ≥ 9 ≥ 7 
 
 
Table 4: Normal values for the Valsalva Ratio (VR) according to age and gender. 
Age range (years) 10-29 30-39 40-49 50-59 60-69 
Minimum values for the VR 
Men 1.59 1.52 1.44 1.36 1.29 
Women 1.46 1.5 1.51 1.47 1.39 
 
 
Figure 1 – Electrophysiology of Swallowing. A – Electrode placement for Single Bolus 
Analysis (SBA) and Dysphagia Limits (DL); B – SBA recordings in normal controls (NC); C – 
SBA recording in NC, Wallenberg syndrome and unilateral IX and X cranial nerve paralysis; 
D – DL in NC and a patient with dysphagia; E – Sequential water swallowing (SWS) in NC 
and a patient with BSI (brainstem infarction); F – Polygraphic Evaluation of Spontaneus 
Swallowing. Details in the text. (Modifed from Ertekin, 2015 with permission).  
 
 
Figure 2 – LEMG electrode insertion techniques. A and B – thyroarytenoid; C – cricothyroid; 
D – lateral cricoarytenoid E and F – posterior cricoarytenoid.  
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Figure 3: Heart rate variability during deep breathing. The respiratory sinus arrhythmia 
amplitude (RSA) is determined by the following formula: (B – A) + ( D – C) + ( F – E) + (H – 
G) + ( J – I) + ( L – K) /6. 
 
Figure 4: Valsalva maneuver in a healthy subject. The Valsalva Ratio (VR) is obtained by the 
division of heart rate at point X by the heart rate at point Y. 
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Figure 5: Five-minute resting heart rate variability. A: Healthy subject. B: Patient with familial 
transthyretin amyloidosis and severe cardiac dysautonomia. Note an almost complete 
absence of variability. 
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non-transferable,	worldwide,	limited	license	to	reproduce	the	Wiley	Materials	for	the	purpose	
specified	in	the	licensing	process.	This	license,	and	any	CONTENT	(PDF	or	image	file)	purchased	as	
part	of	your	order,	is	for	a	one-time	use	only	and	limited	to	any	maximum	distribution	number	
specified	in	the	license.	The	first	instance	of	republication	or	reuse	granted	by	this	license	must	be	
completed				within	two	years	of	the	date	of	the	grant	of	this	license	(although	copies	prepared			
before	the	end	date	may	be	distributed	thereafter).	The	Wiley	Materials	shall	not	be		used	in	any	
other	manner	or	for	any	other	purpose,	beyond	what	is	granted	in	the		license.	Permission	is	granted	
subject	to	an	appropriate	acknowledgement	given	to	the	author,	title	of	the	material/book/journal	
and	the	publisher.	You	shall	also	duplicate	the	copyright	notice	that	appears	in	the	Wiley	publication	
in	your	use	of	the	Wiley			Material.	Permission	is	also	granted	on	the	understanding	that	nowhere	in	
the	text	is	a	previously	published	source	acknowledged	for	all	or	part	of	this	Wiley	Material.	Any	third	
party	content	is	expressly	excluded	from	this	permission.	
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With	respect	to	the	Wiley	Materials,	all	rights	are	reserved.	Except	as	expressly			granted	by	the	
terms	of	the	license,	no	part	of	the	Wiley	Materials	may	be	copied,	modified,	adapted	(except	for	
minor	reformatting	required	by	the	new	Publication),	translated,	reproduced,	transferred	or	
distributed,	in	any	form	or	by	any	means,	and	no	derivative	works	may	be	made	based	on	the	Wiley	
Materials	without	the	prior	permission	of	the	respective	copyright	owner.For	STM	Signatory	
Publishers			clearing	permission	under	the	terms	of	the	STM	Permissions	Guidelines	only,	the	terms	
of	the	license	are	extended	to	include	subsequent	editions	and	for	editions			in	other	languages,	
provided	such	editions	are	for	the	work	as	a	whole	in	situ	and	does	not	involve	the	separate	
exploitation	of	the	permitted	figures	or	extracts,				You		may	not	alter,	remove	or	suppress	in	any	
manner	any	copyright,	trademark	or		other	notices	displayed	by	the	Wiley	Materials.	You	may	not	
license,	rent,	sell,	loan,	lease,	pledge,	offer	as	security,	transfer	or	assign	the	Wiley	Materials	on	a	
stand-alone	basis,	or	any	of	the	rights	granted	to	you	hereunder	to	any	other	person.	
	
The	Wiley	Materials	and	all	of	the	intellectual	property	rights	therein	shall	at	all	times	remain	the	
exclusive	property	of	John	Wiley	&	Sons	Inc,	the	Wiley	Companies,	or	their	respective	licensors,	and	
your	interest	therein	is	only	that	of	having	possession	of	and	the	right	to	reproduce	the	Wiley	
Materials	pursuant	to	Section	2	herein	during	the	continuance	of	this	Agreement.	You	agree	that	you	
own	no	right,	title	or	interest	in	or	to	the	Wiley	Materials	or	any	of	the	intellectual	property	rights	
therein.	You	shall	have	no	rights	hereunder	other	than	the	license	as	provided	for	above	in	Section	2.	
No	right,	license	or	interest	to	any	trademark,	trade	name,	service	mark	or	other	branding	("Marks")	
of	WILEY	or	its	licensors	is	granted	hereunder,	and	you	agree	that	you	
		
shall	not	assert	any	such	right,	license	or	interest	with	respect	thereto	
	
NEITHER	WILEY	NOR	ITS	LICENSORS	MAKES	ANY	WARRANTY	OR	REPRESENTATION	OF	ANY	KIND	TO	
YOU	OR	ANY	THIRD	PARTY,	EXPRESS,	IMPLIED	OR	STATUTORY,	WITH	RESPECT	TO	THE	MATERIALS	OR	
THE	ACCURACY	OF	ANY	INFORMATION	CONTAINED	IN	THE	MATERIALS,	INCLUDING,	WITHOUT	
LIMITATION,	ANY	IMPLIED	WARRANTY	OF	MERCHANTABILITY,	ACCURACY,	SATISFACTORY	QUALITY,	
FITNESS	FOR	A	PARTICULAR	PURPOSE,	USABILITY,	INTEGRATION	OR	NON-INFRINGEMENT	AND	ALL	
SUCH	WARRANTIES	ARE	HEREBY	EXCLUDED	BY	WILEY	AND	ITS	LICENSORS	AND	WAIVED	BY	YOU.	
	
WILEY	shall	have	the	right	to	terminate	this	Agreement	immediately	upon	breach	of	this	Agreement	
by	you.	
	
You	shall	indemnify,	defend	and	hold	harmless	WILEY,	its	Licensors	and	their	respective	directors,	
officers,	agents	and	employees,	from	and	against	any	actual	or	threatened	claims,	demands,	causes	
of	action	or	proceedings	arising	from	any	breach	of	this	Agreement	by	you.	
	
IN	NO	EVENT	SHALL	WILEY	OR	ITS	LICENSORS	BE	LIABLE	TO	YOU	OR	ANY	OTHER	PARTY	OR	ANY	
OTHER	PERSON	OR	ENTITY	FOR	ANY	SPECIAL,	CONSEQUENTIAL,	INCIDENTAL,	INDIRECT,	EXEMPLARY	
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OR	PUNITIVE	DAMAGES,	HOWEVER	CAUSED,	ARISING	OUT	OF	OR	IN	CONNECTION	WITH	THE	
DOWNLOADING,	PROVISIONING,	VIEWING	OR	USE	OF	THE	MATERIALS	REGARDLESS	OF	THE	FORM	
OF	ACTION,	WHETHER	FOR	BREACH	OF	CONTRACT,	BREACH	OF	WARRANTY,	TORT,	NEGLIGENCE,	
INFRINGEMENT	OR	OTHERWISE	(INCLUDING,	WITHOUT	LIMITATION,	DAMAGES	BASED	ON	LOSS	OF	
PROFITS,	DATA,	FILES,	USE,	BUSINESS	OPPORTUNITY	OR	CLAIMS	OF	THIRD	PARTIES),	AND	WHETHER	
OR	NOT	THE	PARTY	HAS	BEEN	ADVISED	OF	THE	POSSIBILITY	OF	SUCH	DAMAGES.	THIS	LIMITATION	
SHALL	APPLY	NOTWITHSTANDING	ANY	FAILURE	OF	ESSENTIAL	PURPOSE	OF	ANY	LIMITED	REMEDY	
PROVIDED	HEREIN.	
	
Should	any	provision	of	this	Agreement	be	held	by	a	court	of	competent	jurisdiction	to	be	illegal,	
invalid,	or	unenforceable,	that	provision	shall	be	deemed	amended	to	achieve	as	nearly	as	possible	
the	same	economic	effect	as	the	original	provision,	and	the	legality,	validity	and	enforceability	of	the	
remaining	provisions	of	this	Agreement	shall	not	be	affected	or	impaired	thereby.	
	
The	failure	of	either	party	to	enforce	any	term	or	condition	of	this	Agreement	shall	not	constitute	a	
waiver	of	either	party's	right	to	enforce	each	and	every	term	and	condition	of	this	Agreement.	No	
breach	under	this	agreement	shall	be	deemed	waived	or	excused	by	either	party	unless	such	waiver	
or	consent	is	in	writing	signed	by	the	party	granting	such	waiver	or	consent.	The	waiver	by	or	consent	
of	a	party	to	a	breach	of	any	provision	of	this	Agreement	shall	not	operate	or	be	construed	as	a	
waiver	of	or	consent	to	any	other	or	subsequent	breach	by	such	other	party.	
		
This	Agreement	may	not	be	assigned	(including	by	operation	of	law	or	otherwise)	by	you	without	
WILEY's	prior	written	consent.	
	
Any	fee	required	for	this	permission	shall	be	non-refundable	after	thirty	(30)	days	from	receipt	by	the	
CCC.	
	
These	terms	and	conditions	together	with	CCC's	Billing	and	Payment	terms	and	conditions	(which	are	
incorporated	herein)	form	the	entire	agreement	between	you	and	WILEY	concerning	this	licensing	
transaction	and	(in	the	absence	of	fraud)	supersedes	all	prior	agreements	and	representations	of	the	
parties,	oral	or	written.	This	Agreement	may	not	be	amended	except	in	writing	signed	by	both	
parties.	This	Agreement	shall	be	binding	upon	and	inure	to	the	benefit	of	the	parties'	successors,	
legal	representatives,	and	authorized	assigns.	
	
In	the	event	of	any	conflict	between	your	obligations	established	by	these	terms	and	conditions	and	
those	established	by	CCC's	Billing	and	Payment	terms	and	conditions,	these	terms	and	conditions	
shall	prevail.	
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WILEY	expressly	reserves	all	rights	not	specifically	granted	in	the	combination	of	(i)	the	license	details	
provided	by	you	and	accepted	in	the	course	of	this	licensing	transaction,	(ii)	these	terms	and	
conditions	and	(iii)	CCC's	Billing	and	Payment	terms	and	conditions.	
	
This	Agreement	will	be	void	if	the	Type	of	Use,	Format,	Circulation,	or	Requestor	Type	was	
misrepresented	during	the	licensing	process.	
	
This	Agreement	shall	be	governed	by	and	construed	in	accordance	with	the	laws	of					the	State	of	
New	York,	USA,	without	regards	to	such	state's	conflict	of	law	rules.	Any	legal	action,	suit	or	
proceeding	arising	out	of	or	relating	to	these	Terms	and	Conditions	or	the	breach	thereof	shall	be	
instituted	in	a	court	of	competent	jurisdiction	in	New			York	County	in	the	State	of	New	York	in	the	
United	States	of	America	and	each	party	hereby	consents	and	submits	to	the	personal	jurisdiction	of	
such	court,	waives	any	objection	to	venue	in	such	court	and	consents	to	service	of	process	by	
registered	or	certified	mail,	return	receipt	requested,	at	the	last	known	address	of	such	party.	
	
	
WILEY	OPEN	ACCESS	TERMS	AND	CONDITIONS	
Wiley	Publishes	Open	Access	Articles	in	fully	Open	Access	Journals	and	in	Subscription	journals	
offering	Online	Open.	Although	most	of	the	fully	Open	Access	journals	publish		open	access	articles	
under	the	terms	of	the	Creative	Commons	Attribution	(CC	BY)	License	only,	the	subscription	journals	
and	a	few	of	the	Open	Access	Journals	offer	a	choice	of	Creative	Commons	Licenses.	The	license	type	
is	clearly	identified	on	the	article.	
The	Creative	Commons	Attribution	License	
The	Creative	Commons	Attribution	License	(CC-BY)	allows	users	to	copy,	distribute	and	transmit	an	
article,	adapt	the	article	and	make	commercial	use	of	the	article.	The	CC-BY	license	permits	
commercial	and	non-	
Creative	Commons	Attribution	Non-Commercial	License	
The	Creative	Commons	Attribution	Non-Commercial	(CC-BY-NC)License	permits	use,	distribution	and	
reproduction	in	any	medium,	provided	the	original	work	is	properly	cited	and	is	not	used	for	
commercial	purposes.(see	below)	
		
Creative	Commons	Attribution-Non-Commercial-NoDerivs	License	
The	Creative	Commons	Attribution	Non-Commercial-NoDerivs	License	(CC-BY-NC-ND)	permits	use,	
distribution	and	reproduction	in	any	medium,	provided	the	original	work	is	properly	cited,	is	not	used	
for	commercial	purposes	and	no	modifications	or	adaptations	are	made.	(see	below)	
Use	by	commercial	"for-profit"	organizations	
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Use	of	Wiley	Open	Access	articles	for	commercial,	promotional,	or	marketing	purposes	requires	
further	explicit	permission	from	Wiley	and	will	be	subject	to	a	fee.	
Further	details	can	be	found	on	Wiley	Online	Library	http://olabout.wiley.com/WileyCDA/Section/id-
410895.html	
	
	
Other	Terms	and	Conditions:	
	
	
	
v1.10	Last	updated	September	2015	
Questions?	customercare@copyright.com	or	+1-855-239-3415	(toll	free	in	the	US)	or	+1-978-646-
2777.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	 	 255	
	
	
	
JOHN	WILEY	AND	SONS	LICENSE	TERMS	AND	CONDITIONS	
Jan	22,	2019	
	
This	Agreement	between	Alberto	R	M	Martinez	("You")	and	John	Wiley	and	Sons	("John	Wiley	and	
Sons")	consists	of	your	license	details	and	the	terms	and	conditions	provided	by	John	Wiley	and	Sons	
and	Copyright	Clearance	Center.	
	
License	Number	 4514320866756	
License	date	 Jan	22,	2019	Licensed	Content	Publisher	 John	Wiley	and	Sons	Licensed	
Content	Publication	 Muscle	and	Nerve	
Licensed	Content	Title	 A	novel	phenotype	Of	Zika	virus-related	neurological	disease:	Sensory	
neuronopathy	
Licensed	Content	Author	 Alberto	Rolim	Muro	Martinez,	Marcela	Câmara	Machado	Costa,	
Marco	
Antônio	Caires	Novaes,	et	al	
Licensed	Content	Date	 Sep	23,	2017	
Licensed	Content	Volume	 57	
Licensed	Content	Issue	 2	
Licensed	Content	Pages	2	
Type	of	use	 Dissertation/Thesis	
Requestor	type	Author	of	this	Wiley	article	
Format	Print	and	electronic	
Portion	Full	article	
Will	you	be	translating?	No	
Title	of	your	thesis	/	dissertation	CONTRIBUTION	TO	THE	ETIOLOGICAL	DIAGNOSIS,	PHENOTYPIC	
CHARACTERIZATION	AND	FOLLOW-UP	OF	SENSORY	NEURONOPATHY	PATIENTS.	
Expected	completion	date	 Feb	2019	
		
Expected	size	(number	of	pages)	
		
240	
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Requestor	Location	 Alberto	R	M	Martinez	
Campinas,	Sao	Paulo,	Brazil	
Attn:	Alberto	R	M	Martinez	
Publisher	Tax	ID	 EU826007151	
Total	 0.00	USD	
Terms	and	Conditions	
TERMS	AND	CONDITIONS	
This	copyrighted	material	is	owned	by	or	exclusively	licensed	to	John	Wiley	&	Sons,	Inc.	or	one	of	its	
group	companies	(each	a"Wiley	Company")	or	handled	on	behalf	of	a	society	with	which	a	Wiley	
Company	has	exclusive	publishing	rights	in	relation	to	a	particular	work	
		
(collectively	"WILEY").	By	clicking	"accept"	in	connection	with	completing	this	licensing	transaction,	
you	agree	that	the	following	terms	and	conditions	apply	to	this	transaction	(along	with	the	billing	and	
payment	terms	and	conditions	established	by	the	Copyright	Clearance	Center	Inc.,	("CCC's	Billing	and	
Payment	terms	and	conditions"),	at	the	time	that	you	opened	your	RightsLink	account	(these	are	
available	at	any	time	at	http://myaccount.copyright.com).	
	
Terms	and	Conditions	
	
The	materials	you	have	requested	permission	to	reproduce	or	reuse	(the	"Wiley	Materials")	are	
protected	by	copyright.	
	
You		are	hereby	granted	a	personal,	non-exclusive,	non-sub	licensable	(on	a	stand-			alone	basis),	
non-transferable,	worldwide,	limited	license	to	reproduce	the	Wiley	Materials	for	the	purpose	
specified	in	the	licensing	process.	This	license,	and	any	CONTENT	(PDF	or	image	file)	purchased	as	
part	of	your	order,	is	for	a	one-time	use	only	and	limited	to	any	maximum	distribution	number	
specified	in	the	license.	The	first	instance	of	republication	or	reuse	granted	by	this	license	must	be	
completed				within	two	years	of	the	date	of	the	grant	of	this	license	(although	copies	prepared			
before	the	end	date	may	be	distributed	thereafter).	The	Wiley	Materials	shall	not	be		used	in	any	
other	manner	or	for	any	other	purpose,	beyond	what	is	granted	in	the		license.	Permission	is	granted	
subject	to	an	appropriate	acknowledgement	given	to	the	author,	title	of	the	material/book/journal	
and	the	publisher.	You	shall	also	duplicate	the	copyright	notice	that	appears	in	the	Wiley	publication	
in	your	use	of	the	Wiley			Material.	Permission	is	also	granted	on	the	understanding	that	nowhere	in	
the	text	is	a	previously	published	source	acknowledged	for	all	or	part	of	this	Wiley	Material.	Any	third	
party	content	is	expressly	excluded	from	this	permission.	
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With	respect	to	the	Wiley	Materials,	all	rights	are	reserved.	Except	as	expressly			granted	by	the	
terms	of	the	license,	no	part	of	the	Wiley	Materials	may	be	copied,	modified,	adapted	(except	for	
minor	reformatting	required	by	the	new	Publication),	translated,	reproduced,	transferred	or	
distributed,	in	any	form	or	by	any	means,	and	no	derivative	works	may	be	made	based	on	the	Wiley	
Materials	without	the	prior	permission	of	the	respective	copyright	owner.For	STM	Signatory	
Publishers			clearing	permission	under	the	terms	of	the	STM	Permissions	Guidelines	only,	the	terms	
of	the	license	are	extended	to	include	subsequent	editions	and	for	editions			in	other	languages,	
provided	such	editions	are	for	the	work	as	a	whole	in	situ	and	does	not	involve	the	separate	
exploitation	of	the	permitted	figures	or	extracts,				You		may	not	alter,	remove	or	suppress	in	any	
manner	any	copyright,	trademark	or		other	notices	displayed	by	the	Wiley	Materials.	You	may	not	
license,	rent,	sell,	loan,	lease,	pledge,	offer	as	security,	transfer	or	assign	the	Wiley	Materials	on	a	
stand-alone	basis,	or	any	of	the	rights	granted	to	you	hereunder	to	any	other	person.	
	
The	Wiley	Materials	and	all	of	the	intellectual	property	rights	therein	shall	at	all	times	remain	the	
exclusive	property	of	John	Wiley	&	Sons	Inc,	the	Wiley	Companies,	or	their	respective	licensors,	and	
your	interest	therein	is	only	that	of	having	possession	of	and	the	right	to	reproduce	the	Wiley	
Materials	pursuant	to	Section	2	herein	during	the	continuance	of	this	Agreement.	You	agree	that	you	
own	no	right,	title	or	interest	in	or	to	the	Wiley	Materials	or	any	of	the	intellectual	property	rights	
therein.	You	shall	have	no	rights	hereunder	other	than	the	license	as	provided	for	above	in	Section	2.	
No	right,	license	or	interest	to	any	trademark,	trade	name,	service	mark	or	other	branding	
		
("Marks")	of	WILEY	or	its	licensors	is	granted	hereunder,	and	you	agree	that	you	shall	not	assert	any	
such	right,	license	or	interest	with	respect	thereto	
	
NEITHER	WILEY	NOR	ITS	LICENSORS	MAKES	ANY	WARRANTY	OR	REPRESENTATION	OF	ANY	KIND	TO	
YOU	OR	ANY	THIRD	PARTY,	EXPRESS,	IMPLIED	OR	STATUTORY,	WITH	RESPECT	TO	THE	MATERIALS	OR	
THE	ACCURACY	OF	ANY	INFORMATION	CONTAINED	IN	THE	MATERIALS,	INCLUDING,	WITHOUT	
LIMITATION,	ANY	IMPLIED	WARRANTY	OF	MERCHANTABILITY,	ACCURACY,	SATISFACTORY	QUALITY,	
FITNESS	FOR	A	PARTICULAR	PURPOSE,	USABILITY,	INTEGRATION	OR	NON-INFRINGEMENT	AND	ALL	
SUCH	WARRANTIES	ARE	HEREBY	EXCLUDED	BY	WILEY	AND	ITS	LICENSORS	AND	WAIVED	BY	YOU.	
	
WILEY	shall	have	the	right	to	terminate	this	Agreement	immediately	upon	breach	of	this	Agreement	
by	you.	
	
You	shall	indemnify,	defend	and	hold	harmless	WILEY,	its	Licensors	and	their	respective	directors,	
officers,	agents	and	employees,	from	and	against	any	actual	or	threatened	claims,	demands,	causes	
of	action	or	proceedings	arising	from	any	breach	of	this	Agreement	by	you.	
	
IN	NO	EVENT	SHALL	WILEY	OR	ITS	LICENSORS	BE	LIABLE	TO	YOU	OR	ANY	OTHER	PARTY	OR	ANY	
OTHER	PERSON	OR	ENTITY	FOR	ANY	SPECIAL,	CONSEQUENTIAL,	INCIDENTAL,	INDIRECT,	EXEMPLARY	
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OR	PUNITIVE	DAMAGES,	HOWEVER	CAUSED,	ARISING	OUT	OF	OR	IN	CONNECTION	WITH	THE	
DOWNLOADING,	PROVISIONING,	VIEWING	OR	USE	OF	THE	MATERIALS	REGARDLESS	OF	THE	FORM	
OF	ACTION,	WHETHER	FOR	BREACH	OF	CONTRACT,	BREACH	OF	WARRANTY,	TORT,	NEGLIGENCE,	
INFRINGEMENT	OR	OTHERWISE	(INCLUDING,	WITHOUT	LIMITATION,	DAMAGES	BASED	ON	LOSS	OF	
PROFITS,	DATA,	FILES,	USE,	BUSINESS	OPPORTUNITY	OR	CLAIMS	OF	THIRD	PARTIES),	AND	WHETHER	
OR	NOT	THE	PARTY	HAS	BEEN	ADVISED	OF	THE	POSSIBILITY	OF	SUCH	DAMAGES.	THIS	LIMITATION	
SHALL	APPLY	NOTWITHSTANDING	ANY	FAILURE	OF	ESSENTIAL	PURPOSE	OF	ANY	LIMITED	REMEDY	
PROVIDED	HEREIN.	
	
Should	any	provision	of	this	Agreement	be	held	by	a	court	of	competent	jurisdiction	to	be	illegal,	
invalid,	or	unenforceable,	that	provision	shall	be	deemed	amended	to	achieve	as	nearly	as	possible	
the	same	economic	effect	as	the	original	provision,	and	the	legality,	validity	and	enforceability	of	the	
remaining	provisions	of	this	Agreement	shall	not	be	affected	or	impaired	thereby.	
	
The	failure	of	either	party	to	enforce	any	term	or	condition	of	this	Agreement	shall	not	constitute	a	
waiver	of	either	party's	right	to	enforce	each	and	every	term	and	condition	of	this	Agreement.	No	
breach	under	this	agreement	shall	be	deemed	waived	or	excused	by	either	party	unless	such	waiver	
or	consent	is	in	writing	signed	by	the	party	granting	such	waiver	or	consent.	The	waiver	by	or	consent	
of	a	party	to	a	breach	of	any	provision	of	this	Agreement	shall	not	operate	or	be	construed	as	a	
waiver	of	or	consent	to	any	other	or	subsequent	breach	by	such	other	party.	
		
	
This	Agreement	may	not	be	assigned	(including	by	operation	of	law	or	otherwise)	by	you	without	
WILEY's	prior	written	consent.	
	
Any	fee	required	for	this	permission	shall	be	non-refundable	after	thirty	(30)	days	from	receipt	by	the	
CCC.	
	
These	terms	and	conditions	together	with	CCC's	Billing	and	Payment	terms	and	conditions	(which	are	
incorporated	herein)	form	the	entire	agreement	between	you	and	WILEY	concerning	this	licensing	
transaction	and	(in	the	absence	of	fraud)	supersedes	all	prior	agreements	and	representations	of	the	
parties,	oral	or	written.	This	Agreement	may	not	be	amended	except	in	writing	signed	by	both	
parties.	This	Agreement	shall	be	binding	upon	and	inure	to	the	benefit	of	the	parties'	successors,	
legal	representatives,	and	authorized	assigns.	
	
In	the	event	of	any	conflict	between	your	obligations	established	by	these	terms	and	conditions	and	
those	established	by	CCC's	Billing	and	Payment	terms	and	conditions,	these	terms	and	conditions	
shall	prevail.	
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WILEY	expressly	reserves	all	rights	not	specifically	granted	in	the	combination	of	(i)	the	license	details	
provided	by	you	and	accepted	in	the	course	of	this	licensing	transaction,	(ii)	these	terms	and	
conditions	and	(iii)	CCC's	Billing	and	Payment	terms	and	conditions.	
	
This	Agreement	will	be	void	if	the	Type	of	Use,	Format,	Circulation,	or	Requestor	Type	was	
misrepresented	during	the	licensing	process.	
	
This	Agreement	shall	be	governed	by	and	construed	in	accordance	with	the	laws	of					the	State	of	
New	York,	USA,	without	regards	to	such	state's	conflict	of	law	rules.	Any	legal	action,	suit	or	
proceeding	arising	out	of	or	relating	to	these	Terms	and	Conditions	or	the	breach	thereof	shall	be	
instituted	in	a	court	of	competent	jurisdiction	in	New			York	County	in	the	State	of	New	York	in	the	
United	States	of	America	and	each	party	hereby	consents	and	submits	to	the	personal	jurisdiction	of	
such	court,	waives	any	objection	to	venue	in	such	court	and	consents	to	service	of	process	by	
registered	or	certified	mail,	return	receipt	requested,	at	the	last	known	address	of	such	party.	
	
	
WILEY	OPEN	ACCESS	TERMS	AND	CONDITIONS	
Wiley	Publishes	Open	Access	Articles	in	fully	Open	Access	Journals	and	in	Subscription	journals	
offering	Online	Open.	Although	most	of	the	fully	Open	Access	journals	publish		open	access	articles	
under	the	terms	of	the	Creative	Commons	Attribution	(CC	BY)	License	only,	the	subscription	journals	
and	a	few	of	the	Open	Access	Journals	offer	a	choice	of	Creative	Commons	Licenses.	The	license	type	
is	clearly	identified	on	the	article.	
The	Creative	Commons	Attribution	License	
The	Creative	Commons	Attribution	License	(CC-BY)	allows	users	to	copy,	distribute	and	transmit	an	
article,	adapt	the	article	and	make	commercial	use	of	the	article.	The	CC-BY	license	permits	
commercial	and	non-	
Creative	Commons	Attribution	Non-Commercial	License	
The	Creative	Commons	Attribution	Non-Commercial	(CC-BY-NC)License	permits	use,	distribution	and	
reproduction	in	any	medium,	provided	the	original	work	is	properly	cited	and	is	not	used	for	
commercial	purposes.(see	below)	
		
	
Creative	Commons	Attribution-Non-Commercial-NoDerivs	License	
The	Creative	Commons	Attribution	Non-Commercial-NoDerivs	License	(CC-BY-NC-ND)	permits	use,	
distribution	and	reproduction	in	any	medium,	provided	the	original	work	is	properly	cited,	is	not	used	
for	commercial	purposes	and	no	modifications	or	adaptations	are	made.	(see	below)	
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Use	of	Wiley	Open	Access	articles	for	commercial,	promotional,	or	marketing	purposes	requires	
further	explicit	permission	from	Wiley	and	will	be	subject	to	a	fee.	
Further	details	can	be	found	on	Wiley	Online	Library	http://olabout.wiley.com/WileyCDA/Section/id-
410895.html	
	
	
Other	Terms	and	Conditions:	
	
v1.10	Last	updated	September	2015	
Questions?	customercare@copyright.com	or	+1-855-239-3415	(toll	free	in	the	US)	or	+1-978-646-
2777.	
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Eu, Alberto Rolim Muro Martinez, autor da presente tese de Doutorado intitulada 
CONTRIBUIÇÃO PARA O DIAGNÓSTICO ETIOLÓGICO, CARACTERIZAÇÃO 
FENOTÍPICA E SEGUIMENTO CLÍNICO DOS PACIENTES COM NEURONOPATIA 
SENSITIVA, declaro para os devidos fins, que a presença dos artigos científicos nela 
colocados, não infringe, conforme os documentes acima expostos, os direitos 
autorais transferidos às respectivas editoras.  
